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Novel Paclitaxel Nanoparticles for Enhanced Therapeutic Effects in Breast
Cancer
Abstract
Drug delivery to triple negative breast cancer (TNBC) remains a formidable challenge. Given the lack of
expressions of estrogen (ER), progesterone (PR) and human epidermal growth factor receptor (HER2),
there is no specific prognostic marker for targeting this aggressive cancer. In spite of rapid advancement
in breast cancer with agents such as Trastuzumab in HER2 positive, chemotherapy with cytotoxic agents
remains the mainstay treatment for TNBC. Although these cytotoxic agents are potent in managing the
tumor progression, yet they pose adverse effects on healthy tissues. Paclitaxel (PTX) has been used as a
gold standard chemotherapeutic agent for breast, ovarian, pancreatic and non-small cell lung carcinoma.
Till date, PTX has been used as the first line of treatment for metastatic breast cancer. However, being
biopharmaceutical classification system (BCS) class IV agent PTX suffers low solubility, poor
permeability and remains a major challenge for efficient delivery specific to the tumor sites. Various
formulations of PTX have been developed and approved in some countries, however due to serious
adverse effects, suffer from poor patient outcomes.In this regard, we choose PTX as our model drug to
generate, a safe and efficacious nanoparticle formulation by nanoprecipitation technique. For this, we
screened commonly used pharmaceutical excipients and polymers and found the best candidate with
built-in chemosensitization motifs (tannic acid: TA) and polyvinyl/pyrrolidone (PVP), given their innate
potential to prevent drug efflux and capability to form the structured nanoparticle core due to extensive
hydrogen bonding. The optimized formulation of TA and PVP nanoparticles had an average diameter of
102.22 ± 14.05 nm and 140.53 ± 7.08 nm, respectively. A drug encapsulation efficiency of ~ 96% was
evaluated by LC-MS/MS. Improved in vitro and in vivo efficacies were achieved with respect to plain drug,
attributed to the inhibitory P-gp effects of TA. To expand the scope of the developed formulation for
enhanced specificity to TNBC tumors, we screened endogenous cell membranes (Human neutrophil,
Mesenchymal s
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ABSTRACT
Drug delivery to triple-negative breast cancer (TNBC) remains a formidable
challenge. Given the lack of expressions of estrogen (ER), progesterone (PR) and human
epidermal growth factor receptor (HER2), there is no specific prognostic marker for
targeting this aggressive cancer. In spite of rapid advancement in breast cancer with
agents such as Trastuzumab in HER2 positive, chemotherapy with cytotoxic agents
remains the mainstay treatment for TNBC. Although these cytotoxic agents are potent in
managing the tumor progression, yet they pose adverse effects on healthy tissues.
Paclitaxel (PTX) has been used as a gold standard chemotherapeutic agent for breast,
ovarian, pancreatic and non-small cell lung carcinoma. Till date, PTX has been used as
the first line of treatment for metastatic breast cancer. However, being a
biopharmaceutical classification system (BCS) class IV agent PTX suffers low solubility,
poor permeability and remains a major challenge for efficient delivery specific to the
tumor sites. Various formulations of PTX have been developed and approved in some
countries, however, due to serious adverse effects, suffer from poor patient outcomes.
In this regard, we choose PTX as our model drug to generate, a safe and
efficacious nanoparticle formulation by nanoprecipitation technique. For this, we
screened commonly used pharmaceutical excipients and polymers and found the best
candidate with built-in chemosensitization motifs (tannic acid: TA) and
polyvinyl/pyrrolidone (PVP), given their innate potential to prevent drug efflux and
capability to form the structured nanoparticle core due to extensive hydrogen bonding.
The optimized formulation of TA and PVP nanoparticles had an average diameter of
102.22 ± 14.05 nm and 140.53 ± 7.08 nm, respectively. A drug encapsulation efficiency
of ~ 96% was evaluated by LC-MS/MS. Improved in vitro and in vivo efficacies were
achieved with respect to plain drug, attributed to the inhibitory P-gp effects of TA. To
expand the scope of the developed formulation for enhanced specificity to TNBC tumors,
we screened endogenous cell membranes (Human neutrophil, Mesenchymal stem cells,
RAW 24 6.7). Here we present a final optimized biomimetic nanoformulation of PTX
coated with activated human neutrophil membrane (PVT-NEU NPs). These nanoparticles
have expression of proteins on cell membrane [Lymphocyte function-associated antigen1 (LFA-1), macrophage-1 antigen (Mac-1), platelet endothelial cell adhesion molecule-1
(PECAM-1), P-selectin glycoprotein ligand-1 (PSGL-1)] that have high affinity for
receptors that are overexpressed on the surface of TNBC tumors [Intercellular adhesion
molecule (ICAM-1/2), vascular cell adhesion protein-1 (VCAM-1), junctional adhesion
molecules (JAMs), E-selectin, P-selectin]. Due to these specific receptor-ligand
interactions, PVT-NEU NPs show improved in vitro and in vivo efficacies and reduced
non-specific binding and off-target toxicities, in comparison to uncoated polymeric
nanoparticles. These results suggest, potential of biomimetic nanoparticles as a promising
drug delivery option for metastatic breast cancer.
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CHAPTER 1.

INTRODUCTION

Breast Cancer (BC)
Breast cancer (BC) remains the most commonly diagnosed cancer among women and is
the second leading cause of death after lung cancer in the United States [1]. In 2020, it is
estimated that 276,480 new cases of invasive BC will be diagnosed among women, among which
42,170 women are expected to die.
BC Anatomy Causes and Risks
The anatomy of the human breast is made up of 15-20 lobes, that further branches into
smaller lobules and interlobular ducts, that are responsible for transporting the milk from the
lobules to the nipples, in nursing women. These ducts and lobules are composed of an inner
luminal layer and outer myoepithelial or basal cells. BC begins when the malignant epithelial
cells accumulate and grow out, depending on the region they grow out it is classified into noninvasive and invasive. Non-invasive (carcinoma in-situ) is when the carcinoma is confined in the
lobules and duct. Invasive carcinomas occur when the carcinoma diffuses to the surrounding
connective tissues and metastasize to distant sites. These carcinomas are divided into ductal and
lobular carcinoma, depending on where the tumor is formed. Ductal carcinomas comprise twothird of the total BC and arise from the epithelial cells of the ducts, whereas the lobular
carcinoma arises from the lobules and is about one-third of the total BC cases [2].
Some inevitable risk factors include inherited mutations such as BC type 1 and 2
susceptibility protein (BRCA1), BRCA2, atypical hyperplasia, high breast tissue density, older
age and/or family history. Race and ethnicity also play a role in the development of BC over a
person’s lifetime. Other risk factors include weight gain, obesity, menopausal hormone therapy
cigarette smoking, alcohol, consumption and physical inactivity [3].
BC Major Molecular Classification
BC is a heterogeneous disease and can be classified based on the expression of different
biomarkers, exhibiting diversity in biological characteristics and clinical behavior. The
expression of four biomarkers, estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) and Ki-67 classify BC into four main categories, as
shown in the Table 1-1 [4].
The estrogen receptor (ER)
Estrogen is a steroid hormone that is responsible for the growth and bone metabolism,
development of mammary glands, as well as maintenance of the central nervous system (CNS)
and cardiovascular system. These effects are mediated through a nucleus-initiated

1

Table 1-1.

Major molecular classification of BC

Subtype

Biomarker
expression

Luminal A

ER+, PR+/-,
HER2- and Ki67
low

Luminal B

ER+, PR+/-,
HER2+/- and
Ki67 high

HER2 positive

ER-, PR- and
HER2+

Triple-negative
breast cancer
(TNBC)

ER-, PR- and
HER2-

Histological
properties &
prognosis
Classic, tubular,
lobular and
cribriform
carcinoma.
Low grade
invasive ductal
carcinoma.
Good prognosis.
Micropapillary
carcinoma.
Invasive ductal
carcinoma.
More aggressive
than Luminal A.
Prognosis is not
as well
established as
Luminal A.
High grade
invasive ductal
carcinoma.
Poor prognosis.
High-grade
invasive,
Medullary, and
metaplastic
carcinoma.
Worst prognosis

Available
treatment

Percentage

Best response to
hormonal
therapy,
Variable
response to
chemotherapy

30-70%

Hormonal
therapy in
combination
with anti-HER2
therapy
(Trastuzumab),
depending on the
expression of
HER2, Variable
response to
chemotherapy.
Responds well
with anti-HER2
therapy, and
chemotherapy
Chemotherapy is
the only
treatment.
Olaparib and
Atezolizumab
have recently
been approved
by the FDA for
TNBC patients
with BRCA1/2
mutation and
PD-L1 positive,
respectively.

10-20%

15-20%

5-15%

Sources: Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009). Breast cancer
subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and
survival. Clinical medicine & research, 7(1-2), 4-13 [5], & Weigelt, B., Peterse, J. L., & Van't
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Table 1-1.

(Continued)

Veer, L. J. (2005). Breast cancer metastasis: markers and models. Nature reviews cancer, 5(8),
591-602.

3

estrogen receptor, which belongs to the nuclear hormone receptor superfamily. Around 70-75%
of the total BC cases are ER-dependent. They can either be Luminal A or Luminal B, varying on
the expression of proliferation associated genes. Overall, both the subtypes of ER+ BC; Luminal
A and B have a good prognosis with excellent long-term survival. Treatment options available
for ER-dependent pathway in the form of:
x

Selective ER agonist Tamoxifen, that inhibits BC cells by competitive antagonism with
estrogen at the binding site. In normal breast, it behaves as an antagonist and inhibits the
growth of cancer cells, although it functions as an agonist in the bone and the
endometrium [6].

x

Selective ER inhibitor Fulvestrant, due to the absence of any estrogenic activity,
functions far more effectively than Tamoxifen and is able to prolong the effect of the
treatment and also reduce the chances of developing drug resistance, which remains a
major hindrance in tamoxifen therapy [7].

x

Aromatase inhibitors Letrozole and Anastrazole, suppress the activity of aromatase
enzyme, preventing the conversion of androgen to estrogen especially in menopausal
women. Aromatase inhibitors in BC [8].
Human epidermal growth factor receptor 2 (HER2)

HER2 belongs to the human epidermal growth factor receptor (HER) family that is
responsible for cell growth, survival, cell differentiation, and proliferation. It exerts oncogenic
behavior due to the overexpression of the HER2 gene [9]. HER2 directed therapy although
exerted increased risk of disease-free survival and poorer overall survival. However, it responds
well to anti-HER2 therapy such as a monoclonal antibody, Trastuzumab, and dual EGFR and
HER2 receptor tyrosine kinase inhibitors such as Lapatinib [10]. Trastuzumab in combination
with chemotherapy improves cancer recurrence rates and overall survival by 50% and 33%
respectively in contrast to chemotherapy alone [11].
Progesterone receptor (PR)
PR plays a vital role in mammary epithelial cell proliferation and differentiation [12]. The
effect of PR on cancer cells is controversial. It has been reported that the effects of PR on cancer
cells causes binding of nuclear PR and translocating of the PR complex to the nucleus, thus
causing activation of the target genes [13]. At the same time, reports have been available
showing that inclusion of progesterone during hormone therapy for ~ 5.6 years results in
increased risks in BC with intervention. However, even after cessation of therapy chances of risk
remains high several years after stopping the regimen. Researchers have shown may be the level
of progesterone in the stem cell niche could initially mitigate the chances of early cancer lesions
during the early post-intervention period. Although the risk of BC is an elevated postintervention period as cancer has probably progressed to an advanced stage prior to treatment
cessation and would no longer be dependent on progesterone treatment [14]. Although further
studies are being explored to pinpoint the role and mechanistic impact of progesterone for

4

progression of BC, that could shine light on the therapeutic intervention for advanced stage
triple-negative breast cancer
Triple-negative breast cancer (TNBC)
TNBC represents the most aggressive and heterogeneous subtype of BC. It is
characterized by a lack of expression of ER, PR, and HER2 overexpression. Typically, TNBC
demonstrates an increased mitotic activity, increased expression of proliferation markers such as
Ki67, high nuclear atypia, high nuclear‐cytoplasmic ratio, scant stromal content, central necrosis,
multiple apoptotic cells, invasive and stromal lymphocytic infiltration [15, 16]. Additionally,
tumor growth is rapid, of a higher grade, greater chances of lymph node involvement and
metastasizes mostly to the viscera, especially the lungs and the brain [17]. The distinct cellular
phenotype, aggressive nature, metastatic potential and lack of receptor or targeted therapy,
makes chemotherapy the only treatment modality for TNBC. However, TNBC with the worst
prognosis and high recurrence rate within the first 5 years of therapy [18] and shorter overall
survival of only 9-13 months [19], in contrast to other subtypes of BC, makes therapeutic
intervention for TNBC an unmet need.
Therapeutic Strategies for TNBC, Evaluated by Clinical Trials
As described above, TNBC due to heterogeneity and molecular variability there was no
specific protocol for this type of disease. Although the relentless efforts of researchers have led
to an improvement in the therapy of TNBC, and newer targets are discovered by studying the
genomic variability. Therapies that have shown promising outcomes in TNBC, either alone or in
combination with neoadjuvant therapy that has led them to be evaluated for clinical trial are
summarized below. Figure 1-1 shows the schematic representation of the various treatment
strategies.
Conventional Chemotherapy for TNBC
Chemotherapy with cytotoxic drugs remains the mainstay treatment for TNBC. These are
usually agents such as anthracycline, platinum and/or taxanes either in the neoadjuvant or
adjuvant setting. Anthracyclines such as doxorubicin and epirubicin have shown enhanced
improvement in the response rate of survival by 22 months [20]. These agents have proven to be
beneficial and have shown enhanced sensitivity both when used as a single agent [21, 22] as well
as in neoadjuvant setting [23]. Phase III clinical trial of anthracyclines as an adjuvant agent
versus CMF (cyclophosphamide, methotrexate and 5-fluororacil) by Di et. al. demonstrates that
a 23% decrease in the recurrence rate [24]. A 17% pathological complete response (pcR) in a
Phase II clinical trial was observed in a neoadjuvant setting with anthracyclines agents in
combination with others such as cyclophosphamide, 5-fluororacil and epirubicin [25]. Gluz et al.
demonstrate in a Phase III clinical trial that 5-year disease-free survival was achieved in 71% of
the TNBC patients treated thrice every week in contrast to only 26% improvement with treated
twice weekly when anthracyclines are used in combination [26]. Taken together, although a
higher response rate [27, 28] is observed in TNBC patients, higher recurrence rates and low
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Figure 1-1. Schematic illustration of various treatment strategies for TNBC
Although chemotherapy remains the backbone for the treatment for most of TNBC patients with
cytotoxic agents, yet emerging trends are evolving. These mostly include immunotherapy
(checkpoint inhibitors), targeted therapy (inhibitors of various pathways) and novel formulation
strategies (neoformation, ADC).
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overall survival [29], has limited the usage of response rate as a determinant for therapeutic
superiority. Other associated side effects include acute toxicity such as irreversible cardiotoxicity
myelotoxicity, alopecia, nausea, and vomiting [29-31] with these agents.
Platinum agents have proven to be beneficial for the treatment of TNBC patients with a
BRCA mutation when used in combination as well as single agents [32]. A Phase II clinical trial
(NCT00148694) at Dana Farber Cancer Institute suggested that 21% of patients received pcR
with single-agent cisplatin and 15% response when excluding the BRCA1 mutations suggesting
the importance of platinum agents as adjuvant or neoadjuvant therapy in BRCA mutants [21].
BRCA1 mutant has shown increased sensitivity to platinum agents because of the ability to
repair DNA, however, it may become resistant and may be required to be provided in
homologous combination [22]. A Phase II clinical trial suggests carboplatin and PTX with or
without trastuzumab showed a 67% increase in pcR [33]. In another Phase II clinical trial
cisplatin combination with epirubicin and fluorouracil in addition to PTX versus without the
PTX treatment improved the response rate by 40% [34]. A higher response rate of 34% was
observed in women treated with platinum and docetaxel [35]. Thus, a combination of platinum
agents has shown to have higher efficacy than when used alone. Although therapy with platinum
agents are of special interest when treating a TNBC patient with a BRCA defect.
Taxanes either as a single agent or in combination with anthracyclines have shown to be
beneficial in TNBC subtype in contrast to other subtypes of BC, attaining pcR of up to 40% [36].
Cancer and Leukemia Group B (CALGB) conducted a trial on 9344 subjects, demonstrate that
there was particularly improvement in disease-free survival in TNBC patients treated PTX versus
in all other subtypes of BC [37]. BC International Research Group (BCIRG) led another 001 trial
and particularly yielded an advantage in the group that was cotreated with PTX over
cyclophosphamide, suggesting that there is significant inhibitory effect of PTX especially on the
TNBC cohort [38]. Further, a non–platinum-based neoadjuvant therapy with cyclophosphamidevincristine-doxorubicin-prednisolone shows a 15% increase in the pcR in comparison to all the
other regimen, suggesting TNBC apart BRCA mutation subset, have greater with taxanes in
comparison to other regimens [39].
Targeted Therapies
The molecular heterogeneity of TNBC makes it difficult for physicians and clinicians to
have a standard care guided approach for the treatment. Although, advancement in the molecular
classification and genome sequencing, the development of targeted therapy is improving. From a
variety of gene expression analysis, six main subtypes of TNBC have been proposed, viz. basallike 1, basal-like 2, immunomodulatory, mesenchymal, mesenchymal stem-like, and luminal
androgen receptor (AR) [40]. Numerous clinical trials are ongoing to investigate a variety of
targeted therapy for TNBC, such as PARP inhibitors, phosphatidylinositol 3- kinase (PI3K/AKT)
inhibitors, mitogen-activated protein kinases/ extracellular signal-regulated kinases (MAPK) and
cyclin‑Dependent Kinase (CDK) 4/6 inhibitors.
Poly(ADP-ribose) polymerase (PARP-1) inhibitor leads to an increase in the doublestrand DNA causing an increase in apoptosis [41]. PARP-1 inhibitor has been particularly
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beneficial in BRCA1 and BRCA2 mutant cells because of their ability to sensitize cells [42, 43].
Although BRCA mutations account for only 20% in TNBC population, yet several PARP
inhibitors have gained clinical approval such as olaparib, veliparib, niraparib, rucaparib and
talazoparib. In a phase III clinical trial in TNBC patients with BRCA mutation demonstrate that
oral PARP inhibitor olaparib increases the progression-free survival to 7 months in contrast to
4.2 months in the placebo group. US Food and Drug (FDA) recently in January 2018 approved
the first PARP inhibitor: olaparib for the treatment of advanced-stage BRCA mutant TNBC [44].
talazoparib was used as monotherapy in the neoadjuvant setting in a phase II clinical trial:
NCT02282345, for patients with BRCA mutations. Among the twenty patients enrolled,
seventeen were TNBC positive. After 6 months of treatment followed by surgery and adjuvant
chemotherapy, 53% of patients achieved pCR [45]. Currently, a larger single-arm Phase II study
is ongoing (NCT03499353) by Pfizer. Also, EMBRACA study conducted on HER2 negative
advanced BC improved the overall survival to 24.3 months, in contrast to only 6.3 months in
patients receiving only chemotherapy. This lead to the approval of the second PARP inhibitor,
Talazoparib for germline BRCA mutation in October 2018 [46].
The PI3K/AKT regulates cell growth and glucose metabolism. There are complexities
associated with the activated PI3K/AKT pathway, although activated PI3K/AKT pathway is high
in TNBC [46]. Ipatasertib, an oral AKT inhibitor is used in a LOTUS (NCT02162719), a phase
II clinical trial in TNBC patients, in combination with PTX demonstrated improved progressionfree survival from 9 months to 4.9 months, with PTX [47], with also improvement in overall
survival of 23.1 months versus 18.4 months with PTX [48]. Recently, an ongoing clinical trial
phase II with combination of PTX and ipatasertib is being conducted as neoadjuvant therapy in
stage I-III TNBC (NCT02301988) patients. Inhibition of epidermal growth factor receptor
(EGFR), a transmembrane tyrosine kinase receptor by PI3K/AKT pathway has proven to be
useful used in the treatment of TNBC. However, cetuximab a humanized monoclonal antibody
used in combination with other taxanes failed to show any improvement in the TNBC subtype
[49]. In a similar study, of phase II trial by the Translational BC Research Consortium
demonstrates that cetuximab used alone or in combination with platinum agents such as cisplatin
and carboplatin, failed to show any impressive result by the anti-EGFR antibody [50]. This is
probably because only 50% of the TNBC cases are EGFR positive [51].
AR accounts for 13-37% among TNBC patients [52], with more prevalence among older
people [53]. However, the role of AR as a prognostic marker in TNBC is not clear, as there are
contradictory reports about the characteristics of AR in TNBC. Some suggest it is associated
with low nuclear grade, and low proliferative rate and is unrelated to be a prognostic marker
[54], whereas some suggest they have a higher nuclear grade and high lymph node metastasis
and higher mortality rate [55]. Although, there are several clinical trials with AR and have shown
promising results. Enzalutamide, is a novel targeted AR inhibitor that competitively binds to the
AR and prevents translocation to the nucleus [56]. NCT02750358 is a Phase II ongoing clinical
trial for determining the compliance rate of enzalutamide as adjuvant therapy for a 1-year dose
[57]. In another Phase II, clinical trial demonstrates clinical benefits are achieved and
enzalutamide may be a therapeutic option for patients who have received chemotherapy. To
further evaluate the efficiency of enzalutamide with PTX a phase IIB is currently ongoing.
Bicalutamide also an AR inhibitor, has shown to have promising results in a phase III trial for
metastatic TNBC patients [58].
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The role of activation MAPK was initially investigated in vitro, which causes loss or
downregulation of various genetic and epigenetic functions that are associated with
chemoresistance. MEK inhibitors are known to cause efficient suppression of chemoresistance
either alone or in combination with other chemotherapeutic drugs. Significant inhibitory effects
were seen with combination treatment of cobimetinib with PTX [59]. Another study
demonstrates, MEK inhibitor selumetinib given in combination with either buparlisib or the
platelet-derived growth factor receptor inhibitor pazopanib showed effective inhibition of brain
metastases in TNBC patients [60]. An ongoing clinical trial shows MEK inhibitor trametinib in
combination with gemcitabine showed complete response in the patient with metastatic TNBC
[61]. However, there have been serious toxicities prohibiting phase II clinical study of MEK
inhibitor with mTOR or PI3K inhibitors [62, 63].
CDK is responsible for hyperphosphorylation of retinoblastoma protein (RP) and causes
G1-S phase transition in the cell cycle [64]. CDK inhibitors thus were explored as a potential
target for TNBC. Palbociclib is a selective inhibitor of CDK was explored in clinical trials for
TNBC with positive RP expression and demonstrated a partial response in 50% of the patients,
improving disease-free survival for equivalent or more than 6 months [65]. There are several
other clinical trials conducted either alone or in combination with other chemotherapy.
Antibody-Drug Conjugates (ADC)
ADCs are targeted therapy where the toxic anticancer drug targets the cancer cells
through the specific binding of an antibody that has specificity for receptors on the surface of
cancer cell. There have been lots of ongoing research using ADCs for TNBC with some of them
discussed below.
Trophoblast antigen 2 (Trop2) [66] is another target via ADC for TNBC. IMMU-132,
also known as sacituzumab govitecan is an ADC that targets Trop2 and have been used in
combination with three PARP inhibitor; olaparib, rucaparib and talazoparib and have shown
improved overall response [67]. Another compelling ADC, glembatumumab vedotin (GPNMB)
that combines the monomethyl auristatin E (MMAE) (a potent microtubule-disrupting agent)
shows improvement in disease-free progression in Phase I/II clinical trial [68]. However, finding
suggests that a 100 mg dose caused some toxicity of grade 3 and 4, may limit the usage of these
agents [69]. Ladiratuzumab vedotin is another ADC explored for targeting TNBC and is
composed of a humanized IgG1, MMAE and a monoclonal antibody for targeting oestrogenregulated gene (LIV-1). LIV-1 is overexpressed in 90% TNBC tumors but is not significantly
expressed in normal tissues. In a phase I study with ladiratuzumab vedotin a 25% overall
response rate was achieved. Although there are toxicities issues such as alopecia, neutropenia
and peripheral neuropathy. Ongoing studies are still conducted to evaluate the efficiency of
ladiratuzumab vedotin as monotherapy or in combination with chemotherapy for TNBC [70].
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Immunotherapy
TNBC is known to have the highest mutations [71] among all other types of BC. The role
of tumor-infiltrating lymphocytes plays a major role in disease progression in TNBC. Thus,
activation of these cytotoxic T cells would be initiating an antitumor immune response. T cells
show the expression of immune checkpoint inhibitors: cytotoxic T-lymphocyte antigen 4
(CTLA-4) and programmed death-1 (PD-1). PD-1 inhibitors are the most extensively studied
checkpoint and is a cell surface protein expressed on the infiltrating tumor lymphocytes that
induce inhibition of T cell by binding to two ligands: PD-L1 and PD-L2 [72]. Researchers are
actively involved in evaluating the role of these checkpoint inhibitors and have shown some
encouraging results for the treatment of TNBC
Among these PD-1 inhibitor, pembrolizumab was evaluated as a first-line therapy among
PD-L1 positive TNBC patients. In which 87% of the patients had received either neoadjuvant or
adjuvant chemotherapy, with overall survival outcome being 16.1 months [73]. In another phase
II trial, I-SPY 2 trial (NCT01042379), 69 patients were HER- and 29 TNBC patients, received
either neoadjuvant PTX and/or pembrolizumab, followed by dose-dependent doxorubicin and
cyclophosphamide. The raw pathological complete response was improved to 71% with
pembrolizumab compared to 19% in the control arm, whereas the estimated pcR was 62% with
pembrolizumab versus 22% in the control arm [73]. The beneficial results achieved through ISPY 2 trial led to the phase III trial, KEYNOTE-552 (NCT03036488) and KEYNOTE-355
(NCT02819518) which are currently ongoing. Another PD-L1 inhibitor that has achieved
impressing outcomes among TNBC patients is, atezolizumab. Impassion130 trial, NCT02425891
which was a phase III trial, among metastatic or advanced stage TNBC patients receiving
Abraxane with/without atezolizumab plus placebo. 1.4 fold improvement was achieved among
patients receiving atezolizumab, with progression-free survival of 2.5 months, versus 1.7 months
who did not receive atezolizumab, overall survival was also improved to 9.5 months, with no
significant improvement observed among patients without atezolizumab [74]. Based on these
results, the FDA accelerated the approval of atezolizumab with Abraxane for the treatment of
metastatic TNBC patients who are PD-L1 positive. Further ongoing phase III trial
NCT03125902 is being evaluated with patients receiving either atezolizumab and PTX versus
PTX and placebo for first-line therapy in TNBC.
Due to the heterogeneity and the inherent nature of TNBC to develop multi drug
resistance (MDR) to conventional chemotherapeutics, several ongoing clinical trials with
combination therapies or targeted therapies or immunotherapies or ADC, are being evaluated to
identify predictable biomarkers that will improve treatment outcomes among TNBC patients.
Although, the paradigm is shifting and lots of attention is being given to the development of
novel and nano-based therapies for TNBC.
Nano-Based Therapies for TNBC
The lack of these cellular receptors makes the delivery of therapeutics for TNBC patients
a crucial need. Nanotechnology-based delivery systems have been beneficial to provide
significant intratumoral delivery both by active and passive targeting. Passive targeting occurs by
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a phenomenon known as enhanced permeability and retention (EPR) effect. This phenomenon
occurs because of the tumor vasculature that is hyper vascularized with enhanced vascular
permeability causing fluid retention and lack of lymphatic drainage. This results in extravasation
within tumor tissues and increased accumulation of therapeutics at the intertumoral site, whereas
they get cleared into the lymphatic system of healthy cells [75]. However, achieving therapeutic
concentrations inside the tumor site is a challenge with passive targeting and as a result of which
compromising with the biotherapeutic window of the drug. Although, active targeting relies on
conjugating the surface of the nanoparticle to biocompatible targeting moieties such as aptamers,
antibodies, peptides, that has specificity to the antigens or receptors at tumor site [76, 77]. This
approach provides a myriad of advantages over conventional therapeutic approaches, such as:
x

Target specific delivery

x

Minimizes systemic or non-specific toxicities

x

Prolonged biodistribution with intravenous administration

x

Increase of therapeutic window, resulting in transport of maximal payload

x

Less immunogenic reaction

x

Controlled drug release, improving half-life and systemic circulation

x

Increase in drug solubility, chemical stability and efficacy of poorly water-soluble
chemotherapeutic agents.

x

Combined therapy has been able to deliver multiple therapeutic agents by synergistic
effects, and useful for multimodal functional, such as imaging and/or theranostic agent
[78-80].

Some of the commonly employed nanoparticles that have been explored further are
polymeric nanoparticles, micelles, dendrimers, liposomes, nanoconjugates. These systems are
further modified for delivering not only drugs but also oligonucleotides, DNA or proteins [81].
Polymeric nanoparticles
Polymeric nanoparticles are nanosized range materials that are synthesized using either
natural or synthetic biodegradable and biocompatible polymers. Depending on the characteristics
of the polymer of choice, both hydrophilic and hydrophobic drugs can be encapsulated into these
nanoparticles that can be released by surface or bulk erosion, swelling or diffusion. Studies have
shown that polymeric nanoparticles made of polyethyleneglycol-poly(epsilon-caprolactone)
(PCL-PEG-PCL) encapsulating docetaxel successfully improved the in vivo survival rate of mice
in contrast to marketed docetaxel formulation due to the prolonged circulation of the
nanoparticles for EPR effect. Similarly, poly(lactic-co-glycolic acid) polymer (PLGA)polyethyleneglycol (PEG) nanoparticles were utilized to deliver cisplatin in TNBC xenograft
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mouse model with significant tumor inhibition and prolongation of half-life, although systemic
toxicities were observed in normal organs such as kidney and liver [82].
These loopholes of passive targeting have led into the utilization of nanoparticles by
decorating the surface with active moieties allowing longer circulation, causing higher
concentration accumulating in tumor tissues compared to normal tissues. Passarella et al. utilized
a biology-based screening technique called Phage Display, to identify the glucose-regulated
protein (GRP78), a radiation-induced cell surface receptor that is known to have higher
pathologic grade and known to cause metastasis, lower chemotherapeutic response, patient
survival and cancer prognosis in TNBC [83]. By conjugating a novel peptide (Gly–Ile–Arg–
Leu–Arg–Gly) to polymeric nanoparticles made of polyester and encapsulating anticancer agent
PTX, the authors display targetability at irradiated xenograft TNBC mice model and significant
delay in tumor growth in contrast to untargeted nanoparticles [84]. In another approach, a protein
polymer called elastin-like polypeptides (ELP) was used to form nanoparticles that assemble into
<100 nm and was surface decorated with FKBP, which is a cognate receptor for potent yet
poorly soluble rapamycin. These nanoparticles prolonged circulation time and increased the halflife by 26 folds, with enhanced anti-tumor efficacy and lower cytotoxicity than free drug in
TNBC xenograft mouse model [85]. Enhancer of zeste homolog 2 (EZH2) was found to be
overexpressed in TNBC and is found to be responsible for poorer overall patient survival.
Delivery of siRNA via chitosan nanoparticles directed to target the EZH2 in the orthotopic
MDA-MB-231 TNBC mouse model has shown to cause a significant reduction in tumor growth
[86].
Polymeric micelles
Polymeric micelles are formed using hydrophilic and hydrophobic polymers, that forms
Van der Waals bonds to form a hydrophobic core which usually encapsulates the drug either by
physical entrapment or chemical bonds. The outer shell on the other hand being hydrophilic, aids
prolong circulation and prevents rapid clearance by the reticuloendothelial system (RES) [87]. A
block copolymer of poly (ethylene glycol)-poly (glutamic acid) (PEG-PGlu) conjugated to the
active metabolite of topoisomerase I inhibitor irinotecan (SN-38) forms polymeric micelles
around 20nm. Significant tumor inhibition in an orthotopic mouse model has made this a
promising candidate and is in Phase II clinical trial for TNBC patients [88]. Active targeting by
polymeric micelles was designed by Kutty et. al. using D-tocopheryl polyethylene glycol
succinate (TPGS) polymer, encapsulating docetaxel conjugated to cetuximab, that specifically
targets EGFR on the TNBC tumors by 205.6 and 223.8 folds in contrast to the marketed
formulation of docetaxel, Taxotere® [89].
Liposomes
Liposomes are composed utilizing the lipid bilayer characteristics, which allows the
formation of spherical vesicles as large as 400 nm, enclosing an aqueous core. The lipid bilayer
being amphiphilic allows the interaction of the hydrophilic surface of the lipid with the central
aqueous core-forming lipid spheres, whereas the hydrophobic region can be modified as per drug
delivery needs. The ability of drug loading both in the aqueous core or lipid bilayer and the
possibility of active and passive targeting makes liposomes an attractive alternative for
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researchers. Researchers have utilized the lipid-based nanocapsules to entrap lipophilic drug
ferrocenyl tamoxifen derivative FcOHTAM and demonstrated improved antitumor effects in
TNBC xenograft model that is resistant to tamoxifen treatment [90]. Lipid-based nanoparticles
were constructed from chemically modified cholesterol-terminated poly (acrylic acid) and crosslinked with diamine linkers for active targeting. The authors demonstrate a high drug loading
capability of doxorubicin via this approach exhibiting superior tumor growth inhibition and no
systemic toxicity in comparison to free drug in orthotopic TNBC murine model [91]. A similar
finding by Ahn et. al. show liposome vesicles encapsulate arsenic trioxide, which due to doselimiting toxicity and rapid clearance was not well explored despite having potential antitumor
activity. The stabilized 100 nm size ranged liposomal vesicles resulted in enhanced antitumor
efficacy than parent drug in orthotopic murine model, probably due to the prolonged retention of
the drug in the lipid bilayers, improving the pharmacokinetic parameters and efficacy profile
[92]. Pegylated liposomal formulation of doxorubicin and gemcitabine showed remarkable
responses in TNBC patients, however adverse effects such as metastasis to the skin have limited
its use [93]. In an attempt of active targeting, integrin α3 that is overexpressed in TNBC models
and is known to cause tumor angiogenesis, proliferation, therapeutic resistance, and poor
prognosis, is attached to the surface of PEG-PCL based liposomes. The authors attach a cyclic
octapeptide LXY (Cys–Asp–Gly–Phe(3,5-DiF)–Gly–Hyp–Asn–Cys) and achieve enhanced
accumulation of co-administered drugs (doxorubicin and rapamycin) at the tumor site, resulting
in improved antitumor efficacy in in vivo TNBC model [94]. Active targeting of eEF-2K which
has shown to cause tumorigenesis and is associated with a poor prognosis in TNBC, by neutral
liposomal siRNA formulation leads to significant inhibition in tumor growth in orthotopic TNBC
mouse model [95]. EndoTAG-1 is a PTX-loaded liposome formulation for targeting the activated
tumor endothelial cells has entered Phase III clinical trial after showing promising results in
contrast to plain drug in TNBC patients [96].
Dendrimers
Dendrimers are repeating branched monomers arising radially from the central core,
formed by the polymerization reaction. These dendrimers are usually 10-100nm in size with an
amphiphilic nature having a hydrophobic core and a hydrophilic outer periphery [97]. Due to the
polyvalent nature of dendrimers like micelles, gene delivery, active targeting can also be possible
by conjugating ligands or imaging compounds. Wang et. al. utilizes a fourth-generation
poly(amidoamine) dendrimers conjugated to antisense oligodeoxynucleotides (AODNs) for
targeting the vascular endothelial growth factor (VEGF) expressed in TNBC cells. The authors
report increase accumulation of dendrimers in TNBC-xenograft mouse model with and a
significant reduction in expression of VEGF, in comparison to unconjugated nanoparticles due to
prolong circulation [98]. Gene delivery using dendrimers was further displayed by Finlay et al.
where a third-generation poly(amidoamine) dendrimer was used to deliver YTZ3-15 that can
knockdown the TWIST1 transcription factor and is associated with aggressive behavior,
metastasis and cellular migration through epithelial-mesenchymal transition (EMT) in TNBC
cells [99].
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Nanoconjugate
Nanoconjugates are nanoplatforms that are covalent complexes that can bind to
multifunctional groups, providing an opportunity to a conjugate peptide(s) of interest such that
cell- or tissue-specific targeting can be achieved [100]. Mittapalli et.al. construct an ultra-small
hyaluronic acid-PTX nanoconjugates of 2-3 nm that can target CD44 receptor located on the
surface of metastatic cancer. CD44 receptor-mediated endocytosis results in 10 folds increase in
cellular uptake and significant improvement in overall survival of animals in a TNBC mouse
model of brain metastasized in contrast to the plain drug [101]. The multifunctionality of
nanoconjugates was further explored and demonstrated when poly (β-L-malic acid) (PLMA)
nanoplatforms was formed by conjugation of a monoclonal antibody (2C5), and for active
targeting: anti-mouse transferrin receptor (TfR) antibody and oligonucleotides (MASONs). This
approach allows active targeting of EGFR-positive TNBC cells, resulting in significant tumor
inhibition via the EGFR pathway thus controlling tumor progression [102]. A similar
nanoconjugate was constructed utilizing PLMA nanoplatforms and produces significant tumor
inhibition with no systemic toxicity in TNBC xenograft mice. This strategy was employed for
active targeting of three oligonucleotides, leading to a significant arrest of EGFR and laminin411 which are known to cause tumor growth and angiogenesis [103, 104]. A folate-drug
nanoconjugate of folic acid and tubulysin B hydrazide (EC1456) entered clinical trial for many
types of aggressive cancer including TNBC subtype [105].
Carbon nanotubes
Carbon tubes are cylindrical structures made from benzene rings and are insoluble in any
solvent and thus can be modified chemically to become water soluble or can be functionalized
with multiple groups. This unique, nanoneedle shaped, monolithic structure allows passive
diffusion to the lipid layer, can be multi-functionalized and can be considered an important drug
carrier for cancer therapeutics [106, 107]. Carbon nanotubes single-walled (around 1-2 nm, one
layer) or multi-walled (around 5-100 nm, multiple layers), depending upon the number of
cylindrical layers. Chemical modification of single-walled carbon nanotubes via an ester bond,
yielded a branched polyethylene glycol chain to which PTX was conjugated to the water-soluble
carbon nanotubes. This conjugate exhibited 10 times higher tumor uptake than the conventional
Taxol® and little toxicity in murine 4T1 breast TNBC model. The improved circulation is
probably because of the PEGylation that resulted in more suppression in tumor growth due to the
enhanced permeation and retention [108]. Another interesting application of these carbon
nanotubes is based on photo thermal-induced ablation, where nanotubes promote cell membrane
permeabilization and necrosis, eliminating both tumor mass and BC stem cells, suggesting this
could be an effective treatment option for tumor resistant and preventing recurrence [109].
Novel Targeting Approaches
Novel techniques such as active targeting by attaching ligands (such as small molecules,
peptides, aptamers, and antibodies) on nanoparticles to specifically recognize and bind to
receptors on target cancer cells, has revolutionized the world of cancer treatment. Such
techniques include conjugating the nano-carrier systems to biomolecules including ligands and
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antibodies [110, 111]. Biological cells such as lymphocytes, macrophages, exosomes,
erythrocytes, platelets are used as whole-cell carriers to carry the drug-loaded nanoparticles and
execute better tumor targeting and potentially destroying the cancer cells (Figure 1-2).
Such strategies would also efficiently minimize off-targeting problems, maximize the
therapeutic window and would ensure maximum survival rate and improve the quality of the
patient’s life. The novel mechanism shows enhanced specificity for cancer cells with minimal
side-effects, increasing the therapeutic efficacy up to 100-fold against drug-resistant cancer stem
cells [111]. The reappearance of cancer after a post-treatment and disease-free period is the result
of inappropriate drug targeting and low cancer selectivity [112, 113]. Thus, the application of
nano-carriers for active targeting in cancer drug delivery will exponentially alleviate the nonspecific accumulation offering enhancement of therapeutic efficiency [110, 114]. The
distinguished physical and chemical properties of nanoparticles make them the appropriate drug
delivery carriers. These include their rigidity, hydrophobicity, size, and charge, that facilitates
their penetration into biological barriers and effectively deliver the drug at tumor sites [115-117].
These approaches have allowed alteration in the pharmacokinetics and biodistribution of the drug
[116]. It is now possible to use chemotherapeutic drugs to specifically target tumor cells by
conjugating them with nanoparticles. The previous issues of poor solubility and low
bioavailability of the conventional anticancer drugs have been overcome by nano-formulating
them [118]. They can not only conjugate the required targeting therapeutic agents but can also
deliver it without compromising its activity [119]. This makes nanotechnology one of the
greatest man-made wonders of recent times. It has changed the face of diagnosis and treatment of
fatal diseases.
Hematopoietic Stem Cells as Carrier for Targeted Delivery
The remarkable characteristics of hematopoietic stem cells give rise to other blood cells.
It makes them an appropriate fit for an efficient drug delivery system in nanomedicine. These
blood cells can be broadly divided into three main categories: Erythrocytes (RBCs), Leukocytes
(WBCs), and Thrombocytes (platelets). These hemocytes play an important role in the defense
mechanism of the body against a wide range of pathogens and foreign particles. Drug delivery
systems should achieve maximum therapeutic efficacy and minimal side effects to be considered
as potential treatment modalities. Thus, the biological drug delivery system (using blood cells as
drug carriers) ensures the biocompatibility and biodegradability of the nanoparticle-loaded cell
carriers. The biochemical characteristics favor the non-immunogenicity of blood cells
guaranteeing successful drug delivery at target sites [120]. Thus blood cells serve as the natural
biological carriers that can bypass the immune surveillance and efficiently deliver the drugs to
target cells [121]. Some of the hematopoietic stem cells based nanocarriers that have shown
clinical potential in various cancer model has been summarized in Table 1-2.
Erythrocytes
Erythrocytes or red blood cells (RBCs) are the ideal biological carriers for nanomedicine
that can operate without inducing immunological response and provide numerous advantages
such as long circulation time, abundant surface ligands, and flexible morphology. RBCs are the
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Figure 1-2. Schematic illustration of the preparation of cell membrane coated
nanoparticles
An array of various techniques that could be employed to isolate membranes isolated from the
source cells by different methods: sonication, freeze-thaw method, extrusion by differential
centrifugation, hypotonic lysis buffer and/or Dounce homogenization to finally generate the
empty cell membrane vesicles.
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Table 1-2.
PTX-based cell membrane coated nanoparticles for therapeutic efficiency/
targeting cancer
Cell
type
Lymphocytes
membrane

Nanoparticle
core
Membrane coated on
PLGA nanoparticles,
low-dose irradiation.

Intended
use
Subcutaneous
model using:
MKN45 cells.

Targeted cancer type and benefits
achieved
Nanoparticles caused 56.68% tumor
inhibition, liver accumulation in 96 hours
while LDI caused more tumor
accumulation with ~89% tumor inhibition.

Ref.

Monocytes

pH-responsive
amphiphilic
copolymer,
polyethylene glycolblock-poly[(1,4butanediol)diacrylate-ß-N,Ndiisopropylethyl
-enediamine] (PDB)
and phagocyting this
in Ly6Chi monocyte
isolated from
peripheral blood.
pH sensitive polymer
cationic 2aminoethyldiisopropy
l with IGF1R
targeting peptide,
after PEGylation and
macrophage
membrane.

Metastatic
4T1 BC.

[123]

Platelet
membrane

A synthetic peptide
with dendritic
disulfide conjugate of
PTX coupled with
PEG via click
reaction, to yield a
redox-responsive
micelle that could
capture internal
activated platelets

Xenograft
TNBC
tumors:
MDA-MB231 cells.

Platelet
membrane

Nanogel with TNFα, RGD peptide
(Nanoparticle1).
Dextran nanoparticles
with coated with
platelet membrane
with PTX
(Nanoparticle2)

TNBC tumor
using MDAMB-231 cells.

2 folds increase in tumor accumulation
was observed with the monocyte loaded
nanoparticles, with relatively less
nonspecific uptake in lung and liver,
compared to blank nanoparticles (no
monocytes). Also, highest AUC was
observed 7.20-folds higher than PTX, with
highest tumor suppression of 96.8% over
only 50.4% inhibition was attained with
nanoparticles (without monocytes). Also,
lung metastasis decreased by 99.2% with
these nanoparticles, over 50% decrease
with non-monocytes nanoparticles.
Significantly tumor accumulation and
towards the center of the tumor was
achieved, relative to group without the
non-pH sensitive polymer and without
macrophage coating, due to membrane
coated tumor homing effect and pHsensitive drug release by the polymer. The
peptide also enhanced the fluorescence
intensity due to IGF1R mediated uptake
pathway.
The micelles were recruited to the surface
of the activated platelets, due to
overexpression of P-selectin on the
platelets and adhere to it.
Relative to PTX these targeted micelle
exhibits enhanced targeting to the primary
TNBC tumors as well as lung and liver
metastasis. This is due to the interaction
between activated platelets and ICAM
overexpressed at the metastatic sites, by
tumor cell receptor-targeting strategies.
Nanoparticle1 induces tumor vascular
inflammation and RGD peptide caused
significant accumulation in the tumor by 5
folds, relative to nanoparticles without
RGD. Whereas nanoparticle2 cause greater
tumor accumulation by 5 folds relative to
the nanoparticles without coating.

Macrophage
membrane

orthotopic
BC: MDAMB-231 cells.
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Table 1-2.

(Continued)

Cell
type
RBC
membrane

Nanoparticle
core
Thermo-responsive
hybrid nanoparticle
composed of
poly(caprolactone)ester endcap polymer
(PCL),
dipalmitoylphosphati
dylcholine (DPPC)
poloxamer 188 and
membrane coating.

Intended
use
4T1
orthotropic
tumor
mimicking
metastasis BC.

Targeted cancer type and benefits
achieved
A 12.3, 2.6- and 3-folds increase of
fluorescent dye (DiR) at the tumors, liver
and lung metastasized sites, respectively in
comparison to free DiR. 69.2% and 12.6%
tumor inhibition were achieved by the
nanoparticles, PTX respectively, in
comparison to control. Also, 98.6% lung
metastasis was achieved.

Ref.

RBC
membrane

PCL, poloxamer 188,
co-administrated with
the tumor penetrating
peptide, iRGD and
membrane coating.

Metastatic
4T1 breast
tumor model.

The half time of the cell membrane
nanoparticles was 32.8 hours (5.8 and 16.9
folds higher than that of polymeric
nanoparticles and Taxol, respectively).
These nanoparticles in combination with
iRGD yield 2.89, 3.02 folds higher tumor
fluorescence uptake, 90% tumor growth
inhibition and 94.8% lung metastasis were
achieved. All comparisons were with
uncoated nanoparticles with iRGD and cell
membrane nanoparticles (without iRGD).

[128]

RBC
membrane

Ferric oxide (Fe3O4)
and O-carboxymethyl
chitosan (CMC)
nanoparticles coencapsulated PTX
and doxorubicin with
Arg-Gly-Asp (RGD)
and membrane
coating.

Subcutaneous
xenograft
model of lung
carcinoma.

Synergistic effect of RBC membrane
magnetic nanoparticles and RGD ligand,
on the application of magnetic field,
increased fluorescent uptake at the excised
tumors by ~17 times and significant tumor
reduction in contrast to naked
nanoparticles (without membrane coating
and RGD).

[129]

RBC
membrane

DSPE-PEG-MAL
coupled with tumorpenetrating bispecific
recombinant protein
(anti-EGFR-iRGD)
with RBC membrane
coating.

Subcutaneous
tumors of
gastric cancer
cells: MKN45.

RBC membrane coating prolonged
nanoparticle circulation in the tumors from
2-48 hours. The synergistic effect of antiEGFR-iRGD along with membrane coated
nanoparticles caused tumor inhibition by
61% in contrast to only 21% inhibition
with the PTX, relative to the control.

[130]

RBC
membrane

pH sensitive poly (Lγglutamylcarbocistein)
-nanoparticles
wrapped with RBC
membrane.

Subcutaneous
tumors of lung
cancer cells
NCI-H460.

AUC for 72 hours was 2.44 folds higher
with RBC coating nanoparticles, relative to
non-coated nanoparticles (2082 and 850.2
respectively). Similarly, stronger tumor
inhibition was observed.

[131]
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Table 1-2.

(Continued)

Cell
type
RBC
membrane

Nanoparticle
core
RBC membrane
coated nanoparticles.

Intended
use
Mammalian
intestinal
mucosal cells
(MDCKMDR1)

Neutrophil

CXCL1 chemokine
laden thermosensitive
hydrogel of PLGAPEG-PLGA
nanoparticles,
encapsulated by the
endogenous
neutrophils.

B16F10
murine
melanoma
cells.

Neutrophil

Cationic liposomes
made of 1,5dioctadecyl-Nhistidyl-L-glutamate
(HG2C18),
internalized in mouse
bone marrow derived
neutrophils.

G422
glioblastoma
cells.

Neutrophil

Commercially
available PTX
formulation:
Abraxane dispersed
within human NEs in
combination with
radiotherapy by 5Gy.

Gastric
cancer:
SNU719
tumor-bearing
mice.
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Targeted cancer type and benefits
achieved
Permeability was enhanced by 3.5-& 16.2
folds than free PTX in MDCK-MDR1 cell
monolayers and intestinal mucosa,
respectively. The presence of the RBC
membrane prolonged the circulation time
by increasing the mean residence time of
the nanoparticles by 1.81 folds, AUC by
14.2 folds and Cmax by 6 folds, relative to
free PTX.
Neutrophils sequester the nanoparticles
and in 8 hours shows 82.2% uptake
implying viability of neutrophils were not
affected by the PTX loaded nanoparticles.
Fluorescent dye (DiD)increased
significantly at the tumor site with CXCL1
from 1-8hours, unlike without the CXCL1
group, suggesting the presence of the
chemokine was primarily causing
recruitment of the neutrophil loaded
nanoparticles. Synergistic effect of
CXCL1 and neutrophil loaded
nanoparticles caused the most tumor
inhibition of 67.28%, 2.13 folds higher
without the CXCL1 group (46.95%).
Highest fluorescent intensity of DiR dye
was observed with neutrophil
nanoparticles in the tumor region of the
brain collected from surgically treated
glioma tumors. The nanoparticles migrated
to the infiltrating glioma cells GFP-G422
cells, up to 96 hours, suggesting enhanced
targeting due to neutrophil which causes
inflammatory response after surgery.
AUCbrain was the highest suggesting
highest targeting efficiency due to
neutrophils.
Tumor reduction was maximum when
radiotherapy and neutrophil nanoparticles
were combined. The radiation disrupts the
tumor and allows the neutrophils to be
homed at the tumor site, due to the release
of inflammatory cytokines. Radiation
therapy with only neutrophil (no
nanoparticle) did not produce any
significant anti-tumor effect.

Ref.
[132]

[133]

[134]

[135]

most abundant cells in the blood, comprising almost a quarter of the total volume, performing the
crucial role of transporting oxygen and carbon dioxide throughout the body. Its unique
physiological characteristics make them natural and versatile carriers and are applied to enhance
the specificity of therapeutics and to alleviate the negative effects through the controlled delivery
of targeting and releasing agents. These biconcave discoid cells have a diameter of 7μm which is
responsible for its high drug loading capacity. Upon maturation, RBCs lose their nucleus and
other organelles to increase its surface area manifold. Being enucleate, RBCs become suitable
carriers for drugs that are targeted to the nuclei of diseased cells. Their half-life of over 100 days,
distinguished macromolecular structures portrays their potential as drug delivery systems. The
presence of carbohydrates, proteins, and phospholipids on the outer member layer provides
stability and deformability allowing cells to target extremely small vascular structures. [136].
The erythrocyte membrane simultaneously undergoes reversible changes between expanded and
tight networks to maintain its structural integrity. This process of avoiding intravascular
hemolysis is governed by the cytoskeleton structures of the RBC membrane [137]. The novel
drug delivery system involves the transient, controlled opening of the RBC membrane, the
encapsulation of the nano-carrier loaded anti-cancer drugs, and the subsequent resealing of the
outer membrane.
The application of erythrocytes as drug delivery vehicles in cancer treatment has been
extensively investigated because of its main biochemical and physiological propensities: minimal
toxicity, high drug loading capacity, slow molecular release, biocompatibility, and reduction of
immune reaction ions. It encapsulates anti-cancer drugs such as daunorubicin for leukemia
treatment, 5-fluorouracil (methotrexate) [123], and l-Asparaginase (l-ASNase) [86]. Erythrocytes
encapsulate and protect l-ASNase from degradation and reduce the severity of side effects and
exhibits longer half-life. Thus, increasing the efficiency ten-fold than native l-ASNase in the
treatment of asparagine synthetase-deficient acute myeloid lymphoblastic leukemia. Here,
asparaginase-loaded RBCs serve as ‘bio-reactors’ to deplete asparagine, an amino acid required
for cancer cell growth, from the blood with a tendency of low coagulation disorders and
minimum allergic reactions [124].
Methotrexate (MTX) is an antimetabolite and antifolate agent used in solid tumors and
hematological diseases. MTX-loaded erythrocyte treatment increases the average survival time
of mice bearing hepatoma ascites tumors by 28.5-42.8% than native MTX. This implies the use
of RBCs as a drug delivery system for chemotherapeutic agents, especially in vitro and in vivo
use of antineoplastic agents [138]. The application of whole cells RBC in drug delivery is
myriad, even ranging from loading RBC with Au nanoparticles and are exposed to a nearinfrared laser, the permeability of the membrane increases which allows site-specific drug
release. Magnetic targeting using an external magnetic field was applied to doxorubicin-loaded
RBCs which are bound to iron-oxide nanoparticles pre-coated with a photosensitizer in the
chemotherapy of cancer [139]. The modification of the pharmacokinetic and pharmacodynamics
parameters of the drug by carrier erythrocytes maintains a relatively inert intracellular
environment, decreased fluctuations in concentration, reduces drug side effects. Thus, the
molecular mechanisms of erythrocytes make them perfect candidates as carriers of convention
and new anti-cancer drugs [137].
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Leukocytes
White blood cells (WBCs) or leukocytes are an integral part of the innate immune system
of the body in response to pathogen invasion. When tissue damage, bacterial and viral infections
occur, leukocytes are deployed in circulation to combat those changes. Therefore, inflammation
can be defined as a defense mechanism of the body to fight foreign invaders (physical, chemical,
antigens) and maintain homeostasis [140]. Owing to their aiming movement and transmigration
ability, leukocytes are specifically targeted to deliver nanotherapeutics into diseased tissues. The
pathogenesis of most types of cancers is in correlation to uncontrolled inflammation. Thus,
hijacking leukocytes and deploying them as delivery vehicles to transport anti-cancer
therapeutics across blood vessel barriers directly to the tumor microenvironment [78-80].
Neutrophils
Neutrophils are first-line defenders arriving at the inflammatory site migrating across the
endothelial layer, known as the neutrophil transmigration, to fight pathogens and initiate a phase
of repair. They are the most abundant white blood cells (50-70%) in humans and are thus
excellent candidates as carriers for targeted drug delivery. Neutrophils are associated with tumor
progression as well as tumor inhibition. These neutrophils that infiltrate tumor sites are called
tumor-associated neutrophils (TANs) [141]. The recruitment of TANs is mediated by their
surface protein composition and chemokine activity. They are phenotypically distinct from
normal circulating neutrophils. They can be of two types: Pro-tumorigenic (N2) TANs (produced
in the tumor microenvironment) and anti-tumorigenic (N1) TANs (ability to kill tumor cells).
Targeting these neutrophils would allow better specificity and enhanced therapeutic efficacy of
anti-cancer nanotherapeutics [96].
IL-8 is associated with numerous pro-tumor pathways, thus serves as an excellent target
for treatment via blocking its function. Preclinical tests involving IL-8 antagonists have shown
reduced tumor growth, angiogenesis, metastasis, and increased tumor cell apoptosis [84-87].
Studies have shown that inhibition of BM and ECM breakdowns by TANs derived NE and
MMP-9 can dramatically reduce tumor angiogenesis and lung adenocarcinoma in a murine
model [88]. In another study, the successful downregulation of a murine model tumor ICAM-1
expression via shRNA reduced colorectal adenocarcinoma by 45%. In cancer treatments, where
surgical resection has negative outcomes, anti-TAN therapy serves a potential approach with
higher disease-free survival rates [89,90]. In a recent study, Chu et al demonstrated gold
nanorods (GNRs) linked with anti-CD11b Abs were able to exponentially decrease tumor growth
and increased survival rates in a lung carcinoma model of mice. Photothermal therapy was
undertaken as the therapeutic method because GNRs can absorb infrared light to generate local
heat to destroy the tumor [91]. In one of their previous studies, they combined TA99 monoclonal
antibodies and albumin nanoparticles to treat melanoma in a mouse model. This was achieved
through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), wherein the
albumin NPs were loaded with photodynamic therapy (PDT) agents which activated the
infiltration of neutrophils into tumor sites markedly reducing tumor growth and thus emerging as
a novel strategy for immunotherapy in cancer treatment [92]. Neutrophils have been heavily
employed as immune cell carriers for delivering nanoparticles to inflammation sites. For
example, piceatannol-loaded and TCPA-1/cefoperazone acid-loaded albumin nanoparticles with
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neutrophils as delivery vehicles are used as treatment approaches for acute lung injury and
pyropheophorbide-a loaded albumin nanoparticles are targeted against melanoma [80].
Therefore, neutrophil-mediated delivery of nanotherapeutics has immense potential to
dramatically increase target specificity, therapeutic efficacy, and provide a translational effect.
Their intrinsic properties of transmigration, ability to infiltrate in huge numbers in response to
inflammation, and their first responder nature makes them appropriate biological carriers to
deliver nanotherapeutics [80].
Monocytes/Macrophages
Monocytes are an integral part of immune-oncology with the unique characteristic to be
able to differentiate into tissue macrophage, known as tumor-associated macrophages (TAMs),
after crossing the endothelial barrier. The ability of TAMs to reach the hypoxic areas of tumor
microenvironment makes them excellent targets for a biometric delivery system (BDS). TAMs
constitute 70% of the cell mass in breast carcinoma and can be classified into M1 and M2 types.
M2-like macrophages are responsible for tumor growth and progression whereas M1 phenotype
is associated with killing tumor cells. Owing to their innate phagocytotic capability, monocytes
can be loaded with a variety of nanotherapeutics and serve as “Trojan Horse” delivery vehicles
reaching otherwise inaccessible tumor regions. Once these cells reach the tumor sites, they
differentiate into macrophages and their nanoparticle-based therapeutic function could be
initiated by near-infrared (NIR) illumination, henceforth destroying the TAMs associated with
tumor metastasis [80, 93-96]. In a recent study, Choi et al demonstrated that the tumor’s natural
recruitment of monocytes may be exploited for nanoparticle-based drug delivery and
therapeutics. To avoid any harm to surrounding cellular entities of the host, the drug was loaded
in Au nanoshells, nanoparticles consisting of a silica core surrounded by a thin Au shell. Human
breast tumor spheroids (T47D) were utilized as a model to examine the therapeutic efficacy and
cellular uptake of the Au nanoshells. Photothermal therapy was used and it was observed that
tumor cell death resulted in incident laser powers above a certain threshold. They successfully
demonstrated the potential of monocytes as delivery vehicles into hypoxic tumors and
established a foundation for a novel drug delivery system [97].
Poor efficiency of conventional drug delivery systems into the sites of metastases leads to
high mortality rates of BC. In a study about anti-metastasis therapy, He et al demonstrated that
loading legumain-activated nanoparticles into inflammatory monocytes can actively target lung
metastases of BC and inhibit tumor progression. The cytotoxic anti-cancer drug of mertansine is
conjugated to poly (styrene-co-maleic anhydride) with a legumain-sensitive peptide and selfassembled into nanoparticles (SMNs) and then loaded into Ly6c+ inflammatory monocytes to
prepare the SMNs loaded monocytes delivery system (M-SMNs). In this biometric delivery
system, the SMNs would remain inactive until they come in contact with the metastatic niche.
This prevents early drug release and ensures the living state of monocytes which is required for
the efficient anti-metastatic effect. Upon reaching the tumor microenvironment, the monocytes
differentiate into macrophages to release the anti-cancer drug as free drug molecules by
destroying the macrophages. The study shows plausible evidence of inhibition of the
proliferation, migration, and invasion activities of metastatic 4T1 BC cells [98].
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In another study by Fu et. al., a biometric delivery system (BDS) was established using a
mouse macrophage-like cell line to demonstrate the anti-cancer efficacy of lung metastasis of BC
(4T1 cells). A mouse macrophage-like cell line (RAW265.7) with similar functions to primary
macrophage cells were used as delivery vehicles and loaded with doxorubicin (DOX) to serve as
an anti-cancer BDS. The DOX loaded macrophage system showed tumor suppression, metastasis
inhibition, with an increased life span of the host and reduced toxicity to other healthy tissues
and organs as compared to their control groups. Thus, DOX encapsulating macrophages proved
to be an efficient delivery system into tumor sites and showed an enhanced therapeutic effect by
inhibiting tumor growth to a great extent [142]. Exploiting autologous macrophages (MΦ) for
anti-cancer therapy has been developed in the late 20th century and it still has unexplored areas to
venture upon. Tumors, however, promote normal MΦ functions of tissue repair, resulting in
tumor growth, over inflammatory responses. in the tumor microenvironment, the replacement of
MΦ with genetically engineered monocytes or drug-loaded monocytes can be potential delivery
vehicles for nanotherapeutics. The encapsulation of drugs in MΦ has an added advantage of an
extended half-life, protected from clearance by the endogenous RES system. The multi-faceted
benefits of utilizing MΦ as delivery vehicles have been demonstrated in a study by Escobar et al.
They used a spontaneous BC mouse model (MMTV-PyMT), wherein they performed
hematopoietic stem cell transplants with selective expression of IFNα in TIE2+ tumor-associated
MΦs in the model. The highly localized TIE2+-MΦ-mediated delivery of IFNα reduced lung
metastatic areas 5-fold and primary tumor size 3-fold without apparent toxic effects to the host
organism. The plasticity and versatility of autologous macrophages make them ideal candidates
for novel drug delivery systems to enhance the specificity of cell therapeutics [100-102].
Thrombocytes
Platelets are anucleated, small subcellular fragments of megakaryocytes with a half-life
of 7-10 days that circulate in the bloodstream and are activated during a vascular endothelial
dysfunction or damage [103]. They are associated with inflammatory cells and play a central role
in the cancer microenvironment by cell-cell communication and ability to uptake a plethora of
different molecules [104-106]. Activated platelets are key contributors to tumorigenesis,
metastasis, tumor growth, and angiogenesis. B-thromboglobin and P-selectin, markers of platelet
activation, are abundant in patients with BC, suggesting tumor cell-induced platelet aggregation
(TCIPA) [107]. Once activated, these platelets facilitate cancer cell survival and their adhesion to
the endothelium. Thus, tumor-associated platelets can be potential therapeutic targets and serve
as effective delivery vehicles in anti-cancer treatment modalities [107,108].
Targeting specific platelet receptors and tumor-associated platelets has become an
emergent field of delivery of anti-tumor therapeutics. Zhang et. al. designed a biocompatible
liposomal nanoparticle with a tumor-homing peptide on the surface and loaded with the
reversible platelet inhibitor ticagrelor, known as CREKA-Lipo-T, to demonstrate its ability to
block tumor cell acquisition of an invasive phenotype and tumor cell adhesion of platelets. They
showed target specificity and therapeutic efficiency of CREKA-Lipo-T with respect to 4T1 solid
tumors and established a promising nanoparticle drug delivery system for anti-cancer therapy
[109]. In another study by the same group, they constructed a polymer-lipid-peptide-based drug
delivery system (comprised of matrix metalloproteinase 2 (MMP2)-cleavable peptides, lecithins,
and PEGylated phospholipids to form an enzyme-responsive drug release known as PLP-D-R) to
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co-deliver a platelet-depleting antibody (R300) and chemotherapeutic drug (Dox). They
successfully demonstrated the anti-cancer efficacy of PLP-D-R in an MCF7 tumor-bearing nude
mouse model that showed enhanced tumor suppression with minimal bleeding complications.
Moreover, they also showed enhanced nanoparticle retention (almost thrice as compared to
control groups), tumor regression, and metastasis inhibition in tumor-associated platelet depleted
models of mice [110,111].
Novel strategies involving anti-platelet therapeutics are gathering momentum and
emerging as an alternative approach to conventional anti-cancer modalities. In a recent study,
Guillem-Llobat et. al. demonstrated that the administration of low-dose aspirin, a member of
nonsteroidal anti-inflammatory drugs (NSAIDs) which inhibits prostanoid biosynthesis by
inhibiting the action of COX-1 and COX-2, reduced the formation of lung metastases [112]. In
another study by Wang et. al., it was shown that in P2Y12-deficient mice, which is an ADP
platelet receptor, the co-administration of the drug clopidogrel with aspirin attenuates the
development of hepatocarcinoma and improves survival rates of the host [113]. In a murine
model of lung cancer, Nierodzik et. al. demonstrated how blocking the platelet GPIIb/IIIa
receptor, using the monoclonal antibody 10E5, prevented the cells from metastasizing [114]. In
another study about BC treatment, the curative effect of heparin and fondaparinux against tumor
cells was demonstrated. They achieved this by indirect inhibition of thrombin and Factor Xa,
thereby inhibiting the activation of platelets by BC cells [115]. A study exploiting the utilization
of platelet interactions with pro-metastatic BC cells to develop a platelet-inspired nano vehicle
system for targeted delivery of the anti-cancer drug DOX. Pan et al designed a liposomal nano
construct that can bind simultaneously to GPIIb-IIa like integrins and P-selectin on the highmetastatic MDA-MB-231 human BC cells. They successfully achieved their goal of killing the
tumor cells and enhanced the therapeutic efficiency by their platelet-inspired metastasis-targeted
drug delivery approach [116]. All the above studies establish the potential of utilizing platelets as
delivery vehicles and the promising future of platelet-inspired anti-cancer therapeutics.
Cell-Membrane Coated Nanoparticles for Targeted Delivery
Cell membranes isolated from the parent cell are subjected to a continuous process, to
isolate the various cellular components. Cells are previously treated with hypotonic buffer under
the protection of protease inhibitor are followed by series of ultracentrifugation. This enables the
removal of cell contents, including enzymes, nucleus and other cellular components. The
membranes are then coated on the surface of the nanoparticle core, via extrusion, sonication
and/or electroporation techniques (Figure 1-3). The membranes impart a double layer, owing to
the structure of the lipid bilayer and are about 50-800 nm in size [143, 144]. The transmembrane
proteins and all the relevant membrane-bound antigen required for imparting a biological
characteristic are preserved on the cell membrane, with no loss in functionality during or after
translocating the membrane onto the surface of the nanoparticles [145]. This allows the
nanoparticles to be camouflaged by the cell membranes, preventing degradation by the patient’s
immune system [146]. The cell membrane coated nanoparticles can interact with cells of the
targeted site, due to the presence of receptors, originated from the derived parent cells that make
them able to deliver therapeutics at these targeted sites [147]. Thus these coated nanoparticles
offer advantages in contrast to plain nanoparticles, such as i) prolonged circulation [148]
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Figure 1-3. Strategies to coat the surface of nanoparticles with cell membrane coating
Different types of source cells are employed to generate empty cell membrane nanovesicles that
are extracted from either Erythrocytes/RBC, Leukocytes: neutrophils, monocytes/macrophages,
T-lymphocytes, Thrombocytes/platelets, Mesenchymal stem cells, Cancer cells. These
membrane-derived vesicles retain the surface protein, antigens from the source cells when coated
on the surface of nanoparticles, can directly target or bind to the target site of cancer.
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ii) cell targeting [149], iii) circumventing the immune system clearance [150], iv) detoxification
[151], v) mediating intracellular communications via endocytosis, which can be used to deliver
microRNA, mRNA [152, 153]. However, scalability, production, isolation of these membranes
for a bulk manufacturing process needs to be addressed for better clinical applications.
Erythrocyte membrane-coated nanoparticles
Erythrocytes are the most common cell component with a unique biconcave discoidal
shape of approximately 7–8 μm diameter, allowing a large volume of therapeutic cargo to be
loaded. They bear high mechanical flexibility allowing them to be able to squeeze through very
small blood capillaries even when maintaining the constant surface area. It can circulate for
approximately 120 days and eventually clearance by the RES [154]. Additionally, they prevent
unwanted macrophage uptake, provides specificity to the target, extend biocompatibility,
biodegradability and non-immunogenic nature, limits activation of other competitor cellular
components [155]. Erythrocytes membrane coated nanoparticles are prepared by extracting the
membrane from the cellular components, yet preserving their original protein antigens, that
provides the innate natural targeting ability. Researchers have utilized hypotonic solution to
extract the cellular contents and used the membrane to coat PLGA polymer nanoparticles and
demonstrated the prolonged circulation of 72 hours over non coated PLGA nanoparticles [148]
and suppress 98% lung metastasis in metastatic BC model [127]. Su et al. demonstrated similar
results, erythrocytes membrane coated PLGA nanoparticles prolong circulation due to protein
receptors present on the surface of these membranes and also in combination with integrating
iRGD that provide specific targeting of metastatic breast tumor model. The authors show
inhibition of more than 90% tumor growth and 95% of the lung metastasis with these
nanoparticles as they can escape clearance by RES and circulate longer.
Additionally, the presence of tumor penetrating peptide iRGD serves as a receptor for
lung metastatic sites that overexpress αvβ3 integrin and neuropilin-1, which allows the
nanoparticle to specifically target and penetrate tumors. The authors also report enhanced
retention of membrane coated nanoparticles at the metastatic regions, without the iRGD peptide,
indicating the innate tendency of the erythrocytes membrane proteins to accumulate near the
metastatic and tumor region [128]. Guo et. al. developed a nano vaccine utilizing the ability of
erythrocytes coated nanoparticles to target antigen-presenting cells (especially dendritic cells) for
induction of cytotoxic T lymphocyte-mediated response against tumors. The authors developed
PLGA nanoparticles, coated with erythrocyte membrane entraps melanoma-associated antigenic
peptide and targets dendritic cells because of their ability to specifically target tumor antigens
that promote secretion of pro-inflammatory cytokines such as TNF-α and IFN-γ and causes
enhanced CD8+ T-cell response. This novel antigenic peptide delivery system retarded tumor
growth and suppressed tumor metastasis in a prophylactic, therapeutic, and metastatic melanoma
model. This illustrates the possibility of using erythrocytes derived membranes in the
development of biomimetic nanoparticles to demonstrate tumor-specific immune response [156].
Hybrid nanoparticle infusing two types of bioinspired membranes: erythrocytes and platelets for
prolonging circulation time and the other for expression of adhesion proteins, respectively which
increases site-specific targetability and prevents unwanted macrophage uptake This study
demonstrates the ability of fusing two different types of cell membrane into one nanoparticle
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construct that will possess individual properties of each type of membrane and the endless
number of possibilities that could be further explored [157].
Neutrophil membrane-formed nanoparticles
Neutrophils are the most commonly found leukocytes in humans. They are the first
immune cells that migrate to any infected site caused by bacteria and virus, to prevent the
pathogens from spreading, by the release of cytokines/chemokines and ROS production. This
response is called acute inflammation and involves neutrophil infiltration, which is regulated by
intercellular interaction due to the presence of adhesion molecules on the neutrophils and
vascular endothelium [158]. For example, researchers have demonstrated how activated
neutrophils which express integrin β2 binds to the inflamed vasculature that overexpress ICAM-1
[159]. A similar approach of conjugating nanoparticles to anti-ICAM-1 has also been explored
by various researchers, however, the conjugation process did not show significant targeting
improvement due to the complex tumor microenvironment [160]. Also, the cost ineffectiveness
makes this strategy less useful and makes avenue for exploring the other potential options for
novel targeting approach, such as cell membrane-based or whole-cell nanoparticles. Gao et.
al.[161] shows how human leukemia HL-60 cells was utilized for generating nanovesicles by
nitrogen cavitation method, which highly express integrin β2 and binds to the inflamed vascular
endothelium due to the overexpression of ICAM-1 on them. The authors loaded the nanovesicles
with an anti-inflammatory drug (TPCA-1) to show the ability of these nanovesicles to reduce the
expression of cytokines TNF-α and IL-6, demonstrating their ability to bind to the inflamed
vasculature and producing an anti-inflammatory effect. Red blood cells were used as control to
generate nanovesicles that lacked the expression of integrin β2 and does not bind to the
endothelium, elucidating the utilization of neutrophils to deliver therapeutics specifically at
inflamed vasculature. Another similar study was demonstrated by Kang et. al. [71] utilizing
polymeric nanoparticles coated with the neutrophil membrane to target tumor vasculature and
metastatic tumor cells in 4T1 BC with lung metastasis model. The authors demonstrate PLGA
nanoparticles when coated with neutrophil membrane and loaded with carfilzomib, a proteasome
inhibitor targets the circulating tumor cells or the metastatic niche and the inflamed endothelium.
Thus, demonstrating the potential of polymeric nanoparticle coated with neutrophil membrane
can be used to inhibit early metastasis and preformed metastasis.
Monocyte-derived nanoparticles
Monocytes are circulating white blood cells and play a crucial role in the inflammatory
response and represent around 10% of leukocytes. They differentiate into macrophages or
dendritic cells, with the latter mainly occurring during the active infection [162]. They also have
similar roles as neutrophils and platelets in maintain homeostasis and inflammatory response.
Monocytes have 1-3 days half-life and could be exploited due to their intrinsic targeting ability
especially at the inflamed vasculature or injury site [163]. Researchers have explored monocytes
derived nanovesicles and have shown that these serve as better drug delivery tools over drugloaded exosomes for various disease conditions. Jang et.al. loaded doxorubicin in exosome
derived nanovesicles and show similar inhibition in tumor growth as a 20-fold higher dose of the
same drug without causing any systemic adverse effects. The exosomes nanovesicles possess
counter receptors such as LFA-1 that has specificity for cell adhesion molecules such as ICAM-
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1, VCAM-1 and E-selectin that is overexpressed on the inflamed endothelium cells, enabling the
monocytes to target the circulating cells causing the maximal release of the therapeutic cargo at
the targeted site [164]. On a similar approach, PLGA nanoparticles loaded with doxorubicin and
coated with monocytes that express α4β1 integrin and binds to the cell adhesion molecules such
as VCAM-1 that is overexpressed on the metastatic cancer cells have also been explored [165].
Further application of monocytes derived vesicles for the theranostic purpose has also been
explored and has shown to cause significantly higher brain uptake of 5 hours over non coated
nanoparticles [166]. This type of construct has also been explored for delivery of siRNA and
RNAi, due to the failed attempts to deliver naked RNA which gets degraded and cannot pass
through the membranes to make it to the targeted site. Thus, this construct has improved delivery
of RNA molecules which further can go through the process of RNA interference and suppress
overexpressed oncogenes especially in cancer [167, 168]. The ability of circulating monocytes to
target tumor cells due to the expression of protein molecules on the surface of these monocytes,
make them specific to the cells that prevent cancer progression, metastasis, angiogenesis,
invasion, migration, and resistance to chemotherapy [169].
Platelet membrane-coated nanoparticles
Platelets are small, non-nucleated cytoplasmic body that is present actively circulating in
the blood. They express a wide variety of immune cell receptors and adhesion molecules on their
surface, responsible for mediating immune response. The platelets have the unique ability to be
recruited instantaneously at the site of injury or after an infection which allows them to bind to
the antigens and release blood clotting factors that would heal the wound. The presence of these
various protein antigens on their surface allows immunomodulatory and cell adhesion capability.
Researchers have utilized platelet membrane coated PLGA nanoparticles in two disease models
of coronary restenosis and systemic bacterial infection to deliver docetaxel and vancomycin,
respectively. Enhanced therapeutic efficacy was achieved via these novel biomembranes inspired
polymeric nanoparticles contrast to uncoated nanoparticles. Also, the authors demonstrate the
coating shields the polymeric nanoparticles from unwantedly up taken by macrophages, thus
enhancing nanoparticle deposition at the target site [170]. Doxorubicin loaded in platelet coated
liposomes with two peptides: GPIIb-IIIa-like integrins and P-selectins expressed on their surface.
This construct shows enhanced targetability to bind and destroy specifically metastatic BC cells
over nonmetastatic BC cells in in vitro and in vivo models [171]. Platelet coated PLGA
nanoparticles that have overexpression of P-selectin was also used to deliver tumor-specific
apoptosis-inducing ligand cytokine (TRAIL) and doxorubicin to tumor cells due to specificity for
CD44 receptors, expressed on the surface of tumor cells. Due to the enhanced targetability
between the platelet membrane and cancer cells, the therapeutic efficacy of TRAIL due to
activated extrinsic apoptosis is enhanced resulting in increased apoptosis. This way the authors
synergistically deliver active therapeutics to the tumor cells by targeting via both intrinsic and
extrinsic pathways, eliminating metastatic cells too [172]. Similar approaches were made by
synthesizing silica nanoparticles that were further functionalized with activated platelet
membranes and decorated with tumor-specific peptides such as TRAIL. This construct was able
to specifically target circulating tumor cells and prevents unwanted phagocytosis, due to the
expression of CD47 on the surface of the activated platelets that extends the half-life of the
nanoparticles. This targeting strategy binds to circulating metastatic cells and shows significant
decrease of lung metastases in metastatic orthotopic BC mouse model [173].
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Platelets coated magnetic nanoparticles were applied for theranostic applications for both
cancer therapy and cancer diagnosis. The authors, fabricated Fe3O4 nanoparticles coated with
platelet membranes that express protein moieties which allows longer circulation and prevents
immunogenicity. The application of magnetic nanoparticles allows optical absorption that
extends tumor magnetic resonance imaging (MRI) ability and photothermal therapy (PTT).
Additionally, PTT allows enhanced tumor targetability along with intrinsic targeting ability from
the membrane proteins of the platelets also reducing macrophage uptake. Thus this strategy
provides the application of bioinspired nanoparticle for personalized medicine in various disease
state [174].
Paclitaxel
History
Paclitaxel (PTX) is one of the most common and potent chemotherapeutic agents for the
treatment of several types of cancer including BC. It belongs to the taxane family and was first
discovered in 1960’s from the bark of Pacific yew (Taxus brevifolia) in a plant screening
program initiated by the National Cancer Institute (NCI) of the United States. Later in 1971,
scientists named it Taxol and later the chemical structure was explained [175]. In 1979, the
mechanism of action of PTX was discovered by Susan Horwitz as a microtubule stabilizing
agent [176]. After showing somewhat promising results in in vivo mouse tumor models in 1978,
PTX entered clinical trials for the first time in 1984 [177]. PTX was commercialized by BristolMyers Squibb and attained the trademark name “Taxol®” and was assigned the generic name
“PTX” Taxol®, so far in history is the most profitable chemotherapeutic drug and the only drug
to be selected from plant screening program [177, 178]. Initially, PTX was extracted from Taxus
bark, however, to yield 2 grams of the potent compound 4 trees had to be sacrificed, leading to
scarcity of the tree. After tremendous efforts from the medicinal chemist, this complex
compound could be synthesized in approximately 40 step reactions by the acylation of 10deacetylbaccatin III [179]. Taxol® was approved by FDA for BC and non–small cell lung cancer
(NSCLC) in 1994 and 1999 respectively [180]. Nowadays, PTX is approved by FDA for
Kaposi’s Sarcoma (second line), BC (metastatic or non-metastatic), advanced ovarian cancer
(first line), microcytic lung malignant neoplasm (metastatic or non-metastatic). Also used in the
adjuvant or neoadjuvant setting for esophageal cancer, bladder cancer, prostate cancer, cervical
cancer, gastric cancer, head and neck cancer, endometrial malignancy, brain oligodendroglioma
and testicular cancer [181].
Properties
PTX is a tricyclic diterpenoid with a taxane ring and a C-13 side chain that imparts the
cytotoxic activity of the compound. It is a white crystalline powder that melts at 216-217oC [182]
with high lipophilicity of log P 3.5, making it practically insoluble in water with solubility 0.3 0.5 μg/ml [183] and thus has low dissolution rate and low oral bioavailability less than 8% [182].
It is a cytochrome P450-dependent hydroxylase with the carbon at the 2' position allows the
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addition of functional groups or polymer conjugation [184], thus increasing activity, as in the
case of Taxol®.
Mechanism of Action
PTX binds to the N-terminal 31 amino acids of the beta-tubulin subunit of the
microtubule apparatus. PTX promotes microtubules polymerization to maintain the equilibrium
between tubular dimers and microtubule polymers and thus stabilizing them. PTX prevents cell
proliferation by forming an abnormal organization of mitotic spindle, block at the
metaphase/anaphase boundary, as well as incomplete formation of metaphase plate of
chromosomes. These effects cause morphologic changes and DNA fragmentation because of the
programmed cell death or apoptosis [185].
Taxol®: The First Formulation
PTX was formulated by Bristol-Myers Squibb, owing to the low solubility, it was
formulated in a vehicle of polyoxyethylated castor oil (Cremophor® EL or CEL). This was the
first available commercial product of PTX, Taxol® and possessed CEL and absolute alcohol in
equal ratio. It is a clear colorless to the slightly yellow viscous solution. Clinical dosage suggests
each milliliter of the solution contains 6 mg PTX, 527 mg of CEL and 49.7% (v/v) absolute
alcohol [182]. CEL is an inert vehicle commonly employed for formulating poorly water-soluble
drugs. However, it does impart some adverse effects, such as hypersensitivity, nephrotoxicity,
neurotoxicity respiratory difficulties, and vasodilatation occurs. Some of the severe effects
include anaphylactoid hypersensitivity reactions, hyperlipidemia, abnormal lipoprotein patterns,
aggregation of erythrocytes, peripheral neuropathy, bronchospasms and hypotension [186]. It is
administered by slow infusion by diluting with a suitable parenteral liquid such as 5% dextrose.
The half-life ranges between 1.3 and 8.6 hours, 90% of the drug is bound to plasma proteins and
possess a large volume of distribution of about 55 L/m2 [187]. It is primarily metabolized in the
liver by the cytochrome P450 (CYP3A4 and CYP2C8) and less than 10% of the dose is
eliminated through the urine. The pharmacokinetics profile relies on the variable infusion time,
however, it is considered to be non-linear because of saturation in the process of distribution and
elimination [188]. However, due to the smaller change in dose or infusion, systemic exposure
may be very high and may result in adverse toxicities. Additionally, CEL is also reported to alter
the pharmacokinetic profile of the drug such as the reduction in plasma clearance. Altogether,
Taxol® though possesses superior anticancer efficacy, the toxicity issues diminish the sale.
Additionally, severe dose-limiting toxicities include myelosuppression and neutropenia [189].
Nano-Based PTX Formulations for TNBC in Preclinical and Clinical Phase
Nanoparticles have also been utilized particularly in cancer therapy to facilitate
accumulation in the tumors via EPR effect, indicating the potential of nanoparticles to deliver
chemotherapeutics at the specific site [190] and improve the tolerability of cytotoxic agents
[191]. Since chemotherapy still dominates the treatment regimen for TNBC, nanoparticle
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platforms are a strong base for this kind of therapeutics. There is extensive ongoing research to
improve the therapeutic benefits of the nanotechnology-based formulation. With this hope, FDA
has approved in recent times nanotechnology formulations for PTX and DOX, that has shown
improved efficacy yet only show marginal to no improvement with respect to toxicity profile in
comparison to the native drug (PTX) such as Abraxane. Abraxane has shown ~2-fold
improvement in overall response rate in patients [136] in contrast to PTX or Taxol®. However,
many investigators have reported the incidence of neuropathy by Abraxane is significantly
higher than the native PTX drug [192]. Similar nanoparticle formulations of PTX are GenexolPM, SB05, Lipusu®, PNU166945 and many more, were developed and are approved or in
clinical trials but failed to cause any significant improvement compared to the currently available
treatment modality due to dose-limiting toxicities [193].
Albumin-based nanoparticles: Abraxane or nab-PTX
The disadvantages associated with Taxol® caused another nanotechnology based PTX
formulations to be marketed by Abraxis/Celgene with the tradename “Abraxane”. It is a solventfree colloidal suspension that is lyophilized, including six or seven PTX molecules noncovalently bonded to form aggregates of 4–14 nm which further aggregates to form 130 nm in
diameter. It was initially approved by FDA in 2005 for metastatic BC but has eventually been
approved for treating NSCLC, metastatic adenocarcinoma and pancreatic cancer, either as a
single agent or used in combination with other first-line treatment [191]. Pharmacokinetic profile
of Abraxane suggests that clearance and volume of distribution are significantly higher than the
traditional formulation. It is well distributed and binds to the tissue and extravascular proteins
[194].
Preclinical studies demonstrate an improvement in efficacy, in contrast to Taxol® and
33% higher tumor accumulation and less toxicity [138]. Thus, the ease of administration,
reduction in some of the adverse effects such as hypersensitivity reactions, better overall
response, and survival. Although, Abraxane shows a reduced risk of neutropenia yet increased
incidence of neurotoxicity is overserved in combination with Gemcitabine in pancreatic cancer
[195]. Additionally, a randomized clinical trial CALGB 40502, suggests that toxicity profile for
both the treatment groups receiving either PTX or nab-PTX weekly has no improvement, in fact,
more neuropathy and myelosuppression was observed with nab-PTX [196].
Clinical trials on BC patients receiving weekly Abraxane shows it is well-tolerated and
has higher antitumoral activity in contrast to PTX. However, grade 4 neutropenia and grade 3
peripheral neuropathy were observed as dose-limiting toxicities [197, 198]. Gradishar et. al.
conducted a phase III clinical trial on metastatic BC patients with Abraxane showing a
significantly higher response rate of 33% versus 19% improvement with Taxol®. However, no
significant difference in overall survival, which is considered one of the most important
parameters to evaluate clinical efficacy [199]. Another phase III trial treated with Abraxane®
(125 mg/m2) or Taxol® (80 mg/ m2) each given weekly, followed by
epirubicin/cyclophosphamide, shows significant higher pcR especially in the TNBC cohort in
comparison to Taxol® (38% vs 29%). However, Abraxane® was associated with significantly
greater toxicities such as peripheral sensory neuropathy compared with Taxol® (10% vs 3%)
[200].
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No, statistically improvement in the quality of life was noted, although significantly
fewer neutropenia (9% vs 22%) and more neuropathy (10% vs 2%) were overserved in between
groups treated with Abraxane and Taxol® respectively. The most frequent and common side
effects seen after treatment with Abraxane was neurotoxicity and neuropathy. These confusing
results made researchers wonder about the actual efficacy of the drug. This is when Rugo et. al.
decided to investigate the actual therapeutic influence achieved after Abraxane treatment. A
phase III clinical trial was conducted to demonstrate treatment difference with either Abraxane
(150 mg/m2) or ixabepilone (16 mg/m2), with a once-per-week treatment with to Taxol® (90
mg/m2) and in combination with the monoclonal antibody bevacizumab. Among the 799 patients
enrolled, Abraxane showed lesser tumor response than Taxol® (27% vs 38%), overall survival
(23.5 months vs 26.5 months) and progression-free survival (9.3 months vs 11 months)
respectively. Also, Abraxane shows significantly greater hematological and non-hematological
toxicity than Taxol®. Thus, the failed results from this study clearly bring into the question the
actual superiority of this formulation [196]. Altogether, Abraxane though shows some beneficial
higher tumor accumulation and improved disease-free survival, there was any significant
improvement observed in overall survival of patients in contrast to the gold-standard
formulation. Moreover, the heterogeneity of the disease makes treatment to be difficult,
especially when Abraxane fails to show any improvement in peripheral neuropathy, in contrast to
Taxol®.
Liposomes
Lipusu® or PTX liposome for injection. The first liposomal PTX-formulation called
Lipusu® is communalized by LuyePharma Group in China consists of lyophilized powder of
PTX solubilized in liposomes made of lecithin and cholesterol in a ratio of 87:13 w/w % and is
400 nm in diameter. It is approved in China as first-line chemotherapy for ovarian cancer, firstline therapy for NSCLC patients not suitable for radiotherapy or surgery, and for BC. Wang
et.al. investigates the anaphylactic effect of the formulation in contrast to Taxol® showed
responses such as piloerection, anhelation, and syncope, which were not seen in animals treated
with Lipusu®. Although Lipusu® showed some milder hypersensitivity reactions as well [201].
There are several ongoing clinical trials (NCT02142790 for metastatic BC and NCT02142010
for Lipusu with cisplatin in BC) [202, 203] to evaluate the efficacy in comparison to other
standards available regimen.
LEP-ETU® or liposome entrapped PTX easy to use. Another liposomal PTX
formulation developed by NeoPharm cardiolipin, cholesterol, and D-α-tocopheryl acid succinate
(in the molar ration 5:5:90) and are about 150 nm in diameter. Phase I clinical trial to study the
dose-limiting toxicities at 325 mg/m2 associated with the treatment of LEP-ETU® shows
peripheral neuropathy, myelosuppression, and even neurotoxicity [204]. Slingerland et. al.
demonstrates that the pharmacokinetic profile (AUC and Cmax) of LEP-ETU® were similar to
Taxol® [205]. A phase II clinical trial has conducted to determine the safety and efficacy of LEPETU® in thirty-five subjects show sensory polyneuropathy (3%) and neutropenia (6%). Other
than that no significant reactions were observed [206].
EndoTAG-1® or SB05 or MBT-0206 or LipoPac. EndoTAG-1® is a PTX formulation
developed by MediGene and later taken over by SynCore Biotechnology. It is comprised of
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liposomes composed of phospholipid DOTAP and neutral phospholipid DOPC in a 53:47 molar
ratio and are about 200 nm in diameter and positive zeta potential of 25-100 mV in a 0.05 mM
KCl solution at pH 7.5 [207]. The positively charged liposomes promote the PTX uptake into the
tumor endothelial cells. As a result of which combining antivascular effects with conventional
chemotherapy may result in increased permeability within the tumors [208]. However,
preclinical and clinical trial conducted on other types of cancer such as adenocarcinoma,
pancreatic cancer is shown to cause neutropenia and thrombocytopenia. Efficacy in TNBC was
evaluated by Awada and coworkers [96], showing results from a phase II clinical trial comparing
the safety and efficacy of EndoTAG-1® with Taxol® in 140 patients, receiving either weekly
EndoTAG-1® with Taxol® or EndoTAG-1® (twice a week) or weekly Taxol®. However, there
was no significant improvement in the overall survival between the treatment groups (13.0, 11.9
and 13.1 months, respectively). Other adverse effects include pyrexia and chills and about 17.8%
discontinued the therapy due to unbearable adverse events. Ongoing clinical trials evaluating
EndoTAG-1® for treatment of TNBC (NCT01537536 and NCT00448305) [209, 210].
Polymeric micelles
Genexol-PM® or Cynviloq™. Genexol-PM® developed by Samyang Biopharmaceuticals
Corporation is the biggest competitor of Abraxane® approved in South Korea for the treatment of
several types of cancer, such as breast, ovarian cancer, and NSCLC. In 2013, Sorrento
Therapeutics Inc has approved distribution rights in the U.S. and some other countries as well. It
is made up of monomethoxy- poly(ethylene glycol)-block-poly (D, L-lactide) diblock copolymer
that entraps PTX in polymeric micelles, exhibiting a size range from 20-50 nm with a drug
loading capacity of 16.7% w/w. The absence of albumin reduces the risk of microbial
contamination in comparison to Abraxane. A phase III clinical trial (NCT00876486) of the
formulation in contrast to the Abraxane in metastatic BC, shows enhanced efficacy and reduced
toxicity issues [211]. Other clinical trials demonstrate that the MTD of this formulation was
lowered to 180 mg/m2 than that of Abraxane®, although both the regimens showed a similar
incidence of neutropenia and less severe non-hemotoxicity [212, 213]. Although, higher-dose
regimen of 390 mg/m2 has a higher incidence of neutropenia and neuropathy [214]. In phase II
clinical trial by Lee et. al. at a dosing regimen of 300 mg/m2 in metastatic BC patients, 58.5% of
them demonstrate response rates. However, the response rate of Taxol® was similar but
conducted in a much larger group. Also, greater incidence of neutropenia (68.3%), neuropathy
(51.2%) and hypersensitive reaction (19.5%) was observed [215]. Overall, Genexol-PM® showed
a similar response to Taxol®, which initiated the fast track approval through 505(b)(2) for new
drug application (NDA) regulatory pathway for Cynviloq® in the U.S [216].
Paclical®. Paclical® developed by Oasmia Pharmaceuticals, which is composed of XR17, a vitamin A derivative which is made of N-(all-trans retinoyl)-L-cysteic acid methyl ester
sodium salt and N-(13-cis retinoyl)-L-cysteic acid methyl ester sodium salt. It forms micelles of
20–60 nm which encapsulates PTX and is available as a lyophilized powder, administered as
infusion [217]. Pharmacokinetic profile of Paclical® and Abraxane® are similar, suggesting the
opportunity for approval of Paclical in the treatment of metastatic BC [218].
Nanoxel® or DO/NDR/02. Nanoxel® from Dabur Pharma Limited is available for the
treatment of metastatic BC, ovarian cancer, NSCLC and AIDS-related Kaposi’s sarcoma in
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India. It is a micellar solution of size range 80-100 nm, is composed of a pH-sensitive copolymer
of N-isopropyl acrylamide and vinylpyrrolidone monomers which is stable at physiological pH
and drug release in an acidic environment as tumor microenvironment [219]. Ranade et. al
demonstrates in phase I clinical trial the MTD to be 375 mg/m2 with a linear pharmacokinetic
behavior with grade 3 diarrhea and grade 4 neutropenia adverse effects [220]. However, the same
group conducted a phase II trial in anthracycline failed advanced metastatic BC patients and
show though the formulation in comparison to the generic formulation Taxol® has improved
overall response rate, being 40% and 32.3%, the higher incidence of neutropenia of 56.3% versus
50%, higher incidence of neuropathy of 12.5% versus 6.3, respectively [219].
Triolimus®. Triolimus® from Co-D Therapeutics is a polymeric micellar formulation
composed of poly(ethyleneglycol)-block-poly(lactic-acid; PEG-PLA) and encapsulates three
drugs, PTX, rapamycin which is mTOR inhibitor and Hsp90 inhibitor tanespimycin (17-AAG)
ranging about 30-40 nm [221]. After showing promising preclinical results in xenograft models
by the synergistic activity of the three actives, this formulation is in the process of phase I
clinical trial for breast, NSCLC, and angiosarcoma [222].
NK105. NK105 is a micellar formulation composed of polyethylene glycol and modified
polyaspartate by esterification with 4-phenyl-1-butanol of about 85 nm in diameter [223]. The
core encapsulates 23% (w/w) of PTX and demonstrates good drug retention after intravenous.
administration. This formulation has MTD of about 180 mg/m2 in phase I clinical trial with grade
3 neutropenia as the adverse dose-limiting toxicity. Pharmacokinetic profile of this formulation
in comparison to the marketed generic formulation Taxol® has 15 folds higher AUC at the
recommended dose of 150 mg/m2. However, in phase III clinical trial against metastatic BC
patients showed failed to meet the primary endpoint of the study [224].
Polymeric-lipidic nanoparticle: PICN or PTX injection concentrate for
nanodispersion
PICN is a nanoparticle-based formulation composed of polymer and lipid, polyvinylpyrrolidone, cholesteryl sulfate and caprylic acid-forming nanoparticle of 100-110 nm,
developed by Sun Pharma and approved in India for the treatment of metastatic BC. Jain et. al
evaluated the efficacy of this formulation in comparison to Abraxane in phase II/III clinical study
and demonstrate similar efficacy and tolerability profile at MTD of 260 mg/m2. Although the
incidence of most common side effects such as neutropenia, peripheral neuropathy, and
leukopenia was the least at MTD 260 mg/m2 versus PICN 295 mg/m2 and Abraxane 260 mg/m2,
yet there was no statistically significant difference between them [225]. In U.S. PICN is in phase
III clinical trial for the treatment of biliary tract carcinoma (NCT02597465) [226] and just
finished phase I trial when administered alone or in combination with carboplatin
(NCT01304303), the results are yet to be disclosed [227].
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Polymeric conjugates
HPMA copolymer–PTX (PNU166945). PNU166945 is the first polymer-drug conjugate
of PTX, developed by Pharmacia Corporation, conjugating PTX to HPMA by a tetrapeptidil
linker of glycylphenylalanylleucylglycine. Although the formulation has good aqueous solubility
and about 5% w/w drug loading, it failed to have any difference in pharmacokinetic behavior,
illustrating that the conjugation did not have any significant impact on the drug behavior, though
a partial response was observed in one of the twelve patients with advanced BC. However,
clinical studies in phase I was discontinued earlier due to severe neurotoxicity observed [228].
OpaxioTM or PTX Poliglumex, CT-2103 or Xyotax®. OpaxioTM is a polymer drug
conjugate of PTX conjugated to the α-poly (L-glutamic acid) at the 2′-hydroxyl position of the
drug by an ester linkage. It is available as a lyophilized powder and has shown beneficial results
in preclinical studies. In ovarian tumors, uptake of OpaxioTM was about 5-fold higher than
Taxol® with prolonged circulation time [229]. After promising preclinical results,
pharmacokinetic profiling of this compound in comparison to the original drug was conducted by
Boddy et. al and shows prolonged half-life and low renal clearance, however, the achieved Cmax
was 3 times lower than Taxol®. Also, similar dose-limiting toxicity such as neuropathy and
neutropenia similar to taxanes was observed [230]. CT-2103 completed phase II trial for
metastatic BC [231] and is also being evaluated in combination with carboplatin versus PTX and
carboplatin in NSCLC patients [232].
Emulsion
DHP107. DHP107 is an emulsion composed of PTX, monoolein, tricaprylin, and Tween
80, in a ratio of 1: 55: 27.5: 16.5 wt% and developed by Daehwa Pharmaceutical in South Korea.
Phase I clinical trial demonstrates that is well tolerated in patients up to 600 mg/m2 with no
adverse effects of neutropenia. It is approved in South Korea for the treatment of gastric cancer
and is the first product that has shown similar efficacy profile via an oral route in comparison to
intravenous administration of Taxol®. In the U.S. it is undergoing phase II clinical trial as an oral
administration in comparison to the parent drug in metastatic BC patients (NCT03326102) [233].
Tocosol ™. Tocosol ™ is an emulsion of vitamin E, TPGS, and poloxamer-407 with PTX
formulated in the oil in water emulsion, bearing a particle size of 100 nm and high drug loading
capacity, this formulation is shown beneficial results in preclinical studies [234]. However, in
phase III clinical trial it was retracted, due to a similar response rate as Taxol® in metastatic BC
patient [235].
Peptide-conjugates: ANG 1005
ANG 1005 is a drug peptide conjugate of angiopep-2 and PTX that binds to the lowdensity lipoprotein receptor-related protein (LRP)-1 which facilities movement across the bloodbrain barrier (BBB), as LRP-1 is highly overexpressed in BBB. In preclinical model ANG 1005
has shown therapeutic efficacy which has progressed its application in a clinical trial. In phase II
trial among metastatic BC patients promising results have been achieved with the application of
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ANG1005 to treat peripheral metastatic BC and the brain metastasis [236]. It is now in phase III
clinical trial (NCT03613181) [237].
Conclusion
To date, TNBC remains a disease with poor prognosis and poorer patient outcomes
because of the disparity, in terms of molecular and genomic profiles among TNBC classification.
Although major advancement has been made with targeted therapy for other types of BC, such as
for HER2 positive where trastuzumab has proven to be a blessing, yet in the case of TNBC
chemotherapy remains the backbone treatment regimen. A ray of hope has recently emerged
among TNBC patients when FDA approved the first-ever targeted therapy: PARP inhibitors,
olaparib and talazoparib in 2018. Although it is restricted among patients with BRCA1/2
mutation, accounting for only 10-15% among the TNBC population, extensive research is
ongoing leading to positive preclinical and clinical outcomes with combination therapy or
targeted therapy or immunotherapy or ADC. Still, a lot of improvement could be achieved with
other novel and/or nano formulation-based therapies, such as Abraxane, that could lead to greater
hope for enhancing treatment options and health outcomes for TNBC patients. With this aim to
develop a therapy that could be beneficial to the TNBC population, we selected the most
commonly used chemotherapeutic agent PTX and developed a nanoparticle-based formulation.
We further developed and studied this PTX nanoformulation and explored it for generating
biomimetic cell membrane-based nanoparticles, which due to its innate sleath properties improve
circulation time, improve the chance of the particulate drug getting into the tumor via the EPR.
These membranes are also immunocompatible, thus preventing non-specific adverse effects.
Specific Aims
A fundamental problem in the development of targeted therapy for TNBC is the lack of
expression of ER, PR, and HER2. Due to the lack of a prognostic marker, their aggressive nature
and heterogenicity, the mainstay treatment is systemic administration of cytotoxic drugs. These
potent yet cytotoxic agents pose adverse effects on non-targeted healthy tissues with low
penetration of drugs at the primary tumor or the metastatic region. One such commonly used
agent is PTX which is used as a gold standard treatment to tackle TNBC.
We aim to develop a novel therapy using PTX that can, not only have therapeutic benefits
but also possesses specificity and targeting ability to the cancer cells. The central hypothesis of
this proposal is to develop and characterize an effective drug delivery system that can efficiently
target the primary tumor site, thus, maximize the therapeutic window by allowing enhanced
targeting specificity and minimize off-targeting problems, which usually causes low therapeutic
response with conventional drug delivery. For this, we have designed three sub- aims that would
lead us to achieve the final aim of this research.
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Aim 1: To Improve Paclitaxel-Mediated Delivery, by Developing and Characterizing
Polymer-Based Self-Assembled Paclitaxel Nanoparticles for BC
The hypothesis of this aim is the utilization of the self-assembly process, which has
shown to cause synergistic interactions between self-organizing particles and leading to
hierarchically ordered structures. With this motive, we aimed to develop an effective delivery
system for BC cells by self-assembly formation, which will minimize any other
formulator/external agents. We screened a wide array of marketed pharmaceutical polymers to
determine the best nanoparticle-based self-assembly of gold standard chemotherapeutic agent,
PTX. This aim will help us select the nanoparticle-based therapeutics for improving the PTX
mediated delivery.
Aim 2: To Develop and Characterize Nanoparticle-Based Paclitaxel Formulation to
Enhance Therapeutic Benefits Using P-gp Efflux Inhibitor, such as Tannic Acid in TNBC
The hypothesis for this aim is based on our initial finding that suggests a self-assembly
process for the generation of PTX nanoparticle-based formulation as an effective drug delivery
system, that not only enhances the therapeutic efficacies of PTX, but can improve drug efflux
limitations, causing subtherapeutic systemic concentration. Therefore, in this aim, we screened
common pharmaceutical excipients for generating the effective nanoparticle-based system for
TNBC that has chemosensitization motifs and has the potential to enhance the therapeutic effect
of PTX. This aim will generate and characterizing nanoparticle-based formulation of tannic acid,
which is a known inhibitor of P-gp efflux pumps.
Aim 3: To Enhance Targetability of Paclitaxel in TNBC Tumors by Developing and
Characterizing Biomimetic Nanoparticles Using Endogenous Cell Membrane, such as
Human Neutrophils
The hypothesis for this aim is to develop and characterize a specific delivery system that
targets TNBC tumors and reduce off-target toxicities on healthy cells. For this aim, we have
screened endogenous cells and develop, characterize the developed biomimetic nanoparticles
from these endogenous cell membranes to achieve targetability to the TNBC tumors. This
strategy potentiates biocompatibility and prevents clearance by the innate immune system which
recognizes conventional nanoparticles as immunogenic. The presence of abundant protein
moieties present on the surface of the extracted cell membranes allows cell-specific adherence
and targetability to primary TNBC tumors, allowing prolong circulation, retention at the tumor
site and reduce adverse effects.
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CHAPTER 2.

DEVELOPMENT OF POLYVINYL/PYRROLIDONE-PTX SELFASSEMBLIES FOR BC1
Introduction

As discussed earlier BC remains the most commonly diagnosed cancer among women in
the United States [238]. [238]. PTX is a natural compound, (derived from the bark of Taxus t56)
antimicrotubule and well-established chemotherapeutic agent, which exhibits a broad spectrum
of anticancer activity against BC, prostate cancer, leukemia, non-small cell lung cancer, and
ovarian cancer [239, 240]. Due to its hydrophobicity, it is often formulated with cremophor EL
in ethanol solution, i.e. Taxol®. This limits its clinical use due to its adverse side effects, such as
increased risk for fatal hypersensitivity reactions [241], non-linear pharmacokinetics [242],
prolonged peripheral neuropathy [186], and myelosuppression [243], less bioavailability at the
tumor site and therefore reduced efficacy for its action against tumor cells [186, 244, 245]. Other
common side effects of PTX treatment include vomiting, nausea, loss of appetite, and joint pain.
To circumvent these side effects, various alternative nanoparticle-based PTX
formulations were developed. Among them, one of the most widely used formulations is
Abraxane®, which is a cremophor-free and albumin-bound PTX nanoparticle formulation
(diameter ~120 nm), developed as an alternative formulation to PTX (Taxol®) [239]. This serum
albumin-bound PTX nanoformulation is approved by the FDA for the treatment of breast, lung
and pancreatic cancer. This formulation facilitates crossing across endothelial layers of cells and
achieves 33% higher PTX concentration at the tumor site [246]. Additionally, Abraxane® was
able to increase the maximum tolerated dose (MTD) by almost 70-80% when compared to PTX
alone. Another PTX nanoformulation called Genexol PM® was approved in South Korea as a
first-line treatment for metastatic or recurrent BC, non-small cell lung cancer, and also used in
combination with carboplatin for ovarian cancer. It is a polymeric micellar formulation of
polyethylene glycol (PEG), poly (DL-lactide) and PTX. NK-105 (block copolymer of PEG and
polyaspartate modified with 4-phenyl-1-butanol with PTX) is another nanoparticular micellar
formulation that has entered phase III clinical trial for metastatic and recurrent BC. NK-105
prolonged circulation, the enhanced area under the curve (AUC) by 20 times in contrast to PTX
and also has higher antitumor activity. [223]. Other clinically used (or under clinical
development) PTX formulations/nanoformulations include Paclical® (PTX combined with
Oasmia’s excipient technology XR17) [247], Lipusu® (PTX liposome) [248], PTX injection
concentrate for nanodispersion (PICN) [225], SB05 (positively charged liposome embedded with
PTX) [249], LEP-ETU (liposome-entrapped PTX) [250], and Triolimus (micelle containing
PTX, rapamycin and 17-AAG) [251]. Self-assembly and solid dispersion techniques were a
common approach to generate these clinically relevant PTX nanoformulations.
Therefore, the goal of this study was to develop a PTX nanoformulation using a polymerbased self-assembly technique, using a polymer excipient already in use in the pharmaceutical
1
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industry. The self-assembly process is a well-established, simple, and rapid fabrication method to
generate nanosized architecture materials for drug delivery applications [252-254]. We have
selected 8 biocompatible polymers. Table 2-1 provides structures of polymers used in this study.
Among which Poloxamer 188 [a nonionic copolymer containing hydrophobic poly(propylene
oxide) (PPO) and two hydrophilic poly(ethylene oxide) (PEO) units] is a well-known option for
generating micelles by the self-assembling technique where the PEO units align at the outer
lining and PPO falls in the inner core leading to the formation of micelle above the critical
micellar concentration. We expect polymeric micelles will be formed using Poloxamer 188
[252]. Whereas, the rest seven polymers are commonly used as drug delivery carriers for
generating solid dispersions or polymeric nanoparticles [253-255]. The motive of this study is to
minimize any other external agents being added for the formulation development. Self-assembly
is a process where the various components are held together by inter-particulate assembly [256].
Reports are stating that synergistic interactions between self-organizing particles and a selfassembling matrix material can lead to hierarchically ordered structures [257]. Accordingly, we
developed nanostructured formulations of hierarchical order using PTX and various polymers
without the use of any external reagents or binders. Such self-assembly formulations may have
the potential to circumvent the shortcomings of PTX and provide advantages such as ease of
preparation; smaller particle size; an efficient binding ability to PTX; and enhanced particle
uptake in cancer cells. In this investigation, we report an optimized PVP/PTX-SA formulation
which has demonstrated enhanced cellular uptake and exhibited superior in vitro cytotoxicity in
BC cells, compared to PTX.
Materials and Methods
Chemicals and Solvent
All laboratory reagents, solvents, and chemicals were purchased from Sigma–Aldrich Co.
(St. Louis, MO, USA) or Fisher Scientiﬁc (Pittsburgh, PA, USA) unless otherwise mentioned.
Cell culture plastics were purchased from Sarstedt, Inc. (Newton, NC, USA). All chemicals were
used as received without any further puriﬁcation.
Cell Culture, Growth Conditions and Treatment
BC cell lines (MCF7 and MDA-MB-231) were obtained through American Type Culture
Collection (Manassas, VA, USA) and stored at low passage frozen aliquots upon cell culture
expansion. These cell lines were thawed and cultured under sterile conditions for all experiments
(<3-4 months after thawing). Both cell lines were cultured in Dulbecco's Modified Eagle
Medium-High Glucose (DMEM-Hi) medium containing 4.5 g/l of glucose, 10 nM of
nonessential amino acids, 100 nM of sodium pyruvate, 1x antibiotic/antimycotic (Gibco, Thermo
Fisher Scientiﬁc, Grand Island, NY, USA) and 10% heat-inactivated FBS (Atlanta Biologicals,
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Table 2-1.
Polymers employed for self-assembling PTX to produce polymer/PTX selfassembly nanoparticles
Name of polymer
Polyvinyl alcohol (PVA)

Structure of polymer

Polyethyleneimine (PEI)

Poly (methyl vinyl ether-altmaleic hydrochloride)
(PMEAVH)

Poly (allylamine
hydrochloride) (PA-HCl)

Polyacrylic acid (PAA)
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Table 2-1.

(Continued)

Name of polymer
Polyvinylpyrrolidone (PVP)

Structure of polymer

Povacoat F (polyvinyl alcoholacrylic acid-methyl
methacrylate) copolymer

Poloxamer 188 (P188)
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Lawrenceville, GA, USA) at 37 oC in a humidiﬁed atmosphere (5% CO2 and 95% air condition)
(ThermoScientific, Waltham, USA). In all cell culture experiments, monodispersed cell lines
after trypsinization were plated on either 6, 12, or 96-well plates, and were allowed to adhere
overnight to the plate before implementing treatments.
Preparation of Polymer-PTX-SAs (Poly/PTX-SAs)
Eight polymer-based drug delivery vehicles such as polyvinyl alcohol (PVA) (Mw
31,000-50,000), polyvinylpyrrolidone (PVP) (Mw 40,000), polyethyleneimine (PEI) (Mw
25,000), poly(methyl vinyl ether alt-maleic hydrochloride) (PMEAVH) (Mw 216,000),
poly(allylamine hydrochloride) (PA-HCl) (Mw 17,500), Poloxamer 188 (Kolliphor® P 188,
P188), polyacrylic acid (PAA) (Mw 100,000), and Povacoat (Polyvinyl alcohol-Acrylic acidMethyl methacrylate copolymer: Type F, Mw = 40,000), a gift sample received from Daido
Chemical Co., Osaka, Japan), were used in the PTX self-assembly formation. The self-assembly
formation technique is followed by solvent evaporation. Briefly, 5 mg of polymer was dissolved
in 1 ml aqueous medium in 8 ml glass vial under continuous stirring at 400 rpm on a stir plate.
To this solution, 100 μl of PTX dissolved in acetone (1 mg/ml) was added slowly (dropwise) and
the speed increased to 900 rpm. The obtained solution was stirred overnight to evaporate the
acetone resulting in the formation of self-assembled nanoparticles comprised of assembled
polymer chains and PTX, i.e., referred to as polymer-PTX-self-assemblies (Poly/PTX-SAs). The
resultant Poly/PTX-SAs solution was kept refrigerated and used within a week. For all in vitro
cell culture experiments, a fresh batch of Poly/PTX-SAs was used to protect PTX activity in the
formulations.
Characterization of Poly/PTX-SAs
Particle size and zeta potential
The average particle size, particle distribution and zeta potential of the prepared PTX-SA
formulations were measured by the dynamic light scattering (DLS) principle using Zetasizer
(Nano ZS, Malvern Instruments, Malvern, UK). These measurements were done as previously
reported [258], briefly 50 μl of freshly prepared Poly/PTX-SA nanoparticle suspension was
dispersed in deionized water and was probe sonicated (VirSonic Ultrasonic Cell Disrupter 100,
VirTis) for 30 secs. Probe sonication procedure is commonly applied in formulation
development for the formation of nanoparticles and homogeneous solution which minimizes the
interaction of aggregated nanoparticles and to disperse well but not to break particles into smaller
particles. Additionally, the short span of sonication is subjected to ensure that particle suspension
is homogeneous, thus warrants there is no agglomeration occurring in particle suspension.
Particle size measurements were performed in water for 3 mins at 25°C. The average diameter
and distribution of particle size were determined from three runs. Similarly, zeta potential was
measured using nanoparticle suspension that was diluted with 1X phosphate-buffered saline
(PBS). The zeta potential of nanoparticle formulations was also based on the average of 3
readings (each reading = 30 runs).
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Transmission electron microscopy
The size and surface morphology of PVP/PTX-SAs were investigated by JEOL 200EX
transmission electron microscopy (TEM) (JEOL Ltd, Tokyo, Japan) operating at 80 kV. For this,
100 μl of PVP/PTX-SA suspension was dispersed in 1 ml of water were probe sonicated for 30
secs. On a 150-mesh standard TEM grid (Electron Microscopy Sciences, PA, USA), a 20 μl
aliquot of the PVP/PTX-SAs was carefully placed on the shiny side of the grid. It was stained
using 2% w/v uranyl acetate solution. The excess amount of formulation was removed using
filter paper and the grid was allowed to air dry followed by imaging using an AMT camera at a
direct magnification of 100,000X under the TEM system.
Spectral analysis
Fourier transform infrared (FTIR) spectra were employed to determine the formation of
PVP/PTX-SAs. FTIR spectral data were acquired on the Universal ATR sampling Accessory
plate using a Spectrum 100 FTIR spectrophotometer (Perkin Elmer, Waltham, MA). Samples of
PVP/PTX-SAs was lyophilized to obtain dry solid particles using a Labconco Freeze Dry System
(-48°C 133 × 10-3m Bar; Labconco, Kansas City, MO, USA). The samples (PTX, PVP and
PVP/PTX-SA) were placed on the tip of the ATR objective and spectra obtained between 4000
and 650 cm-1.
Fluorescence Binding
Self-assembly formation of polymer and PTX was determined on a SpectraMax Plus
plate reader (Molecular Devices, Sunnyvale, CA, USA). For this study, PTX conjugated dye
(PTX, Oregon Green 488 conjugate with a Flutax-2, Molecular Probes Inc., Life Technologies,
OR, USA) was used, from which the fluorescence quenching of Oregon green 488 on PTX was
achieved by titrating with polymeric/surfactant solutions. Intrinsic fluorescence of 5 μg/ml PTX
solution in 1X PBS was titrated with 0-80 μg/ml of PVP solution. The decay in fluorescence was
studied by exciting at 496 nm and emission between 450-600 nm.
Hemolysis Assay
A healthy human donor blood with sodium citrate as anticoagulant was purchased from
Interstate Blood Bank Inc (Memphis, TN, USA) for the hemolysis test. The hemoglobin releases
from red blood cells (RBCs) upon treatment with 10 μg PTX/well or 10 μg PTX equivalent/well
of Poly/PTX-SAs were quantitatively measured as described earlier [262, 263]. For this assay,
200 μl of RBC suspension (8 × 105) was incubated with 10 μg/well of PTX or Poly/PTX-SAs
(of similar concentration as PTX) and placed in an incubator for 60 mins at 37°C. In this
experiment, sodium dodecyl sulfate (SDS, 1 mg/ml) served as a positive control (100% lysis)
while 1X PBS was used as a negative control. After the incubation of 1 hour, hemoglobin release
into medium (supernatant, 100 μl) was collected, transferred to a 96-well plate, recorded
absorbance at 510 nm using a plate reader (Cytation 3 imaging reader, BioTeK Winooski, VT,
USA). To further confirm our results qualitatively, a few drops of the treated RBC solution was
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smeared on a glass slide and images were captured using EVOS® FL Imaging System
(AMF4300, Life Technologies, Carlsbad, CA, USA). The percentage of hemolysis was
calculated using the following Equation 2-1.
Ψ ݏ݅ݏݕ݈݉݁ܪൌ ቂ

௦௦௦ି௦௧௩௧
௦௦௧௩௧

ቃ ܺͳͲͲ (Eq. 2-1)

Cellular Uptake
For this study, previously reported methods were employed for qualitative and
quantitative uptake of Coumarin 6 (C6) loaded in Poly-SAs in cancer cells [259, 260]. In this
experiment, freshly prepared C6 loaded Poly-SAs were generated following the procedure as
described in section 2.3. The polymer and dye ratio were kept 50:1 (5 mg of polymer and 100 μg
of dye). BC cell lines MCF7 and MDA-MB-231 (5000 cells/well with 100 μl media/well in 96well culture plates) were seeded at 500,000 cells/well with 2 ml medium in 6-well plates. Cells
were allowed to attach to the plate, media was replaced with 5 μg (dye equivalent) C6 loaded
Poly-SAs. To ensure the stability of C6 dye, such that it does not leach out of the
nanoassemblies, a lower incubation time of 3 hours was selected. Since it is a comparative
experiment among 8 different formulations to find out the best one, we have not considered C6
leaching from formulations. After 3-hours treatment, cells were washed twice with 1X PBS to
remove the excess C6 loaded Poly-SAs that may be adhered to the surface of the culture plate or
cells. Then, DMEM phenol red free medium was added to these treated cells and uptake of C6
loaded Poly-SAs in cells were imaged using EVOS® FL Imaging System (AMF4300, Life
Technologies, Carlsbad, CA, USA). Furthermore, the quantitative uptake of C6 loaded Poly-SAs
in cells was determined by trypsinizing, centrifuging and then collecting the cells in 2 ml media,
which were injected (50 μl cell suspension) into an Accuri C6 Flow Cytometer (Accuri
Cytometer, Inc., Ann Arbor, MI, USA). Quantitative uptake of Couamrin 6-SAs measurements
were acquired using the fluorescence levels in FL1 channel (488 excitation, Blue laser, 530 ±15
nm, FITC/GFP). Standard deviations were calculated from 3 replicates.
Biological Assay
Cell viability assay
A calorimetric CellTiter 96® aqueous one solution cell proliferation assay (MTS assay,
Promega, Madison, WI) was used to examine the effect of PTX-SAs on cell proliferation of BC
cells. The measurement of cell viability is based on the ability of viable cells to cleave the
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, salt by mitochondrial dehydrogenase. Briefly, MCF7 and MDAMB-231 (5000 cells/well with 100 μl media/well in 96-well culture plates) were seeded in
regular growth medium and allowed overnight cells to attach to the wells. These cells were
treated with 1.25, 2.5, 5, 10, and 20 nM PTX or PVP/PTX-SAs in order to determine the cell
proliferation capability. Cell lines with no treatment served as controls, respectively. After 48
hours of treatment, 20 μl of MTS reagent solution was added to the cells and incubated for 2
hours at 37°C. Absorbance reading was recorded at 490 nm using a Microplate Reader (BioTeK
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Cytation 3, Winooski, VT, USA). Data were plotted using cell proliferation against the
concentration of treatment, where the proliferation of PVP/PTX-SAs and PTX was determined
by the percentage of the absorbance of treated cells to the absorbance of control or non-treated
cells. All the experiments were performed at least in triplicates.
Clonogenic assay
Clonogenic assay was performed to investigate the effect of PVP/PTX-SAs on BC cells
to form colonies as an in vitro cell survival assay based on the ability of a single cell to grow into
a colony. For this study, BC cells were seeded (250 cells/well) in a 12-well plate and allowed 2
days to attach and start generating smaller colonies. Then, these initiated cell colonies were
treated with 0.25, 0.5 and 1 nM PTX and PVP/PTX-SAs for two weeks. Visible colonies were
fixed, stained with hematoxylin and manually counted (~50 cells considered as a colony) as
discussed earlier [261, 266]. The results are presented as the percentage of colonies as compared
to the control (non-treated cells).
β-Tubulin Stabilization Assay
β-tubulin stabilization assay was performed by immunofluorescence assay to examine
PTX inherent tubulin binding and alteration efficacy of PVP/PTX-SAs [261]. Briefly, 25,000
cells/well were cultured in 4-well chamber slides and cultured overnight to attach to a glass slide
before treatment with 5 nM PTX or PVP/PTX-SAs or respective controls (DMSO or polymer)
for 8 hours. After treatment, cells were rinsed with 1X PBS for 3 mins three times, fixed with
ice-cold methanol for 20 mins, blocked with 10% goat serum for 1 hour. Then, cells were
immunostained overnight with β-tubulin antibody (1:50 cell signaling, #CS2146) at 4 oC on a
rocker with 20 oscillations/min. After incubation with the primary antibody, cells were rinsed
three times with 1X PBS then probed with Alexa Fluor 488 goat anti-rabbit secondary antibody
(1:200, # A11008, Thermo Fisher Scientific, Waltham, USA) for 1 hour. DAPI was used to
counterstain nuclei of cells. Finally, the polymerization of tubulin in cells was visualized under a
laser confocal microscope (Carl Zeiss LSM 710, Thornwood, NY, USA) with a 40×0.7NA oil
immersion objective.
Immunoblot Analysis
For immunoblot analysis, BC cells (1 × 106 in 10 ml medium) were seeded in a 100 mm
culture dish and treated with 10 nM PTX or PVP/PTX-SAs or respective control (DMSO and
PVP) for 48 hours. These cells were lysed with Cell LyticTM M reagent (Sigma–Aldrich Co. (St.
Louis, MO, USA), the protein concentrations were measured, and equal concentrations of total
protein were separated by SDS-PAGE, and the Western blotting methods were followed as
described previously [261, 262]. Primary antibodies [β -actin (#4967), Bax (#2772), BID
(#2003), cleaved caspase7 (#9491), Bcl-xL (#2762), cleaved PARP (#9548) and MDR1/ABCB1
(#13342)] (Cell Signaling Technologies, Danvers, MA) and secondary antibody (horseradish
peroxidase-conjugated goat anti-mouse #7076P2 or goat anti-rabbit #7074P2 secondary
antibody) (Cell Signaling) were used in this study. The specific protein bands were detected
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using enhanced Lumi-Light Detection Kit reagent under a Biorad ChemiDocTM MP System
(Biorad, Hercules, CA, USA).
Statistical Analysis
All statistical analyses were performed with GraphPad Prism 5 Software (GraphPad
Software, San Diego, CA) using Student’s t test. The difference was considered to be significant
for p values of <0.05. DLS (particle size and zeta potential), hemolysis, cellular uptake, and MTS
assay data were expressed as mean ± standard error of the mean. All graphs were generated
using GraphPad Prism 5 Software.
Results
Development of a Suitable Poly/PTX-SA Formulation for BC
A successful self-assembled nanoparticle formulation may deliver a therapeutic agent at
the tumor site more efficiently than the parent PTXPTX drug molecule alone. The selection of
such a self-assembly carrier depends on its physio-chemical and biological characteristics.
Therefore, in this investigation, we used eight commonly used pharmaceutical delivery vehicles
to load PTX by the self-assembly technique which allows the formation of nanoparticles. The
inherent thermodynamic forces direct the nanoparticle formation without the use of external
agents. A similar self-assembly process was studied, described and reported by our group for βcyclodextrin-curcumin and poly(β-cyclodextrin)-curcumin assemblies [263, 264]. These selfassembled nanoparticles are much more stabilized and thus prevent aggregation and flocculation.
To further ensure that solution is homogeneous we have probed sonicated the self-assembled
nanoparticles, this warrants that there is no agglomeration occurring [265]. The formed selfassemblies of PTX with various polymers produced particle sizes ranging from 140.53 nm to
358.86 nm which was measured by dynamic light scattering measurements (Figure 2-1A). A
lower particle size self-assembly was observed with PVP/PTX-SAs (140.53+7.08 nm) and
Povacoat F-PTX-SAs (145.2+5.33 nm) due to strong PTX holding capacity within their polymer
chain networks. High positive zeta potential formulation often induces systemic toxicity. In zeta
potential measurements, most of the Poly/PTX-SA exhibited negative zeta potential (between –
4.34 mV to –13.1 mV) (Figure 2-1B) while PA-HCl (+9.54 mV) and PEI (+3.09 mV) exhibited
positive zeta potential.
To further screen all these Poly/PTX-SAs for cancer therapeutics, a suitable selfassembly formulation must be hemocompatible. This property is highly recommended for any
clinically applied or approved formulation. The safety profile of PTX-SAs on RBCs for
hemocompatibility was examined at 10 μg/well of PTX or Poly/PTX-SAs. Results suggest that
PVP, PVA, PA-HCl, and Poloxamer 188 based PTX-SAs exhibited negligible hemolysis (similar
to the negative control treatment, PBS) while other PTX-SAs demonstrated higher hemolysis
(more than 20% hemolysis) like a free PTX drug (Figure 2-2A). This hemocompatibility
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Figure 2-1. Particle size and zeta potential of Poly/PTX-SAs
50 μl of Poly/PTX-SAs were dispersed in 1 ml distilled water or 1X PBS and probe sonicated for
30 secs. These solutions were measured for particle size and zeta potential using dynamic light
scattering at 25°C using Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK). A) Average
particle size of polymer PTX-SAs was measured for 3 min exhibiting the smallest size for
PVP/PTX-SAs (140.53 nm). B) Zeta potential of Poly/PTX-SAs was measured in 1X PBS and
average of 3 readings (each reading = 30 runs) were presented. Data represented as an average of
three readings that were recorded independently with error bars represented as standard error of
mean.
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Figure 2-2. Evaluation of hemocompatibility behavior of Poly/PTX-SAs
A) Hemocompatibility was assessed using human red blood cells by treating them for 1 hr with
PTX or Poly/PTX-SAs. In this experiment, sodium dodecyl sulfate (SDS, 1 mg/ml) served as a
positive control (100% lysis) while 1× PBS was used as a negative control. The percentage of
hemolysis was calculated using our previously reported method. B) Images of treated red blood
cells on glass slide were captured using EVOS® FL Imaging System (AMF4300, Life
Technologies, Carlsbad, CA, USA). PVP/PVA-PTX-SAs demonstrate intact membrane
morphology in RBCs as PBS, whereas PTX and other Poly/PTX-SAs exhibited toxic behavior
by disintegrating membrane structure of RBCs.
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behavior with PVP and PVA is correlated with intact membrane morphology in RBCs just like a
negative control (PBS) treated RBCs (Figure 2-2B). All other Poly/PTX-SAs exhibited severe
influence on shape and morphology of RBCs (Figure 2-2B). PTX alone exhibited significant
toxic behavior by disintegrating membrane structure of RBCs.
Irrespective of the type of drug formulation, they must interact and penetrate through the
cell membrane of cancer cells, then be released into the cytosol at sufficient concentration to
induce therapeutic benefit. The therapeutic outcomes are improved if the intracellular uptake of
nanoparticle is improved. Thus, higher internalization of formulation in the cells is the key factor
to determine the efficiency of the nanoparticle formulation. The cellular uptake screening was
conducted using dye loaded polymer assemblies which can be detected by green fluorescence in
cells which directly reflects the internalization of the formulation. This study demonstrates an
uptake of C6 pattern in MDA-MB-231 cells as PVP > PVA > PMEAVH> Povacoat F > PAHCL > PEI > Poloxamer 188 > PAA PTX-SAs, whereas similar pattern was observed in MCF7
cells with the highest cellular uptake in PVP/PTX-SA (Figure 2-3A). The mean fluorescence
intensities of PVP/PTX-SAs and PVA/PTX-SA were 16 and 14; ~10 and 9 times higher in
MDA-MB-231 and MCF7, respectively (Figure 2-3A). Fluorescence images of cells is further
evidence for similar uptake characteristics of polymer self-assemblies than that observed in flow
cytometry. PVP and PVA self-assemblies were detected in cancer cells all over the cellular
organelles while other polymers show less fluorescence in these cells (Figure 2-3 B). However,
the higher size range of PVA/PTX-SA of 358.86 nm, minimized the chances of using it as a
potential nanoformulation. Thus, we selected PVP/PTX-SAs for the rest of the study, as PVP is a
better binder for transporting loaded therapeutics into cancer cells. From the DLS,
hemocompatibility, and cellular uptake studies, it can be reported that PVP/PTX self-assemblies
have the optimal size and negative charge while maintaining hemocompatibility and improved
cellular uptake in cancer cells that are may be helpful for cancer therapeutic purposes. Thus, all
our further studies in this manuscript are focused on PVP/PTX-SAs.
Characterization of PVP/PTX SA Formation
To confirm that PVP and PTX form self-assembly nanoparticles, we utilized PTX
conjugated dye (PTX, Oregon Green 488 conjugate) for fluorescence quenching assay. In the
first method, to confirm the efficient binding of PTX with the PVP, a quenching study was
performed against PTX conjugated dye (PTX, Oregon Green 488 conjugate) in 1X PBS solution
(Figure 2-4A). Fluorescence quenching reveals possible interaction of the polymer with PTX
dye. This is an instantaneous process directly couples/self-assembles PTX to the polymer. Such
instantaneous particle formation and integrity was confirmed by hydrodynamic diameter
measurements using DLS. The fluorescence intensity of PTX dye was diminished with the
increase of PVP solution. This directly correlates to the binding potential of PVP with PTX
which indicates the successful formation of self-assemblies. The inclusion of PVP and PTX in
PVP/PTX-SAs can be confirmed using FTIR analysis. The acquired FTIR spectra of the PVP,
PTX, and PVP/PTX-SAs (Figure 2-4B) demonstrate that PTX has distinct visible peaks at 1734
cm-1, 1704 cm-1 and 1645 cm-1 (due to C=O stretching of amide and ester functionality) which
were not visible in PVP/PTX-SA thus suggesting a possible interaction of PVP with PTX
through these functional groups
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Figure 2-3. Cellular uptake of Poly/PTX-SAs
A) Quantitative cellular uptake evaluation All the cells were treated with Poly SAs loaded with
C6 instead of PTX in order to evaluate fluorescent uptake in cells. BC cells (500,000) were
treated with Poly/C6-SAs (5 μg dye equivalent formulations) for 3 hours. These cells were
trypsinized, centrifuged and collected in 2 ml media, which were injected (50 μl cell suspension)
into an Accuri C6 Flow Cytometer (Accuri Cytometer, Inc., Ann Arbor, MI, USA). Mean
fluorescence intensity in FL1 channel (488 excitation, Blue laser, 530 ± 15 nm, FITC/GFP) was
measured. Data represented as mean ± standard error of the mean (n =3), *P < 0.05. B)
Qualitative internalization efficiency of Poly/C6-SAs in BC cells. In above treatment condition,
uptake of Poly/Couamrin 6-SAs in BC cells were viewed using EVOS® FL Imaging System
(AMF4300, Life Technologies, Carlsbad, CA, USA). Bar equals to 200 μm. This study suggests
fluorescence intensity in the order: PVP > PVA > PMEAVH > Povacoat F > PA-HCL > PEI >
Poloxamer 188 > PAA C6-SAs.
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Figure 2-4. Self-assembly formation of PVP/PTX-SAs
A) Self-assembly formation was confirmed by binding potential (quenching) of PTX conjugated
dye (PTX, Oregon Green 488 conjugate (Flutax-2, Molecular Probes Inc., Life Technology, OR,
USA)) with PVP solution (5-80 μg/ml). Fluorescence was studied by exciting at 496 nm and
emission between 450-600 nm. B) FTIR spectra of PVP/PTX-SAs, PTX, and PVP. The presence
of 1033 cm-1 (characteristic PTX peak) and 1270, 1284, 1420 and 1654 cm-1 characteristic PVP
peak) confirms the presence of both PVP and PTX in the self-assembly formation of PVP/PTXSAs. C) Schematic and hypothetical structural presentation of PVP/PTX-SAs. Color,
dimensions, assembly are not comparable to synthesized formulation. Morphology of PVP/PTXSAs imaged by using AMT camera at a direct magnification of 100,000x under the TEM on a
150-mesh standard TEM grid, stained by 2% w/v uranyl acetate solution. The particle size
viewed under TEM ranged between 34.88 to 130.24 nm.
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Further, in the PVP/PTX-SAs spectrum, the intensity of the broad band around 3259 cm-1 was
reduced suggesting another possible interaction motif with the alcoholic O-H functionality too. If
we look into the fingerprint region of the FTIR spectrum for the PVP/PTX-SAs formulation, the
sharp peak at 1033 cm-1 confirms the presence of PTX in the formulation. Lastly, the peaks at
1270, 1284, 1420 and 1654 cm-1 of both PVP/PTX-SA and PTX substantiates the coexistence of
both PVP and PTX in the given formulation. The FTIR study was performed to confirm the
existence of polymer and PTXPTX in its formulation but not to verify the course of selfassembly formation between polymer and PTXPTX. Additional evidence is to examine its
nanoparticle formation using transmission electron microscopy (TEM) for the size and the
morphology of self-assemblies (Figure 2-4C). A clear contrast of self-assembled nanoparticles
formation was observed with positively stained (2% w/v uranyl acetate solution) PVP/PTX-SAs.
From this study, it is evident that the average size of the dry and stained PVP/PTX-SAs found to
be 53.81±2.6 nm (Note: DLS data provides particles in suspension or wet form which always
exhibit higher particle size over TEM measurements). This nanoparticle observation
substantiates and affirms the hydrodynamic size of the nanoparticles measured by DLS.

In Vitro Anticancer Potential of PVP/PTX-SAs
The therapeutic efficacy of PVP/PTX-SAs was evaluated in BC cell lines by MTS
viability and colony formation assay [263]. Both PTX and PVP/PTX-SAs showed a dosedependent antiproliferation effect (1.25-20 nM) in MCF7 and MDA-MB-231 (Figure 2-5A).
The control polymer did not show any effect on cell growth. The in vitro 50% cell growth
inhibitory concentration (IC50) is the quantitative measure of the toxicity induced by the
treatment group on the cells. IC50 values for PTX is 13.12 nM and 12.40 whereas IC50 for
PVP/PTX-SAs is 4.68 and 7.26 nM, for MCF7 and MDA-MB-231, respectively. Similarly,
images of treated cells indicate that the inherent anticancer activity of PTX is preserved in
PVP/PTX-SAs (Figure 2-5B). PVP/PTX-SA formulation is more potent in suppressing cell
growth compared to PTX. A similar superior active performance of PVP/PTX-SAs was achieved
in the colony forming assay, which is another complementary assay to evaluate anticancer
efficacy (Figure 2-6). In this study, PVP/PTX-SAs have shown a significant decrease in colonies
and colony density over PTX for both MCF7 and MDA-MB-231 (Figure 2-6A, B). Such high
anti-proliferative and colonogenic potency of PVP/PTX-SAs at a low effective dose compared to
PTXPTX demonstrates that a lesser concentration of PTX is needed in self-assembly
formulations for effective therapeutic outcomes.
Molecular Activity of PVP/PTX-SAs
At the cellular front, PTX binds to the β-tubulin subunits in microtubules and induces
polymerization of tubulin which disrupts microtubule dynamics, giving rise to mitotic arrest and
thus cell death [266]. To obtain more insight in this aspect of PVP/PTX-SAs, we performed βtubulin stabilization using a specific antibody in immunostaining and imaging by confocal
microscopy. A higher microtubule polymer mass was observed on treatment with PVP/PTXSAs, in contrast with PTX (5 and 10 nM) or respective control groups (DMSO or PVP). Higher
microtubule bundles in cells, suggested by the green fluorescence observed for microtubule
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Figure 2-5. PVP/PTX-SAs significantly inhibit proliferation of BC cells
A) BC cells (MCF7 and MDA-MB-231) (5000 cells/well) were plated in 96-well plates and were
treated with PTX or PVP/PTX-SA at a range of concentration 1 to 20 nM for 48 hours. Cell
viability was assessed by MTS assay by measuring absorbance at 490 nm using microplate
reader., Relative cell viability was measured (using GraphPad Prism 5 Software) with control
(untreated) BC cells, considering as 100%. Data represented as mean ± standard error of the
mean (n =3), B) Representative phase-contrast microscopic images were captured by EVOS®
FL Imaging System to evaluate the effect of PVP/PTX-SAs on the cell morphology. Bar equals
to 200 μm.
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Figure 2-6. PVP/PTX-SAs repress the clonogenic potential of BC cells
A) BC cells (MCF7 and MDA-MB-231) (250 cells/well in a 12-well plate) were treated with
0.25, 0.5, and 1 nM PVP/PTX-SAs and PTX along with their respective controls. On day 14,
cells were rinsed with PBS and stained with hematoxylin to visualize colonies for counting.
Photographs of clonogenic pattern were captured in Multimage™ light cabinet. B) Bar graphs
represent number of colonies formed in each treatment group. Data represented as mean ±
standard error of the mean (n =3).
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staining (Figure 2-7A), is due to the enhanced antitumor activity of PVP/PTX-SAs compared to
PTX. This behavior was more prominent even at 10 nM (Data not shown) concentration with
PVP/PTX-SAs indicating the use of PVP/PTX-SAs may reduce concentrations required to
induce the anticancer effect.
We performed immunoblot analysis to further understand the superior anticancer function
of PVP/PTX-SAs in BC cells. Expression of various proteins such as Bcl-xL, Bid, Bax, Cleaved
PARP, Cleaved Caspase 7, and MDR1 upon treatment with PTX and PVP/PTX-SAs was
assessed (Figure 2-7B). The expression of the key pro-survival protein (Bcl-xL) was effectively
down-regulated by PTX and PVP/PTX-SAs treatment. Also, expression of pro-apoptosis
proteins (Bax, Bid), Cleaved PARP, and Cleaved Caspase 7, increased following PTX and
PVP/PTX-SAs treatment. These events are more prominent in PVP/PTX-SAs strongly suggests
PVP/PTX-SAs induce apoptosis more pronouncedly in comparison to the native drug PTX
[267]. Further, the effect of treatment on MDR1 protein expression was also observed.
Altogether, we can conclude that PVP/PTX-SAs were able to stabilize tubulin polymerization
and cause intrinsic differences in molecular effects, which could effectively induce apoptosis.
Discussion
The main problem of PTX-based chemotherapy is severe systemic toxicity due to the
nonspecific accumulation of anticancer agents. In other words, the administration of PTX with
the use of lipophilic solvents or surfactant(s) may cause insufficient drug levels at the tumor site
or quick clearance due to the aggregation of PTXPTX nanoformulation. Although scientific
literature and clinical evidence suggest some formulations have exhibited superior therapeutic
outcomes, a simple preparative approach like self-assembly formulations of PTX is preferred
[268, 269]. Therefore, the main focus of this study is to develop PTX/polymer-based
nanoformulations by self- assembly technique to enhance the efficacy of PTX in BC treatment.
Polymeric nanoparticles are a well-known alternative in the field of drug delivery for therapeutic
benefits.
In this same regard, we have prepared nanoparticles which are colloidal systems with
PTX entrapped in the matrix. The unique structure of the biodegradable polymeric matrix
provides advantages of target-specific delivery and intracellular penetration. Thus achieving
sustained drug release, preventing frequent administration and an overall broad spectrum of
therapeutic benefits are expected [270]. The unique preparative approach of the self-assembly
technique enables formulation scientists to reduce the usage of external excipients and in the
process reduces the chances of toxicity from the nanocarrier itself. It is reported that the
superiority of self-assembled nanoparticles in the field of drug delivery is favored [268, 269].
The hydrophilic aqueous polymeric solution serves as a bed for the hydrophobic drug through
van der Waals forces/interaction or hydrogen bonding at the core of the particle. Hydrophobic
interaction between the hydrophobic polyvinyl group of PVP and PTX is responsible for the
formation of the nanoformulation. Due to steric stabilization, these nano-drug formulations have
longer retention in the bloodstream whereas their nanosized structures facilitate the
nanoformulation to escape through the leaky vasculature and release of drug at the tumor sites
owing to their enhanced permeability and retention effect [271]. Self-assembled drug
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Figure 2-7. Preferential cell death induced by PVP/PTX-SAs in MDA-MB-231 cells
A) Tubulin stabilization images of PVP/PTX Self Assembly. Effects of PVP/PTX-SA and PTX
through PTX-induced microtubule stabilization by mitotic arrest leading to cell death. Cells have
been treated with equivalent concentrations of 5 nM PTX or PVP/PTX-SA for 8 hr. Imaged by
Carl Zeiss LSM 710. Original magnification 400X. B) MDA-MB-231 cells were treated with 10
nM PVP/PTX-SAs or PTX or respective controls for 48 hours. Cell lysates were analyzed to
detect levels of Bax, Bid, Cleaved Caspase 7, Cleaved PARP, Bcl-xL, and MDR1, with β-actin
as a control. The results were consistent in two independent sets of experiments.
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Self-assembled drug nanoparticles have gained significant interest in the therapeutic field due to
biocompatibility [272], biodegradability, and low immunogenic properties [273, 274].
In this study, we have examined the ability of eight commonly used pharmaceutical
polymers to generate Poly/PTX-SAs. Among these eight polymers, PVP polymer not only was
capable of producing the smallest size (140.53 nm) with negative zeta potential (-6.21 mV)
(Figure 2-1) but exhibited lower toxicity with RBCs (Figure 2-2). This behavior is better than
PTX alone. Additionally, these PVP-C6-SAs exhibit superior interaction with BC cells compared
to other Poly/C6-SAs (Figure 2-3). The size and zeta potential properties of the PVP/PTX-SAs
formulation resembles clinically used PTX nanoparticle formulations such as Abraxane® and
Genexol® PM. A negative zeta potential is favorable for the stability of the particles, prevents
them from binding to the plasma proteins and prolongs the circulation time of the nanoparticles
[275]. Owing to such physicochemical characteristics of these nanoparticles of nanosized range
and negative zeta potential, off-target delivery can be avoided. As it is the inherent nature of
these nanoparticles, they tend to target at the tumor site [276]. The self-assembly formation of
PVP and PTX was further confirmed by TEM (particle assembly leads to 53.81 nm) and a
continuous dose-dependent binding profile with PTX in fluorescence quenching experiments
(Figure 2-4). From the spectral analysis it is confirmed that the presence of chemical
functional/repeating units of PVP and PTX in PVP/PTX-SAs that are found in the particles,
suggesting that the integrity of the polymer(s) and PTX is maintained in the formulation.
PVP is widely used as an inactive pharmaceutical excipient for binder/disperser, film
former, flavoring liquid, and adhesive applications for multiple uses such as tablets, capsules,
ophthalmic solutions, and transdermal patches. Earlier in 1950’s, PVP was used as a plasma
volume expander. More importantly, PVP is considered as a generally safe chemical for many
uses by the FDA. Thus, it may hold promise in delivering PTX too. PVP was earlier
implemented as a binder/stabilizer for PTX in a reverse microemulsion [277], solvent
evaporation [278] and nanoprecipitation methods for PTX/PVP-PCL nanoparticles (110 nm)
[279, 280]. These studies support our current findings that PVP is a better choice for holding
PTX in self-assembly grooves. PVP has been used as a solid dispersion for PTX and docetaxel
[281, 282]. Also, Sharma et al [277] also developed PVP nanoparticle-encapsulated Taxol®. Our
approach is direct self-assembly or solid dispersion method while the above formulation is based
on the reverse microemulsion method. Based on our study, we believe that the self-assembly of
PVP and PTX may happen due to co-precipitation.
To further utilize PVP as a self-assembly binder or delivery carrier for PTX, the
nanoparticle must interact more closely with cancer cells and release effectively into the cytosol
for maximizing the pharmacological effects of PTX. Through this study, we proved that the
PVP/PTX-SAs induce a greater amount of formulation in cancer cells as observed with
fluorescence microscopy and flow cytometry (Figure 2-3). Additionally, PVP/PTX-SAs exhibits
superior anticancer activity in proliferation and clonogenic assays against BC cells, compared to
PTX alone (Figures 2-5 and 2-6).
PTX is a classical and unquestioned microtubule inhibitor which exhibits clinical success.
PTX promotes tubulin polymerization and stabilization of microtubules resulting in G2-M phase
arrest and thus mitotic cell death occurs [283]. Development of improved tubulin-binding drugs
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or improving PTX tubulin-binding and improving the stability of microtubules’ efficiency with
formulations of any type are considered to be attractive in cancer therapeutics. In this
investigation, we observed that our lead PVP/PTX-SAs are acting significantly on cell tubulin
dynamics and tubulin polymerization, thus contributing to mitotic block in two BC cells (Figure
2-7A) [284]. This determines the impact of PVP’s role in this formulation as a drug carrier. In
cancer therapeutics, apoptosis induced by the Bcl-2 family is an important parameter as it allows
prediction of the mitochondrial pathway [285]. In this regard, our study results showed distinct
effects of PVP/PTX-SAs on apoptotic signaling with reduced expression of Bcl-xL, a profound
expression of pro-apoptotic proteins (Bax and Bid), and the expression profile of Cleaved PARP,
and Cleaved Caspase 7, in comparison to control and native drug treatments. This demonstrates
that enhanced apoptotic cell death occurs with PVP/PTX-SAs treatment than with conventional
exposure [286]. These results further affirm enhanced toxicity effects of prepared samples and
are well consistent with the results of proliferation and clonogenic assays.
Altogether, PVP/PTX-SAs demonstrated that these nanoparticles are taken up by BC
cells and induce superior anticancer activity in BC cells (Figure 2-8). Further, PVP is known to
provide extensive stability to the therapeutic molecules and reduction of renal clearance [287].
These data support the feasibility of developing PVP/PTX-SAs as nanoparticle-based
therapeutics for improving the therapeutic benefits of PTX. If needed further to generate this
PVP/PTX-SAs targeted drug delivery technology, we have designed numerous experimental
targeted delivery protocols [258, 259, 261] that will be implemented to achieve higher
therapeutic benefits of this self-assembly nanoparticle formulation through targeted
approachability.
Conclusion
Introducing clinically relevant PTX (a hydrophobic anticancer drug) into self-assembled
nanoparticles was successfully achieved. Based on particle size, cellular uptake, and hemolysis
assays, PVP/PTX-SAs were found to be better formulations over seven other Poly/PTX-SAs. We
observe superior anticancer effects of PVP/PTX-SAs through inhibition of proliferation and
colony formation, which were further confirmed by tubulin stabilization and immunoblot
analysis. These findings highlight the advantages of the implementation of PVP/PTX-SAs in
comparison to other conventional PTX formulations. Although this approach led us to develop
nanoparticles that showed better efficacy in comparison to conventional Taxol®, yet their real
time benefits need to be warranted in other in vitro and in vivo models to gain mechanistic
insights.
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Figure 2-8. Schematic and hypothetical structural representation of PVP/PTX-SAs
Color, dimensions and assembly are not comparable to synthesized formulation.
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CHAPTER 3.

TANNIC ACID-INSPIRED PTX NANOPARTICLES FOR ENHANCED
ANTICANCER EFFECTS IN BC CELLS2
Introduction

BC is one of the most commonly diagnosed cancers in American women in the United
States [288]. Currently, 1 in 8 women (about 12%) may develop BC in their lifetime. American
Cancer Society 2018 statistics projected that about 266,120 new BC diagnoses and 40,920 deaths
will occur due to this disease [288]. Apart from hormonal therapy, chemotherapy is the most
effective treatment for BC. Historically, the importance of taxane drugs in BC is well
established. PTX is a taxane derived from the bark of Taxus brevifolia, first isolated and
structure elucidated in 1971 [175]. The first generation pharmaceutical formulation (Taxol®) is
well known for improving the overall survival rate and progression-free survival of patients [289,
290]. It was approved for the treatment of various cancers including BC. Despite the therapeutic
benefits, the presence of Cremophor EL and ethanol in this formulation exerts serious adverse
effects.
Various nanomedicine technologies have been put forth into the development of PTX
delivery systems that not only increase the bioavailability of PTX, but also lower Taxol®associated systemic toxicities [291]. For instance, a clinically successful PTX nanoformulation is
Nab-PTX, composed of solvent-free PTX protein-bound particles (Abraxane™). This
formulation potentiates the selective uptake of PTX in tumors (~33% greater tumor uptake vs.
conventional PTX) and shows improved therapeutic index, lower systemic side effects, and
avoids steroid premedication. Nab-paclitaxel was FDA-approved in 2005 for chemotherapeutic
treatment of metastatic BC. Its later clinical trials led to FDA approval to treat non-small cell
lung cancer (2012) and metastatic pancreatic cancer (2013). Similarly, many other PTX
preclinical nanoformulations, notably Genexol PM®, NK-105, Paclical®, Lipusu®, PICN, SB05,
LEP-ETU, and Triolimus, have received heightened attention in cancer treatment. However,
many of these formulations have not made an impact similar to Nab-PTX. Many dietary
polyphenolic compounds derived from plant sources are known to exhibit anti-cancer and
chemosensitization properties. Strong scientific evidence suggests [292] that the incorporation of
bioactive compounds in one’s diet can often reduce the risk of cancer and other chronic diseases.
These foods are consumed daily by humans and are thus non-toxic. Among many naturally
occurring polyphenolic compounds, tannic acid has received much attention lately due to its
excipient value in pharmaceutics, giving it medicinal value. Furthermore, TA has been employed
in generating several biocompatible products for biomedical applications.
Tannic acid belongs to a subset of hydrolyzable tannin congeners commonly found in a
variety of plants, fruits, grains, nuts, and tea leaves. Lately, TA has attracted attention as being an
additive molecule, one that can provide improved solubilization of various hydrophobic drugs
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(amphotericin B, curcumin, rapamycin, PTX, or docetaxel) for localized to parenteral
applications. TA renders such additive features due to its low viscosity (easy for generating
formulations), excellent water solubility (not all polyphenols exhibit water solubility), and
biocompatibility. TA inherently possesses such desired nanocarrier properties primarily because
it can bind to drug molecules via hydrophobic interactions, which in turn forms a self-assembled
crosslinked network via acting as hydrogen-bonding donor [293, 294].
In our previous chapter, we utilized the self-assembly process for the generation of
hierarchically ordered structures, to generate a polymer-based nanoparticle system. However,
despite having a potential therapeutic effect in comparison to PTX, yet faces disadvantages
associated with the conventional delivery system, such as drug efflux [295, 296] and nontargetability, due to the presence of extracellular matrix [297]. Thus, the goal of this chapter was
to generate PTX nanoformulations by combining pharmaceutical excipients that not only impart
solubilization of PTX but also contribute to chemosensitization, such as prevention of
development of drug resistance. In our pilot study, the generation of a series of pharmaceutical
small-molecule excipient-based PTX formulations, and then screening for specific/strong
binding, lower particle size, and enhanced cellular uptake in BC cells, indicate that the TAbound PTX nanoparticles (TAP NPs) formulation is the best candidate for further study.
Therefore, the aim of this study was to design, optimize, and evaluate the improved in vitro
therapeutic efficacy of TAP NPs in BC.
Materials and Methods
Chemicals and Solvents
Aquaplex® (randomly methylated β-cyclodextrin, catalogue no. AP-OLEC2), Trappsol®
(carboxymethyl-β-cyclodextrin (CM-β-CD), catalogue no. TCMBPY), β-cyclodextrin (β-CD,
catalogue no. TBCD-P), and hydroxypropyl-β-cyclodextrin (HP-β-CD, catalogue no. THPB-P)
were received from CTD Holdings, Inc. (Alachua, FL). L-ascorbic acid (L-AC, catalogue no.
A7506), D-α-tocopherol (D-α-TP, catalogue no. 57668), Tween 80 (T80, catalogue no. P1754),
D-mannitol (DM, catalogue no. M4125), D-sorbitol (DS, catalogue no. S1876), citric acid (CA,
catalogue no. 251275), tannic acid (TA, catalogue no. 403040), and 4-(2-Hydroxyethyl)
piperazine-1-ethanesulfonic acid, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)
(HEPES, catalogue no. H3375) were purchased from Aldrich (St. Louis, MO, USA). LC-MS/MS
mobile phase solvents (methanol, formic acid and acetonitrile) were purchased from Aldrich. All
of these chemicals, reagents, and solvents were analytical or HPLC grade and were used as
received without further purification.
Cell Culture
The BC cell lines (MDA-MB-231 and MCF-7) were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA). These cell lines were cultured in Dulbecco's
Modified Eagle Medium (DMEM) that was supplemented with phenol red, 10% fetal bovine
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serum, 100 U/ml penicillin and 100 U/ml streptomycin (Thermo Fisher Scientiﬁc, Grand Island,
NY). For all experiments, cell lines were incubated at 37°C in a humidified 5% CO2 and 95% air
atmosphere (Thermo Fisher Scientific, Waltham, MA, USA). At 80-90% confluency, these cells
were trypsinized, counted using Trypan Blue (0.4%) and seeded as per specific experiments.
Cells were allowed to adhere to the plate surface overnight before implementing any further
treatment.
Preparation of Nanoparticles
We have screened a set of eleven commonly used water-soluble pharmaceutical
excipients/small molecules Aquaplex®, Trappsol®, L-AC, CA, DM, β-CD, HP-β-CD, D-α-TP,
DS, T80, and TA to achieve the best PTX nanoformulation. The PTX nanoparticles were
prepared by the solvent evaporation method. Being lipophilic, PTX was dissolved in acetone
(stock concentration, 1 mg/ml). Pharmaceutical excipient(s) (5 mg) were dissolved in 1 ml of
ultrapure water (Milli-Q® Integral ultrapure water, 18.2 MΩ-cm) in 8 ml flat-bottom glass vials
on a Benchmark digital magnetic stir plate (400 rpm, ABC Scientific, Glendale, CA, USA) at
room temperature. To this solution, PTX in acetone solution (100 μl of 1 mg/ml) was slowly
added dropwise to this solution. The stirring speed was increased to 900 rpm and the solution
was allowed to stir overnight to ensure that all of the acetone evaporated, leaving behind the
nano self-assembly of small molecule and PTX, referred to as pharmaceutical excipient-PTX
nanoparticles (PE-PTX NPs). For particle size, zeta potential, cellular uptake, and hemolysis
experiments, a fresh batch of PE-PTX nanoparticles was always prepared. Note: the tannic acidPTX nanoformulation will be referred to as TAP NPs (Tannic Acid-Paclitaxel Nanoparticles).
This is a specifically optimized formulation with low particle size, superior cellular
internalization, and better hemocompatibility.
Particle Size and Zeta Potential
The hydrodynamic mean particle size (nm) and the size distribution/polydispersity (PDI)
of PE-PTX NPs were measured by Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK)
based on the dynamic light scattering principle. These measurements were performed at 25°C
with an angle of detection of 173°. For this determination, 50 μl of 100 μg/ml of PE-PTX NPs
were added to 1 ml of ultrapure water and subjected to probe sonication (VirSonic Ultrasonic
Cell Disrupter 100, The VirTis Company, Gardiner, NY) for 30 secs. The average diameter and
distribution of particle sizes of the samples were reported from 3 runs (each run took ~2 min).
The zeta potential of these nanoparticles (50 μl of 100 μg/ml PE-PTX NPs in 1 ml of 1X PBS)
was determined by a laser Doppler microelectrophoresis technique using Zetasizer. Each
measurement was carried out in triplicate (each reading = 30 runs). Additionally, we determined
the particle size and zeta potential of the optimized formulation (TAP NPs) in HEPES buffer at
pH 6, 7, 7.4 and 8 to investigate the alteration in size distribution and charge with the change in
pH. For this purpose, freshly prepared 1 mM of HEPES buffer using HEPES salt in ultrapure
water was prepared. The pH of the buffer solutions was adjusted with 0.1 N HCl and NaOH
solutions and stored at 25oC.
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Quenching Assay
Binding affinities of the pharmaceutical excipients to PTX (PTX conjugated to Oregon
green 488 conjugate with a Flutax-2, Molecular Probes Inc., Life Technology, OR, USA) were
determined following fluorescence decay of PTX using a SpectraMax Plus plate reader
(Molecular Devices, Sunnyvale, CA). PTX conjugated to Oregon green 488 was used instead of
PTX for this experiment. The PTX conjugated to Oregon green 488 at a concentration of 5 μg/ml
was set for this study. The concentrations of PE solutions were as follows: 0, 5, 10, 15, 20, 30,
80, and 130 μg/ml. The fluorescence spectra were obtained by exciting these solutions at 496 nm
and emission set between 450-600 nm. All measurements were performed at room temperature.
The fluorescence decay profiles of PE-PTX samples were used to calculate the number of
binding sites and the binding constant (k) [298].
Cellular Uptake
The cellular uptake of these nanoformulations in MDA-MB-231 and MCF-7 BC cells
was determined by tracking fluorescent dye C6-loaded NPs. C6 was loaded in pharmaceutical
excipient nanoparticles (PE-NPs) similarly as described in Section 2.3. For the qualitative
cellular uptake experiment, 0.5×106 cells were seeded in a 12-well plate and allowed to adhere to
the plate surface overnight. On the next day, the cells were treated with PE-NPs at a
concentration of 5 μM for 3 hours. After treatment, cells were washed with 1X PBS, then phenol
red-free DMEM medium was added and imaged under the GFP channel (Ex 470 nm/Em 525
nm) of EVOS® 214 FL Imaging System (AMF4300, Life Technologies, Carlsbad, CA, USA).
For semi-quantification of C6 loaded in PE-NPs inside the BC cells, they were trypsinized using
0.25% Trypsin-EDTA, pelleted down, washed twice with 1X PBS, collected, and dispersed in 1
ml phenol red-free DMEM medium. These cell suspensions were injected into the Accuri C6
Flow Cytometer (Accuri Cytometer, Inc., Ann Arbor, MI, USA) and fluorescence levels were
detected in FL1 channel using 220 FITC/GFP green filter with an excitation at 488 nm (Blue
laser, 530 ± 15 nm).
Hemocompatibility
The hemolysis assay was performed to determine the hemocompatibility of PE-PTX NPs
with freshly collected human blood samples from Interstate Blood Bank, Inc., (IBBI, Memphis,
TN, USA). The IBBI has appropriate ethical approval and authority to collect blood samples and
distribute for research and clinical work. The blood sample (1 ml) was centrifuged at 2000 rpm
for 5 mins, then the supernatant was discarded and the red blood cell (RBC) pellet was
suspended in 10 ml isotonic PBS and 200 μl of cell suspension was used for the
hemocompatibility assay. This RBC solution was treated with 10-100 μg/well PTX (in DMSO)
or an equivalent concentration of PTX in PE-PTX NPs in a 96-well plate and incubated for 1
hour at 37°C. For this experiment, PBS and sodium dodecyl sulfate (SDS at 1 mg/ml) served as
negative and positive experimental controls, respectively. After the incubation period, the
hemoglobin released into the medium was collected and transferred into a fresh 96-well plate and
hemoglobin optical density was quantified using a spectrophotometer (Cytation 3 imaging
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reader, BioTeK Winooski, VT, USA) at λmax570 nm. The percentage of hemolysis was
calculated using Equation 2-1. To confirm our results, a few drops of the treated RBCs were
collected after the quantification and smeared on a glass slide using the coverslip and imaged
using the EVOS® FL Imaging System (AMF4300, Life Technologies, Carlsbad, CA, USA).
Physiochemical Characterization of TAP NP Formulation
Freshly prepared solution samples of TAP NPs were lyophilized in the Labconco Freeze
Dry System (-52°C 133 x 10-3 m Bar; Labconco, Kansas City, MO, USA). The freeze-dried
samples were used to record physicochemical characterization data, such as Fourier Transform
Infrared (FTIR) spectra; thermogravimetric analyzer (TGA) scans; and X-ray diffraction (XRD
data. FTIR spectra of TAP NPs were recorded on a Universal Attenuated Total Reflectance
(UATR) Accessory plate by a Spectrum 100 FTIR spectrometer (Waltham, MA). The
lyophilized samples were placed on the tip of the UATR diamond objective and a pressure of
90 N/cm2 was applied. Spectra were acquired between 4000 and 650 cm-1 at a scanning speed of
4 cm-1 for 32 scans. The averaged data were presented as FTIR spectra (%T vs. cm-1) and
analyzed using Spectrum 100 software. A Q50 thermogravimetric analyzer (TA Instruments,
New Castle, DE) was used for TGA analysis under a dry nitrogen atmosphere with a flow rate
and heating rate of 10 ml/min and 10°C /min, respectively. Thermogravimetric profiles were
recorded from 50°C to 500°C. A Rigaku D/Max-B diffractometer (Rigaku Americas Corp,
Woodlands, TX) with cobalt-alpha radiation (k = 1.5 Å) was used for phase identification for
crystalline material analysis. XRD patterns were acquired over 2θ range from 25o–70oC. The
morphology and particle size of TAP NPs (after drying on grids) were determined using a JEOL
200EX transmission electron microscope (TEM) (JEOL Ltd, Tokyo, Japan) coupled with an
AMT camera. For this study, TAP NPs (20 μl of 100 μg PTX-equivalent/ml of TAP NPs) were
placed onto the shiny side of the copper grid (150 mesh, Electron Microscopy Sciences, PA,
USA). A 2% w/v aqueous solution of uranyl acetate was used to stain TAP NPs to increase
contrast property. The air-dried TAP NPs were imaged under the TEM at a direct magnification
of 100,000x.
Quantitative Analysis of TAP NPs
LC-MS/MS analysis
The concentrations of PTX in the TAP NPs were measured by liquid chromatographytandem mass spectrometry (LC-MS/MS) using an LC system (Shimadzu Corporation, Kyoto,
Japan) connected to a Triple Quad 5500 tandem mass spectrometer (AB SCIEX, Framingham,
MA). The mobile phase was water with 0.1% formic acid and acetonitrile with 0.1% formic acid
(v/v). The gradient elution was as follows: the starting condition was set at 50% mobile phase B
and was kept at 50% for the first min. The percentage mobile phase B was then increased from
50% to 100% from 1-2 min, maintained at 100% up to 4 mins, and then decreased to 50% up to 5
mins, and maintained at 50% until 6 mins elapsed time. The flow rate was set at 0.8 ml/min and
total run time was 6 mins, with a retention time of 2.36 mins for PTX. Docetaxel (DTX) was
used as an internal standard. Separation was achieved using XTerra® MS C18 Column
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Reversed-Phase 3.5 μm Spherical Hybrid, 4.6 mm x 50 mm (#186000432, Waters, Milford,
MA). The following mass spectrometry ionization parameters were used: positive electrospray
ionization mode, curtain gas pressure set at 20 psi, collision-activated dissociation at 10 psi, ion
spray voltage at 5500 V, the temperature at 60°C, gas 1 and gas 2 pressure at 50.0 psi,
declustering potential at 51.0 V, entrance potential at 10.0 V, collision energy at 21.0 V, and
collision exit potential at 24.0 V. Analytes were quantified using multiple reaction monitoring to
monitor the ion transitions of m/z 876.3→308.0 for PTX and m/z of 830.4→549.2 for DTX. The
calibration standards for the analysis of drug encapsulation efficiency study were prepared in
PBS, whereas CelLyticTM M (C2978) was used for the calibration standard preparation for
cellular uptake study. The range of linear response of PTX was 0.039-40 μg/ml with R2=0.9916
in PBS and 0.01-10 μg/ml with R2=0.9959 in cell lytic buffer.
Encapsulation efficiency
Encapsulation or entrapment efficiency (EE) of PTX in TAP NPs was quantified by using
LC-MS/MS. TAP NPs were centrifuged at 10,000 rpm for 10 mins to remove larger particles and
non-encapsulated drug as a pellet. Supernatants were analyzed for drug content using LCMS/MS. The EE was calculated by Equation 3-1.
 ܧܧൌ  ሾݏܲܰܲܣܶ݊݅݃ݑݎ݂݀ݐ݊ݑ݉ܣሺρ݃ሻȀ݃ݑݎ݂݀ݐ݊ݑ݈݉ܽܽ݅ݐ݅݊ܫሺρ݃ሻሿ  ൈ ͳͲͲ (Eq. 3-1)
Intracellular drug uptake
To determine in vitro intracellular concentration of PTX in MDA-MB-231 cells, cells
were seeded in 150 mm petri dishes and allowed to attain 60-70% confluency. Each of the petri
dishes at the defined time point was treated with 500 ng of PTX or equivalent concentration of
PTX in TAP NPs. Control cells without any treatment served as a control for this study. After 2,
4, and 6 hours of treatment, cells were washed with 1X PBS to remove any unwanted drug
adhering to the cell surface, followed by trypsinization and centrifuging at 1000 rpm for 5 mins.
For extraction of internalized drug from cells, the trypsinized and centrifuged pellet was resuspended in CelLyticTM M buffer and sonicated using 30 cycles of Ultrasonic Homogenizer
(Biologics, Inc.), active every 10 secs for a 5 mins duration at 200 W, on an ice bath. The
internalized drug extracted from cells was measured by LC-MS/MS. Data were represented in
triplicates or greater number of determinations.
Biological Assays
Cell proliferation assay
MTT assay was performed to assess the superior cytotoxicity of TAP NPs over PTX on
BC cells. Briefly, 5×103 BC cells (MDA-MB-231 and MCF-7) in 100 μl of media were seeded
in a 96-well plate and allowed to rest in the incubator at 37°C overnight. Cells were treated with
1-50 nM PTX or 1-50 nM PTX-equivalent TAP NPs, and controls of untreated cells, DMSO, and
plain TA, respectively, for 48 hours. Afterward, cells were incubated with 20 μl of MTT reagent
and incubated for 2-3 hours until the formazan salts formed. The media was aspirated out very
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carefully (as not to disturb any formazan crystals) and 100 μl of DMSO was added to dissolve
the salt formation [299]. The absorbance was recorded using a Microplate Reader (BioTeK
Cytation 3, Winooski, VT, USA) at 570 nm. Each treatment concentration was studied in
triplicate determinations. The cell proliferation ability of PTX or TAP NPs was determined as
the percentage in contrast to the control (DMSO or TA). Changes in cell morphology following
treatment were imaged using EVOS® FL Imaging System at 20X magnification.
Clonogenic assay
This study was performed to investigate the influence of TAP NPs on the clonogenic
forming ability of BC cells. Briefly, MDA-MB-231 and MCF-7 (250 cells/well in 1 ml) were
seeded in a 12-well plate and allowed to adhere to the plate and grow smaller colonies in 2 days.
Then cells were treated with 0.25, 0.5, and 1 nM PTX and 0.25, 0.5, and 1 nM PTX-equivalent
TAP NPs and respective controls (no treatment and TA-treated BC cells). These cells were
allowed to rest in the incubator for the next 15 days, with intermittent changing of medium but
no drug added. After 15 days visible colonies were processed for staining with hematoxylin and
imaged according to our previous reports [300]. The number of colonies formed was represented
as bar graphs to represent the difference in the effect of each treatment group. The results are
presented as the percentage of colonies in contrast to the control groups (non-treated cells).
Cellular migration
Cell migration was analyzed using the Boyden’s chamber cell migration assay [301, 302].
Briefly, MDA-MB-231 (0.5×105) cells were suspended in serum-free media with 5 and 10 nM of
PTX or equivalent amounts in TAP NPs, added to the upper chamber of the 96-transwell inserts
(catalog no.3374, Corning, NY, USA). These inserts were then placed inside the 96-well plates
in pure media (10% FBS). After 24 hours incubation, the migrated cells at the lower inside of the
Transwell inserts were fixed with 4% formaldehyde and stained with crystal violet, with cells on
the upper side of the insert being removed with a cotton swab. Inserts were imaged using the
EVOS® FL Imaging System, the number of migrated cells were counted and expressed as a
percentage with respect to the migrated control cells (cells with no treatment).
Cellular invasion
Cellular invasion was measured using the BD Biocoat Matrigel Invasion Chambers (BD
Biosciences) [302]. MDA-MB-231 (3.5 × 104 cells) were seeded in the matrigel invasion
chambers (BD Biosciences, Bedford, MA, USA) in serum-free medium and treated with 5 and
10 nM PTX or 5 and 10 nM equivalent PTX of TAP NPs for 24 hours. 10% FBS medium was
placed into the lower chamber as chemoattractant. The invaded cells were fixed with methanol
and stained using crystal violet. The plates were imaged and were counted as described in section
2.10.3.
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Drug Resistance Assays
P-gp ATPase activity
To investigate the effect of TAP NPs on the inhibition of P-gp efflux pump, the P-gpGlo Assay Systems (Promega, USA) was used per manufacturer’s instructions. This assay can
be used to determine the effect of a compound to characterize inhibitors of P-gp ATPase activity.
Na3VO4 is used as a negative control and verapamil is used as a positive control for drug
stimulation of P-gp ATPase activity. The test compounds were PTX, TAP NPs, and TA, while
untreated samples served as our experimental control. The manufacturer’s protocol was followed
for the experiment.
TM

Rhodamine-123 efflux assay
To study the difference in P-gp expression with the treatment of TAP NPs, the RH123
accumulation assay was employed [303]. For this study, 0.5×106 of MDA-MB-231 BC cells
were seeded in a 6-well plate and allowed to adhere to the surface overnight. The next day, cells
were treated with 5 and 10 nM of PTX or 5 and 10 nM of PTX-equivalent TAP NPs. After 48
hours, 2.62 μmol/l of RH123 was incubated with cells for 30 mins. Following incubation, cells
were washed with 1X PBS and imaged using phenol red-free DMEM medium under an EVOS®
214 FL Imaging System [260]. For semi-quantification, cells were then trypsinized, pelleted
down, washed with 1X PBS, and suspended in phenol red-free DMEM medium and analyzed
using Accuri C6 Flow Cytometer in FL1 channel with an excitation at 488 nm (Blue laser, 530 ±
15 nm).
β-tubulin Stabilization
The treatment effect of TAP NPs on tubulin stabilization was studied by confocal
imaging. For this, MDA-MB-231 (0.25 × 106) cells were grown on coverslips and were treated
with 5 and 10 nM PTX or PTX equivalent TAP NPs for 8 hours. Blank TA and cells with DMSO
treatment served as our experimental control. The treated cells were fixed in 4%
paraformaldehyde in PBS, pH 7.4 for 15 mins at room temperature. Fixation was subsequently
quenched with 0.1 M glycine and washed in PBS. After washing, cells were blocked in 10% goat
serum/5% BSA/0.5% TritonX-100 in PBS for 1 hour at RT. Following blocking, sections were
incubated with 1:50 Anti-beta Tubulin antibody (#ab6046, Abcam, Cambridge, MA) overnight at
4°C, on a rocker at 20 oscillations/min. The next day, after washing in blocking buffer three
times for 5 mins each, cells were probed using Goat anti-Rabbit IgG (H+L) Cross-Adsorbed
Secondary Antibody, Alexa Fluor 488 (catalog no. A11008) and DAPI to label nuclei for 1 hour.
After washing in PBS four times for 5 mins each, coverslips were mounted using Prolong
Diamond Antifade Mountant (catalog no. P36961) and imaged using a laser confocal microscope
(Carl Zeiss LSM 710, Thornwood, NY, USA) with a 40×0.7NA oil immersion objective. All
images were captured using the same laser power and gain settings to ensure comparability for
intensity analysis. Fluorescent intensities were quantified using Image J. Data were represented
by measuring fluorescent intensities from 18 individual cells.
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Western Blotting
MDA-MB-231 BC cells (1 ×106) were seeded in a 100 mm dish and allowed to adhere to
the surface overnight. The next day, these plates were treated with 10 nM PTX or 10 nM PTXequivalent TAP NPs, and their respective controls of untreated cells and TA treated cells, for 48
hours. Cell lysates were formed using 2X SDS lysis buffer (Santa Cruz Biotechnology, Santa
Cruz, CA) and the protein was quantified using Bradford assay and run on a SDS-PAGE [304,
305]. The expressions of specific proteins were determined with an immunoblotting assay as
described above. Protein expressions confirmed by immunoblotting were β-actin (#4967), BclxL (#2762), Bad (#9268), p53 (#2527), Cleaved Caspase-7 (#9491), MDR1/ABCB1 (#13342),
and Cleaved PARP (#9548) (Cell Signaling Technologies, Danvers, MA). The protein bands
were developed under the ChemiDocTM MP System (Bio-Rad, Hercules, CA, USA) with the help
of Lumi-Light Detection Kit.
RNA Extraction and Microarray Studies
The gene regulatory effects of TAP NPs on BC cells were evaluated by microarray
studies. For this, MDA-MB-231 cells (1×106) were seeded in a 100 mm dish and allowed to
reach 60-70% confluency before treating with PTX and TAP NPs for 24 hours. The RNA was
extracted, purified, and processed as described in our previous study [306]. The RNA integrity
was confirmed through NanoDrop™ 2000 (Thermo Fisher Scientific, Waltham, MA, USA). In
this study, the clariomTM S Human gene array (Affymetrix, Santa Clara, CA, USA) was
employed as gene chips, and the assay was performed per the manufacturer’s protocol.
Statistical Analysis
All data were generated and analyzed using GraphPad Prism 5.03 Software (GraphPad
Software, San Diego, CA) and results are presented as mean ± standard error of mean (SEM).
Statistical significance was performed using a student’s t-test analysis when comparing between
two groups. When comparing the statistical significance among multiple treatment groups oneway ANOVA post-hoc Tukey HSD test was performed and a p-value <0.05, was considered
significant when compared to control.
Results
Screening of Pharmaceutical Excipients for PTX Delivery
The main purpose of conducting this study was to develop a nanoformulation against BC
that would possess superior anticancer activity [307]. For this purpose, we developed
nanoformulation(s) of PTX utilizing eleven commonly used pharmaceutical excipients:
Aquaplex®, L-ascorbic acid, citric acid, beta-cyclodextrin, carboxymethyl-beta-cyclodextrin, Dmannitol, hydroxypropyl-beta-cyclodextrin, D-α-tocopherol, D-sorbitol, tannic acid, and Tween
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80. The drug–loaded, self-complexed nanoparticles were prepared with a self-assembly
technique. Incorporation of PTX dissolved in acetone occurred when the drug solution is placed
in a polymer excipient solution overnight. Evaporation of acetone allows nanoparticles to form a
suspension in an aqueous phase. The resultant nanoparticles generated with all the above
pharmaceutical excipients were screened and characterized for particle size and size distribution,
surface charge, drug binding efficiency, hemocompatibility, and cellular uptake in cancer cells
(Table 3-1). Figure 3-1A represents particle sizes of all the PE-PTX NPs generated. Among
these, TAP NPs and Tween 80-PTX NPs demonstrate good particle sizes of <100 nm, which is
considered optimal from a drug delivery standpoint. However, Tween 80-PTX NPs, despite
having a low particle size of 80.68+7.13, the lower number of available binding sites and low
binding rates limits its further optimization.
The PTX-conjugated Oregon green 488 quenching ability with all pharmaceutical
excipients was determined with a fluorescence spectrophotometer. The fluorescence intensity of
the PTX dye decreases with the increase of pharmaceutical excipients. This quenching is at a
maximum with tannic acid as seen in Table 3-1 (Column 4: Dye quenching). In contrast to all
the other ten pharmaceutical excipients employed, TA has the minimum area under the curve
(AUC), demonstrating that PTX dye is quenched by TA, which causes the most reduction in
AUC (Figure 3-1B). This is directly correlated to the binding ability of tannic acid to PTX by
attractive forces such as hydrogen bonding and electrostatic interactions. The superior binding
efficiency with tannic acid was confirmed from the higher number of binding sites (1.4) and
binding constant (0.03) over other pharmaceutical excipients. Table 3-1 shows ascorbic acid has
a similar reduction in AUC, the total number of binding sites and binding constant as tannic acid;
however, its large particle size of 321.63 nm (as formulated into nanoparticles) limits its further
use.
Tannic acid-PTX nanoparticles (TAP NPs) formation by the self-assembly process was
confirmed by space-filling energy-minimized (MM2) molecular modeling using ChemBio3D
Ultra 14 Suite (CambridgeSoft Corporation, A subsidiary of PerkinElmer, Inc.). The spacefilling energy-minimized molecular models of different ratios of TA:PTX (1:1, 2:1, 3:1, 4:1, 5:1,
6:1, 8:1, 10:1 and 12:1) indicates thermodynamically feasible TA-PTX self-assembly formation
(Figure 3-2A). Among many ratios employed for the formation of TAP NPs, TA: PTX ratio of
24:1 leads to a well-organized nanoparticle structure with particle size and zeta potential of
102.22±14.05 nm and -8.85±0.44 mV. The presence of excess TA was utilized as a stabilizing
agent of the nanoformulation, as previously reported [140]. The illustration of the self-assembly
formation of TAP NPs is shown in Figure 3-2B. The nanoparticles generated should be well
internalized inside the cytosolic membrane to be able to deliver therapeutic benefits. In this
regard, we loaded the nanoparticles with a fluorescent dye (C6) to be able to detect through the
GFP channel of the microscope/flow cytometer. This study was investigated using BC cell lines
MDA-MB-231 and MCF7. The cellular internalization was observed to be in the order of tannic
acid > Tween 80 > CM-β-CD > ascorbic acid > aquaplex > β-CD > HP-β-CD > D-mannitol >
citric acid > tocopherol > D-sorbitol for MDA-MB-231, and tannic acid > Tween 80 > CM-β-CD
> ascorbic acid > aquaplex > citric acid > β-CD > tocopherol > D-mannitol >HP-β-CD > Dsorbitol for MCF7 (Table 3-1, Column 7 and 8). Tannic acid demonstrated significantly
increased cellular uptake in contrast to all the C6-loaded excipient nanoparticles, through
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Table 3-1.
Preliminary evaluation of pharmaceutical excipient-based paclitaxel
nanoparticles for developing BC therapeutics
Fluorescence
quenching
Pharmaceutical
excipienta

Particle
size
(nm)

Zeta
Dye
potential quenching
(mV)
(AUC×106)b

Aquaplex®

355.93+
15.97
321.63+
23.22

-4.32+
0.81
-2.25+
0.65

323.60+
27.90
252.50+
14.51

L-Ascorbic acid
(L-AC)
Citric acid (CA)
Trappsol®,
(CarboxyMethylβ-CD)
β-cyclodextrin
(β-CD)
Hydroxypropyl
β-cyclodextrin
(HP-β-CD)
D-Mannitol
(DM)
D-Sorbitol (DS)
Tannic acid (TA)
D-α-tocopherol
(D-α-TP)
Tween 80 (T80)

Mean
fluorescence
intensity
(MFI×105) c
MDA- MCF7
MB231

%
hemolysis
at 50 μgd

1.37+
0.092
1.87+
0.031

0.86+
0.014
0.98+
0.010

2.06+
0.01
3.78+
0.34

0.23+
0.002
2.18+
0.045

0.40+
0.002
2.18+
0.067

50.17+
0.35
7.21+
0.59

1.65

Number
of
binding
site(s)
0.80

Binding
rate
constant
(k)
0.003

0.94

1.38

0.035

-3.60+
0.65
-6.98+
0.78

1.17

0.57

0.008

1.26

0.73

0.012

254.31+
7.58

-5.07+
0.66

1.34

1.05

0.012

0.49+
0.008

0.32+
0.004

12.71+
0.68

213.56+
8.55

-5.59+
0.46

1.47

0.94

0.010

0.47+
0.004

0.18+
0.001

19.24+
3.82

308.33+
19.77
149.76+
4.61
102.22±
14.05
161.06+
21.25
80.68+
7.13

-8.87+
0.46
-7.05+
0.30
-8.85+
0.44
-6.28+
0.05
-6.63+
0.39

1.50

0.41

0.001

2.58

0.63

0.001

0.94

1.40

0.038

1.70

0.46

0.003

2.20

0.43

0.001

0.27+
0.001
0.14+
0.026
4.24+
0.045
0.18+
0.001
2.30+
0.266

0.23+
0.013
0.14+
0.017
4.91+
0.030
0.21+
0.004
2.49+
0.149

1.03+
0.03
6.18+
0.59
5.15+
0.02
9.96+
0.34
9.96+
0.02

a

5 mg/ml of each pharmaceutical excipient was used to generate PE-PTX nanoparticles
Oregon green 488 conjugated to PTX (5 μg/ml) was quenched with 130 μg/ml of PE solutions
c
Coumarin 6 loaded Pharmaceutical excipient nanoparticles (5 μg/ml equivalent coumarin 6
nanoparticles) were treated on breast cancer cells
d
ASTM E2524-08 standard considers hemolysis of <5% safe compounds are safe for human
consumption.
b
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Figure 3-1. Characterization during the screening process
A) Particle size measurement of all the eleven developed nanoformulation as measured by DLS.
B) The binding potential was confirmed by quenching of PTX conjugated dye (PTX, Oregon
Green 488 conjugate (Flutax-2, Molecular Probes Inc., Life Technology, OR, USA)) with
pharmaceutical excipient-PTX (PE-PTX) NPs (5-130 μg/ml).
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Figure 3-2. Formation and optimization of TAP NPs
A) Space-filling energy-minimized (MM2) molecular modeling shows generation of
thermodynamically stable TA-PTX self-assembly. Various ratios as shown above were
employed to generate MM2 models of TA-PTX self-assembly. B) Hypothetical representation of
24:1 ratio of TA: PTX self- assembly, so called Tannic acid Nanoparticles (TAP NPs). For visual
clarity, PTX in hypothetical structure is represented as
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determinations both by flow cytometry (Table 3-1) and the EVOS® FL Imaging System (Figure
3-3A). To implement our generated nanoparticles from bench to bedside, the toxicity profile of
the formulations needs to be assessed. Hemocompatibility assay of these pharmaceutical
excipient-PTX nanoparticles (PE-PTX NPs) were investigated at varying concentrations ranging
from 10-100 μg/well PTX alone and 10-100 μg/well PTX-equivalent PE-PTX NPs. Table 3-1
data show that 50 μg PTX is toxic to RBCs with ~ 63% hemolysis (Figure 3-3B). There was no
significant difference observed with varying concentrations of TAP NPs, while many PE-PTX
NPs were not toxic in nature. Indeed, TAP NPs exhibited a safer profile. This behavior was
further evaluated by the morphological changes of red blood cells that are incurred after
incubating with PTX alone and PE-PTX NPs, respectively (Figure 3-3C). TAP NPs
demonstrated no morphological changes in the structure of RBCs on treatment (similar to
negative control or PBS).
Altogether, the screening of various pharmaceutical excipient based PTX nanoparticles,
studied by particle size, zeta potential, PTX binding, cellular uptake, and hemolysis data suggests
that tannic acid is considered a safe vehicle for PTX delivery, and thus is considered to be the
best candidate for further investigation.
Characterization of TAP NPs
DLS data demonstrated that TAP NPs measured approximately 102.22±14.05 nm
(Figure 3-4A). No specific change in particle size was seen for 6 days after storing the
nanoformulation at room temperature, except for day 7 (Inset of Figure 3-4A), which suggests
that TAP NPs are stable at room temperature for at least a week. Although, extended stability
study needs to be validated in future studies. The effect of changes in pH with nanoparticle
generation was examined by using HEPES buffer (pH range 6-8). Change in size is represented
in Figure 3-4B. These data further suggested that at all recorded pH values (6, 7, 7.4, 8), TAP
NPs demonstrate well-assembled nanoparticles of 154.13, 116, 82.16, 71.55 nm at pH values 6,
7, 7.4 and 8 respectively. TA is a weakly acidic polyphenol with gallic acid molecules that are
capable of donating protons. At higher pH, more phenolate binding sites are available for
effective complexation with PTX. This leads to more packed self-assembly formation of TAP
NPs with lower particle size at higher pH 8 compared to pH 6 (Fig. 3-4B). The TAP
nanoparticles exhibited spherical morphology as seen in Figure 3-4C. As seen under the TEM,
TAP NPs measure an average of 60.55±3.03 nm.
To confirm the presence of PTX and tannic acid in TAP NPs, the molecular composition
was investigated by FTIR spectroscopy (Figure 3-4D). The characteristic peaks at 1700 cm-1,
1603 cm-1, and 1198 cm-1 belong to C=O stretching, aromatic C=C stretching, and phenolic C-O
stretching for tannic acid, whereas characteristic vibrational peaks of PTX include 3350 cm-1 (NH stretching) and 1703 cm-1 (C=O stretching) [24, 25]. The characteristic peak of phenolic C-O
at 1198 cm–1 of TA is shifted to 1100 cm–1 in TAP NPs, while the characteristic band of the
aromatic ring at 1603 cm–1 and ester band at 1700 cm-1 are observed in TAP NPs. Also, the main
characteristic peaks of PTX at 3350 cm–1 and 1650 cm–1 can be detected in TAP NPs due to N-H
and C–C stretching, respectively, indicating the presence of PTX in TAP NPs. Interactions
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Figure 3-3. In vitro screening during screening process
A) Qualitative internalization efficiency of PE-NPs in MDA-MB-231 cells for 3 hours. Images
were captured after incubation with EVOS® FL Imaging System (AMF4300, Life Technologies,
Carlsbad, CA, USA). B) Hemocompatibility of PE-PTX NPs was assessed by incubating 10-100
μg/well PTX equivalent of nanoparticles in each well for 1 hour. (SDS, 1 mg/ml) served as a
positive control while PBS was used as a negative control. No significant difference in
percentage of hemolysis was observed for TAP NPs at all tested concentrations. C) Qualitative
assessment of hemocompatibility of PE-PTX NPs by incubating nanoparticles with RBC for 1
hour. Images demonstrate intact membrane morphology for negative control (PBS), whereas
positive control (SDS) and most of the other PE-PTX NPs exhibited toxicity (seen from the
disintegrating morphology of RBC).
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Figure 3-4. Physio-chemical characterization of TAP NPs
A-B) Dynamic light scattering analysis of TAP NPs: stability over 1-week and in different pH
solutions as measured using Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK) at 25°C.
A) TAP NPs exhibited particle size of 102.22±14.05 nm. Inset: representative particle size of
TAP NPs stored at 25°C for 1-week. B) Stability of TAP NPs in HEPES buffer solutions (pH 6,
7, 7.4 and 8). Data presented as mean + standard error of the mean (n = 3). C) A representative
transmission electron microscopic (TEM) image of TAP NPs. Image was acquired by using
JEOL 200EX TEM at a direct magnification of 100,000× (scale = 100 nm). D) Fourier-transform
Infrared (FTIR) spectral analysis of TA, PTX and TAP NPs acquired on a Universal Attenuated
Total Reflectance (UATR) accessory plate by a Spectrum 100 FTIR spectrophotometer
(Waltham, MA), between 4000 and 650 cm-1 at a scanning speed of 4 cm-1 for 32 scans. TAP
NPs show characteristic TA peaks at 1603 and 1700 cm-1 and PTX peaks at 3350 and 1650 cm–1,
confirming the presence of functional moieties of TA and PTX in TAP NPs. E)
Thermogravimetric analysis (TGA) was recorded for TA, PTX and TAP NPS from 50 to 500°C
by a Rigaku D/Max-B diffractometer (Rigaku Americas Corp, Woodlands, TX) with cobaltalpha radiation (k = 1.5 Å). There is no significant change in thermogram of TAP NPs in
comparison to TA and PTX. F) X-ray diffraction (XRD) was acquired at 2θ range of 25 –70°C
suggesting TAP NPs has both TA and PTX present in amorphous or dissolution state.
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between tannic acid and PTX are mainly through the ester functions, aromatic rings, and
hydrogen bonding mediated by the phenolic hydroxyl groups, which suggest attractive forces
occur between tannic acid and PTX in TAP NPs, but there is no evidence of covalent bond
formation. The physical state of tannic acid and PTX in TAP NPs may influence various drug
delivery properties. Thermogravimetric and XRD analyses were employed to study such
interactions and the physical state of TA and PTX complex structure. Thermograms of tannic
acid (Figure 3-4E) show two major weight loss peaks between 55-100oC due to curing,
reformation, and oxidation, while another appears at 250-400°C due to severe degradation of
tannin intermolecular bonding. In the case of PTX, it exhibited a strong degradation pattern
above 228oC. When PTX is incorporated into TA assemblies, TAP NPs demonstrate degradation
patterns very similar to tannic acid, but it retains its PTX degradation phenomenon too. XRD
patterns of PTX demonstrate several sharp peaks around 5.38, 9.62, 10.74, 11.85, and 12.96°
(2θ) (Figure 3-4F), while TA shows broad peaks at 9.75 and 20.63o (2θ). However, XRD of
TAP NPs does not show such characteristic peaks of either TA or PTX. This suggests that both
TA and PTX are present in the form of amorphous or dissolved states in TAP NPs.
Encapsulation Efficiency and Intracellular Drug Uptake of TAP NPs
The aims of drug entrapment are either enhanced delivery or improved uptake in cancer
cells, and reduction in off-target toxicity. The encapsulation efficiency of PTX in TAP NPs was
determined by LCMS/MS and was > 96.49±0.43%. Drug activity is dependent on crossing the
cellular membrane and forming drug depots in cellular compartments. For this reason, qualitative
analysis of cellular transport of C6 loaded in pharmaceutical excipient nanoparticles (PE-NPs)
was examined in MDA-MB-231 cells in a time-dependent manner and cellular internalization of
C6 was imaged by EVOS® FL Imaging System at 40X magnification, as seen in Figure 3-5B.
After confirming the uptake of TAP NPs in BC cells, we examined cellular transport of PTX
from a plain PTX drug solution vs. TAP NPs in BC cell line MDA-MB-231 in a time-dependent
manner. Cellular internalization of the drug in cancer cells was analyzed using LC-MS/MS; see
chromatogram: standard curve for the LC-MS/MS analysis (inset) (Figure 3-5A). The cellular
internalization behavior of free PTX and TAP NPs are shown in Figure 3-5B. The maximum
PTX concentration measured was 955.24+110.13 ng/ml for 6 hours from TAP NPs in contrast to
free PTX, which attained a maximum concentration of 572+33.44 ng/ml after 6 hours of
treatment. As seen in Figure 3-5B, it is evident that the plain PTX concentration was similar at
all of the tested time points, suggesting PTX concentration inside BC cells was probably due to
efflux by the P-gp transporters on the cell membrane. The drug concentration inside the cells
increased over time with TAP NPs treatment, suggesting that significantly higher accumulation
of drug was achieved (equivalent to 95.52% of drug internationalization through TAP NPs in 6
hours, whereas free PTX could only achieve a maximum of up to 57.19% in the same amount of
time). A plausible mechanism for an enriched amount of PTX in the cellular compartment with
TAP NPs is due to the presence of TA, which is reported to inhibit P-gp function by partly
inhibiting ATPase [308]. We, therefore, suggest that TAP NPs provide higher drug
concentration at the target and result in improved therapeutic efficacy over that of the free drug.
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Figure 3-5. Intracellular uptake of TAP NPs in BC MDA-MB-231 cells
A) Chromatogram of PTX from TAP NPs as seen by LC-MS/MS. B) Cellular uptake of C6
uptake in BC MDA-MB-231 cells were confirmed by fluorescence microscopy an EVOS® 214
FL Imaging System, in a time dependent manner with dye loaded nanoparticles. C) Intracellular
uptake of TAP NPs by LC-MS/MS in MDA-MB-231 after treatment with PTX and TAP NPs for
2, 4 and 6 hours. Drug internalization of 95.52% was achieved by TAP NPs in 6 hours in
contrast to only 57.19% by native drug PTX for the same time. Data presented as mean +
standard error of the mean (n = 3). A Liquid chromatography–tandem mass spectrometry (LCMS/MS) (Shimadzu Corporation, Kyoto, Japan) connected to Triple Quad 5500 tandem mass
spectrometer (AB SCIEX, Framingham, MA. all tested concentrations. To study the migratory
and invasive nature of cancer cells and the effect of TAP NPs and plain PTX, we conducted the
Boyden migration assay and the Matrigel invasion assay on MDA-MB-231.
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TAP NPs Inhibits Proliferation, Clonogenic Formation, Migration and Invasion in BC
Cells
The MTT assay was used to evaluate in vitro cytotoxicity effects of TAP NPs and PTX
(50-1.5 nM equivalent) on MDA-MB-231 and MCF7 BC cells after 48 hours of treatment.
Untreated cells served as a positive control for the experiment. As shown in Figure 3-6A, both
TAP NPs and PTX exhibited a dose-dependent antiproliferative effect. After 48 hours of
treatment, there was a significant reduction in IC50 values of TAP NPs compared to the native
drug PTX. The IC50 values were 6.29 nM and 14.34 nM for TAP NPs in MDA-MB-231 and
MCF7 respectively. A significant reduction in fold change of 2.62 and 1.94 in MDA-MB-231
and MCF7 was observed, respectively. This suggests TAP NPs are more potent in inhibiting the
proliferation of BC cells than free PTX. Figure 3-6B shows a clear change in morphology of
MDA-MB-231 and MCF7 on administration of TAP NPs and PTX (5 nM). To further confirm
the superior cell proliferation effect of TAP NPs, the clonogenic potential of MDA-MB-231 and
MCF7 were determined for two weeks after treatment with TAP NPs and PTX (Figure 3-6C
through D).
Untreated cells and free PTX served as positive and negative control. As seen in Figure
3-7A,B, there was a significant inhibition of clonogenicity with TAP NPs in contrast to PTX at.
Cells were treated with TAP NPs and free PTX (5 and 10 nM, PTX equivalent) and allowed to
migrate across the Transwell inserts for 24 hours as shown in Figure 3-7A,B. No obvious
inhibition was seen in control (untreated cells) or blank TA treatment, whereas TAP NPs showed
significant migratory inhibition over free PTX at all tested concentrations, with 1.26- and 2.96fold inhibition at 5 and 10 nM, respectively. Similar results were achieved by the Matrigel
invasion assay Figure 3-7C,D, where MDA-MB-231 cells were treated with 5 and 10 nM of
TAP NPs and PTX (PTX equivalent) for 24 hours. TAP NPs had similar inhibitory effects on
invasive BC cells with 46.78% and 16.27% inhibition of cells in contrast to 64.62% and 49.53%
inhibition observed with free PTX treatment at 5 and 10 nM, respectively. There was a statistical
difference in the inhibition profile of TAP NPs at 5 and 10 nm in comparison to the native PTX
at the same concentration. These results suggest that TAP NPs not only deliver enhanced
therapeutic benefit over the free drug, but also inhibit cell migration and invasion, or possibly
limit metastasis-related death for clinical applications.
TAP NPs Lower P-gp Expression in BC Cells
To evaluate P-gp function in cancer cells following treatment with TAP NPs and PTX, Pgp-GloTM assay and RH123 efflux assay were performed. The P-gp-Glo assay relies on the ATP
dependence of the light-generating reaction of firefly luciferase. For this experiment, Na3VO4 is
used as a selective inhibitor of P-gp and Verapamil, which is a substrate for P-gp transport, and
may inhibit P-gp activity by competitively interfering with the transport of other substrates [309].
Since Na3VO4 inhibits P-gp activity, less ATP is consumed, resulting in brighter signals or
higher average light units (RLU). TA has been previously reported [308, 310] to be involved in
the modulation of drug efflux and shows similar P-gp inhibitory activity. However, higher
consumption of ATP was observed, indicating PTX is being effluxed by the P-gp membrane, in
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Figure 3-6. Anticancer efficacy of TAP NPs in BC cells
A) Cell proliferation by MTT assay markedly decreased proliferation of BC cells (MDA-MB231 and MCF7) after treatment with 1-50 nM PTX or TAP NPs for 48 hours. Untreated cells
were used as control. Absorbance was recorded by a Microplate Reader (BioTeK Cytation 3,
Winooski, VT, USA) at 570 nm. B) Bright field microscopy images after MTT analysis show
significant changes in cell morphology after 48 hours treatment with TAP NPs and PTX.
Imaging was done by an EVOS® FL Imaging System (20X magnification, scale = 200 μm). C)
Inhibition of colony formation by TAP NPs and PTX (equivalent to 0.25, 0.5 and 1 nM PTX) on
MDA-MB-231 and MCF7 cells for 15 days were observed for the colony forming ability of BC
cells. Imaged in Multimage™ light cabinet. Data presented as mean + standard error of the mean
(n = 3). D)
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Figure 3-7. Anti-metastatic potential of TAP NPs
A) Migration assay to determine inhibition potential of BC (MDA-MB-231) cells after exposure
to 5 and 10 nM of PTX or TAP NPs (PTX equivalent) for 24 hours. Imaged using EVOS® FL
Imaging System. B) Representative bar graphs of the number of migratory cells with each
treatment group, where untreated (control) cells served as an experimental control and was
considered as 100% and other treatment groups expressed as percentage with respect to the
migrated control cells. B) Matrigel Invasion assay showing similar effects, upon treatment with
TAP NPs and PTX (5 and 10 nM equivalent to PTX) for 24 hours. C) Invasive cells following
incubation with PTX and TAP NPs were fixed with methanol and stained using crystal violet.
Imaged using EVOS® FL Imaging System. D) Percentage inhibition of invasive BC cells upon
treatment and data represented as a bar graph with respect to untreated (control) cells which also
served as our experimental control. Data represented as mean + standard error of the mean (n =
3).
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contrast to TAP NPs, which are probably effluxed less due to the presence of TA in the
formulation (Figure 3-8A). A statistical difference in the RLU of TA and TAP NPs in
comparison to Verampil was observed, confirming the P-gp inhibitory effects of TA and because
of TA in TAP NPs, as well. RH123 showed enhanced accumulation of the fluorescent dye, as
shown in Figures 3-8B,C. RH123 is an established substrate for evaluating the ability to inhibit
P-gp mediated transport. As seen in Figure 3-8C, statistically lower accumulation occurs with
free PTX treatment, probably due to high P-gp expression, which extrudes drug/dye from the
cells, in comparison to TAP NPs. As predicted, a higher fluorescence was observed with TAP
NPs suggesting significant inhibition of drug efflux. This is correlated to the fact that tannic acid
is known to have a chemosensitizing effect [310] on cancer cells that possess P-gp inhibitory
efflux, which explains the enhanced accumulation achieved by TAP NPs. Overall, we can
suggest that our TAP NPs developed for this study not only have the potential of providing
enhanced therapeutic effects but also prevent the development of drug resistance by preventing
or lowering drug efflux.
Effect of TAP NPs on Microtubule Stabilization, Oncogenic Protein Expression, and
Microarray Studies
The molecular effects which PTX or the taxane group of drugs exhibit cause the
microtubules to stabilize, promoting mitotic arrest and cell death [311]. To ensure that the
molecular activity of microtubule stabilization is intact in TAP NPs and to compare the apoptotic
ability against PTX, tubulin stabilization assay was conducted by immunostaining and imaging
via confocal microscopy. As shown in Figure 3-9A, control cells show distinct microtubule
bundles, which can undergo regular cellular processes such as cell division. In agreement with
previous reports [312, 313], cells treated with TAP NPs and free PTX show distinct thicker
microtubule bundles (more distinct at 10 nM treatment). Graphical representation of the changes
in fluorescent intensity was quantified using ImageJ software, and significant enhanced Mean
Intensity (arbitrary units) was observed for both 5 and 10 nM of TAP NPs in contrast to PTX
(Figure 3-9B).
There was a statistically significant increase in microtubule bundles in TAP 10 nM in
comparison to PTX, 10 nM. Thus, suggesting greater cytotoxic effects that TAP NPs impart on
BC cells. This is probably occurring because the majority of the native drug PTX is effluxed out
by cancer cells, as demonstrated by the P-gp evaluation assays. This suggests that the tubulin
stabilization process can inhibit mitosis, motility, and intracellular transport, eventually resulting
in apoptotic cell death [311]. Further, to evaluate the effect of TAP NPs on the expression of proapoptotic, apoptotic, and pro-survival proteins, immunoblot analysis was conducted. As shown
in Figure 3-9C, the decreased expression of Bcl-xL was observed with TAP NPs treatment,
whereas enhanced expression was observed for pro-apoptotic and apoptosis-associated proteins
(Bad, Cleaved PARP, and Cleaved Caspase-7). Furthermore, the decreased expression of
multidrug resistance (MDR) protein (no resistance developed) and increased expression of p53
(tumor suppressor protein) confirms the activation of apoptosis by TAP NPs, which induce
cancerous cell death. Microarray results suggest that TAP NPs promote pro-apoptotic
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Figure 3-8. Inhibition of drug resistance by TAP NPs
A) P-gp-Glo assay showing ATP consumption by different treatment groups having variation in
average light units (RLU). Na3VO4 and Verapamil were negative and positive controls
respectively, where higher ATP consumption signifies lower RLU. TAP NPs show 1.42-fold
higher RLU in contrast to native drug PTX, which is more effluxed out by the P-gp membranes.
B) RH123 (2.62 μM) dye shows higher accumulation in MDA-MB-231 cells after incubation for
30 mins when cells were treated for 48 hours with TAP NPs in contrast to PTX. TAP NPs
exhibited significantly increased accumulation, suggesting TAP NPs prevent drug efflux. C)
Mean fluorescence intensity in FL1 channel (488 excitation, Blue laser, 530 + 15 nm,
FITC/GFP) was measured for different treatment groups. PTX 10 nM treatment showed 3-fold
lower intensity over TAP NPs (equivalent to 10 nM PTX). Data presented as mean + standard
error of the mean (n = 3).
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Figure 3-9. Molecular mechanism of TAP NPs in inducing apoptosis in BC cells
A) β-tubulin stabilization assay representing confocal images after treatment with 5 and 10 nM
PTX or PTX equivalent TAP NPs for 8 hours on MDA-MB-231. Distinct bundles of
microtubules were seen in control cells suggesting their proliferating nature, which changed to
thicker clusters of microtubules after treatment with TAP NPs and PTX, suggesting stabilization
of microtubules accounting for the innate nature of the taxane drug. B) Quantitative analysis of
the florescent intensity by Image J software shows significant lower Mean Intensity (arbitrary
units) in contrast to TAP NPs. Data represented as mean + standard error of the mean (n = 3). C)
Western blot analysis of whole cell lysates of MDA-MB-231 that was treated with 10 nM PTX
or 10 nM PTX equivalent TAP NPs and their respective controls for 48 hours and
immunoblotted for Cleaved PARP, MDR1/ABCB1, Cleaved Caspase-7, p53, Bad, Bcl-xL and βactin. The results were consistent in two independent sets of experiments. D) Heat map of
differentially regulated gene expression of pro-apoptotic and anti-apoptotic signaling leading to
apoptosis in MDA-MB-231 BC cells after exposure to TAP NPs. E) Heat map representing gene
expression of ABC family.
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and inhibit anti-apoptotic gene expression validated through a heat map (Figure 3-9D).
Furthermore, the gene level expression of ABC family, depicting inhibition of MDR/P-gp was
confirmed through microarray analysis, as represented in a heat map (Figure 3-9E).
Discussion
PTX is a well-known potent anticancer drug used in the treatment of various cancers
including BC. Still, there is a constant effort made towards achieving better therapeutic benefits
of PTX antitumor effects in cancer. Furthermore, there is a paucity of information regarding the
PTX mechanisms of action which need to be better understood. Literature evidence demonstrates
nanoparticle technology plays a crucial role in the field of medicine. Currently, more than 65
nanomedicine-based formulations are FDA-approved and enjoy widespread use in clinical
applications. In chemotherapy, nanoformulations are often used to 1) minimize toxicity
associated with anticancer agents, 2) enhance pharmacokinetics, pharmacodynamics, and the
bioavailability of drug molecules and 3) preferentially target, accumulate, and release drugs at
the tumor site, due to the Enhanced Permeation and Retention (EPR) mechanism. Among many
nanomedicines, Abraxane® is a frequently used chemotherapy in clinical practice, with about 1
billion-unit sales. This implies that PTX is still a widely used anticancer molecule in current.
treatment regimens. Therefore, it is apparent that a simple nanoformulation made up of a
pharmaceutical excipient that has chemosensitization properties would improve therapeutic
outcomes and could greatly impact the current treatment modality. The choice of polymer
excipient dictates the physicochemical and biological properties of drug nanoformulation.
Toward this end, we report in this study the preparation of PTX nanoparticles using eleven
structurally different polymer excipients. Our aim is to avoid complex chemistry and to not use
organic solvents, to prevent nonspecific uptake. Self-assembly formation (through favorable
particle size generation and zeta potential), efficient excipient-drug complexation (shown by
fluorescence dye quenching and evaluating binding efficiency), favorable hemolysis behavior
(hemoglobin release from RBC due to toxicity), and cellular uptake by cancer cells (shown by
appropriate analytical methods) were successfully utilized to synthesize and choose the best
formulation that could be used for a future nanomedicine for PTX drug delivery. Our screening
data, from a set of eleven commonly used pharmaceutical excipients for generating PTX
nanoparticles, confirmed that tannic acid is highly recommended to achieve an instantaneous
self-assembly formation through hydrogen bonding and other attractive forces (Table 3-1, and
Figures 3-1 through 3-3).
Pharmaceutical excipients are often used to improve the aqueous solubility of various
hydrophobic drugs, which can be applied for localized, oral, and parenteral (intraperitoneal or
intravenous), and/or device-associated delivery methodologies. Tannic acid has been previously
implemented as an anticancer and chemosensitizer [314], also to solubilize various anticancer
molecules such as doxorubicin, to prevent adverse side effects of chemotherapy such as
cardiotoxicity [315]. In this study, it was found that TA can efficiently bind with PTX molecules
in a nanoparticle matrix, giving rise to particle sizes of less than 100 nm as seen under
transmission electron microscopy. The TA matrix core allows PTX to encapsulate within the
core, allowing a high encapsulation efficiency of 96.49±0.43%. A number of investigations
suggest that nanoparticle formulations whose particle size is ~100 nm can be capable of

84

penetrating deeply into tumor tissues via the EPR mechanism [316] and negatively charged
nanoparticles are associated with higher cellular uptake [317]. Conventional drug delivery
approaches have already resulted in FDA approvals for oncology purposes.
Tannic acid is a naturally occurring polyphenol that has other potential benefits, such as
being an antioxidant [318], an antiviral [319], an anti-inflammatory, and it also has
chemotherapeutic potential. Our strategy of selecting tannic acid relies on the fact that since it is
a PARP-1 inhibitor, it can reduce PARP-1 mediated cell death and thus causes NAD+ depletion
[315, 320]. Based on this evidence, we developed tannic acid-PTX nanoparticles (TAP NPs) to
potentiate chemotherapeutic efficiency. The generated TAP NPs were characterized for particle
size in HEPES buffer to mimic the buffering activity in the body and to have clearer insights
about the in vitro effects that TAP NPs could encounter (Figure 3-4B). TEM (Figure 3-4C)
confirms that the particle size distribution of TAP NPs is in agreement with DLS measurements
(102.22±14.05 nm). To further confirm that TAP NPs maintain the functional integrity of both
tannic acid and PTX, spectroscopic (FTIR), thermogravimetric, and X-ray diffraction
characterizations were conducted (Figure 3-4D,F), which confirm the coexistence of both
components. Furthermore, a time-dependent increase in cellular internalization of dye-loaded
nanoparticles (Figure 3-5A) and enhanced PTX uptake into the intracellular components of
cancer cells (Figure 3-5B) were observed, indicating that TAP NPs may overcome P-gp efflux
mechanism. This is further supported by P-gp-Glo assay and higher accumulation of RH123
(Figures 3-8A through C), both of which confirmed drug efflux was significantly greater in the
case of plain drug than with TAP NPs. This confirms tannic acid does have a role in inhibiting
efflux by the P-gp transporters located on the surface of the cancer cells, as previously reported
[16, 29].
To further demonstrate the superior anticancer ability of TAP NPs, an MTT assay was
performed (Figure 3-6A). The cytotoxicities of TAP NPs and PTX were compared in both of the
BC cell lines. Significant decreases in the IC50 values were observed with TAP NPs (Figure 36A,B). Similar effects were observed in clonogenic assays (Figure 3-6C,D). There is an
impressive development in the treatments for BC, yet metastasis-related recurrence is the major
impediment and probably the major reason for BC-related deaths. Thus, therapy resulting in
inhibition of migratory signaling is an effective strategy to prevent these circumstances. Our
study demonstrates that TAP NPs resulted in an enhanced inhibitory effect on both migratory
and invasion properties of BC cells (Figures 3-7A,C). This confirms that TAP NPs not only
extend enhanced drug availability for tumor sites but also curb metastasis as well, preventing
drug resistance.
PTX causes the stabilization of polymerized microtubules in cancer cells, thus preventing
cells from further proliferating. This causes mitotic cell cycle arrest. PTX is reported to inhibit
the growth of microtubules in MDA-MB-231, causing cell cycle arrest during mitosis [321]. Our
results are consistent with literature reports which clearly show that TAP NPs can prevent drug
efflux, which facilitates greater amounts of drugs reaching cancer cells due to the presence of
Tannic acid [308]. This is shown by suppression of microtubule mass by TAP NPs, causing cell
death probably in prophase itself, compared to free PTX, for which cell morphology suggests
that cells treated with free PTX have passed prophase and could have proliferated. Our
investigation suggested that TAP NPs were efficiently involved in stabilization of β-tubulin
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(Figure 3-9A,B) where a significant increase in mitotic arrest is a direct correlation of apoptotic
death. An enhanced microtubule polymer mass was elucidated for TAP NPs 10 nM treatment,
suggesting the enhanced effectiveness of TAP NPs over that of PTX. Bad is a proapoptotic
protein and Bcl-xL is an anti-apoptotic protein. Bad counteracts the action of Bcl-xL, as
evidenced by an immunoblotting assay (Figure 3-9C). Cleaved PARP is the hallmark protein
that demonstrates apoptosis. Enhanced levels of apoptosis-associated proteins (Cleaved PARP
and Cleaved Caspase- 7) lead to the induction of apoptosis as demonstrated with TAP NPs
exposure. The comparatively lower expression of Cleaved PARP and Cleaved Caspase-7 with
PTX treatment demonstrates the synergistic effect due to the combination therapy of a PARP-1
inhibitor (tannic acid) and PTX. p53 is the tumor suppressor gene that causes cell cycle arrest in
the G1 or G2 phase [322]. Literature suggests drug efflux as one of the mechanisms for drug
resistance, activating MDR-1 gene due to the drug treatment, which causes overexpression of Pgp, thus inducing chances of a tumor developing drug resistance [323]. Adoption of therapeutic
strategies that overcome the MDR phenomenon remains highly sought after in the clinical
setting. The self-assemblies of TA and PTX complexes can alter this phenomenon, facilitating
the uptake of TAP NPs, which can significantly reduce the drug resistance protein MDR1, as
seen in Figure 3-9C. Similar results were obtained from the heat maps, showing the inhibition of
MDR1 and ABC-related proteins. These results explain the profound activity of TAP NPs in
contrast to native drug treatments, demonstrating the chemosensitizing ability of our formulation
(Figure 3-9D,E). Taken together, the data show that we have developed TAP NPs that have
superior anticancer potential, prevent chances of cancer recurrence and drug resistance, and lead
to apoptosis.
Altogether, this is successful feasibility and proof-of-concept study that promises the
formulation of a universal anticancer molecule through a simple self-assembly process using
tannic acid. Using the polyphenolic tannic acid as a shell for the nanoparticle provides not only a
potent anticancer moiety but can also prevent cancer recurrence. This simple system resulted in
an improved therapeutic outcome in cell-based BC cell line models.
Conclusion
In summary, tannic acid provides improved PTX self-assembly nanoparticle formation
via strong hydrogen bonding over that of ten other polymer excipients tested. This self-assembly
approach offers an improved alternative strategy to generate nanoparticles using natural or small
molecule excipients such as tannic acid which is classified as an FDA-approved pharmaceutical
excipient and is considered safe and can also be utilized to develop a potent yet non-toxic
nanoparticle formulation. The formation of TAP NPs was confirmed by characterizing the
complexes with FTIR, electronic microscopy, XRD, and TGA analysis. The TAP NPs efficiently
internalized into the cytoplasm of MDA-MB-231 cells. TAP NPs mediated delivery of PTX,
resulting in superior anticancer (through proliferation and clonogenic assays) and antimetastatic
(through migration and invasion assays) profiles over PTX alone. Additionally, TAP NPs
induced greater β-tubulin stabilization in BC cells, ultimately leading to apoptosis. Microarray
analysis further suggested a unique superiority of TAP NPs over free PTX in BC treatment that
reconfirms our finding of superior activity imparted by TAP NPs. This correlates to the fact that
native drug suffers P-glycoprotein mediated drug efflux, which is the root cause of the
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development of Multidrug resistance (MDR) [324]. This lay a solid platform for TAP NPs which
can further be implemented in improving current treatment modalities for BC that possess not
only potent anticancer effects but extends therapeutic benefits by minimizing drug efflux [324]
and off-target effects, as demonstrated in the graphical representation (Figure 3-10)
These key findings altogether indicate that tannic acid, when used to formulate effective
yet nontoxic anticancer nanoparticles with drugs such as PTX, has an excellent potential for
translation from the bench to bedside cancer therapy. Our efforts to develop a “first-generation”
representative nanoparticle can be further developed and optimized as a targeted nanoparticle
formulation for enhanced BC treatments. Although, nanoparticles are efficacious yet face a high
probability of activating the innate immune mechanism which would result in the destruction of
the foreign particles. To prevail over this obstacle, active nano-carrier systems are conjugated to
biomolecules including ligands and antibodies [110, 111]. Such strategy could be applied to
modify the TAP NPs into even more active nano therapy treatments.
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Figure 3-10. Schematic representation of TAP NPs inhibiting P-gp efflux
TAP NPs are retained longer in the cancer cells due to the presence of TA, which is an inhibitor
of P-gp efflux transporter preventing TAP NPs from getting efflux out of the cell membrane by
the P-gp transporters. However, native drug PTX is effluxed out from the cells due to the innate
nature of P-gp transporters that tend to expel chemotherapeutic agents. Thus, TAP NPs extend
better anticancer efficacy over native drug.
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CHAPTER 4.

BIO-MEMBRANE INSPIRED NANOPARTICLES FOR ENHANCED
THERAPEUTIC EFFICACY IN TNBC
Introduction

BC remains the second most commonly diagnosed cancer among women in the United
States after skin cancer [325], with about 12% probability for women to develop BC in their
lifetime. The estimated deaths for 2019 from BC are about 16% of the total cases with metastatic
BC being the cause of 90% of the deaths [326]. Although there have been significant advances in
the treatment of BC which has provided survival benefits to patients, yet the survival statistics of
the metastatic BC hinders clinical benefits, due to the aggressive nature that proliferates and
advances to multiple sites [327]. Currently, the mainstay treatment for metastatic BC remains
systemic administration of therapeutic agents based on the specific subtype they belong to, such
as hormone therapy, chemotherapy by cytotoxic agents such as anthracyclines, taxanes, and
platinum-based compounds [328]. These chemotherapeutic agents are delivered systemically
with the expectation that at least a fraction of the dose would be reaching the metastatic sites,
thus demonstrating poor bioavailability. However, these agents demonstrate anticancer benefits,
yet the median survival is ≤ 24 months [329], with a 27% relapse within 5 years survival rate and
these treatments often are followed by relapses, recurrence, and other adverse toxicities. Among
these cytotoxic agents PTX is the most commonly administered taxane and is used as the firstline treatment for metastatic BC. PTX is formulated as Taxol® with Cremophor EL and ethanol
and exerts serious adverse effects such as sensory axonopathy and ganglio-neuropathy when
administered in combination with cisplatin [330]. It is also known to induce neutropenia, severe
peripheral neurotoxicity which often ranges from 30% to 40% of patients receiving
chemotherapy [331]. Other risk factors include arthralgias and myalgias [332] and even diabetes
mellitus [121]. The advancement of a nanotechnology-based drug delivery system has made
significant improvements in overcoming conventional limitations.
Nanoparticles based drug delivery system offers enhanced permeation and retention
(EPR) effect that renders them to penetrate the leaky tumoral neovasculature allowing
nanoparticles of poorly soluble drugs to circulate longer, deliver chemotherapeutics specific site
[333] and improve the tolerability of cytotoxic agents [334]. With this respect, Abraxane, an
albumin-bound PTX nanoparticle formulation (nab-PTX) was developed to reduce toxicity
issues of Taxol® and have shown ~2-fold improvement in the overall response rate of patients
[191, 199] in contrast to PTX or Taxol®. However, despite the therapeutic advantages extended
by nanoparticles, delivery to the metastatic and advanced stage BC remains a major hindrance
due to the clearance by reticular endothelial system (RES) which produces subtherapeutic
concentration for tumor penetration or due to the presence of dense extracellular matrix [297].
To improve tumoral delivery active targeting by attaching ligands such as polymers (poly
(ethylene glycol) or pluronics), cationic peptides, aptamers, and antibodies on nanoparticles have
been employed [335, 336]. This strategy provides active targeting to the receptors that are
discretely unregulated on cancer cells thus allowing receptor-mediated endocytosis that provides
cell-specific adherence and uptake of nanoparticles at specifically to target site [337-339].
Decoration with cationic or polymeric moieties causes immunogenicity issues probably caused
by the recognition of surface charged protein by RES [297, 340]. Most of the studies that are
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“actively targeting” mainly involve coating the surface with these moieties that offer the
advantage of selectivity yet is mainly harbored around the idea of EPR effect, resulting in
targeting only the primary tumor, with little or no attention given to the metastatic area. Thus,
new strategies are in dire need that not only targets the primary tumor but also the metastasis
tumor microenvironment.
Among all the new strategies employed for targeted therapy, one such strategy is the
functionalization of particles with bio-inspired artificial cell membranes or naturally derived cell
membranes. The advantages are myriad, because of the utilization of naturally occurring cells
they are intrinsically biocompatible, biodegradable, and nonimmunogenic [341]. Additionally,
the presence of proteins, glycan, and sialic acid moieties on the natural cell membrane serves as a
receptor/ligand for receptor-mediated endocytosis or for suppressing immune attack [342]. Thus,
with this aim, we have isolated cell membranes from natural cells with specific “self-marker”
expression on them that allows them to be internalized not just at the primary tumor site but also
to the metastatic regions. Rationalizing from our preliminary and research findings, we
hypothesize this approach will target the primary tumor and the metastatic tumor
microenvironment with minimal adverse effects on healthy cells, due to cell-specific binding to
the antigen-receptor on aggressive and metastatic TNBC. We believe this strategy can extend
unique, personalized nanomedicine with non-immunogenicity and therapeutic superiority for
targeting metastatic BC. Our preliminary results show activated human neutrophil membrane
shows enhanced intercellular uptake by TNBC over normal breast epithelial cells at a particular
concentration. Our initial findings suggest, PVP [287] and tannic acid prevents potential P-gp
efflux [343]. Thus we used these two excipients to generate PVT (Polyvinylpyrrolidone-Tannic
acid self-assembled) nanoparticles after evaluating their enhanced efficacy in TNBC cells [300].
To testify our hypothesis, we used polyvinylpyrrolidone (PVP) nanoparticles and tannic acid to
form the core for the nanoparticles that also provide anticancer effects, as demonstrated in our
previous study, such as prevents drug efflux [344]. Therefore, the aim of the study was to
develop and characterize PVT nanoparticles coated with cell membranes isolated from human
neutrophil, along with membranes from four more different natural cells (Natural killer:NK-92,
Mesenchymal stem cells: MSC, Jurkat: JUR and RAW264.7:RAW) and screen the best
candidate for targeting TNBC, both in in vitro and in vivo models.
Materials and Methods
Chemicals and Solvents
Tannic acid (catalog no. 403040), PVP (MW 40,000), TMA Cores: tissue and cell
microarrays (Catalogue no. BR243v) were procured from US Biomax. Inc, 96 low attachment
plates were procured from Corning, HEPES (catalog no. H3375) were purchased from Aldrich
(St. Louis, MO, USA). All chemicals, reagents, and solvents were used as received without
further purification.
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Cell Culture
Humanized BC cell lines (MDA-MB-231, MDA-MB-468, and MCF-7) and NK-92,
Mesenchymal Stem Cells, Jurkat, RAW264.7 were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). Human Neutrophils were procured from Astarte
Biologics that are tested for bloodborne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C, and
HTLV-1 to ensure safety. Breast cell lines were cultured in Dulbecco's Modified Eagle Medium
(DMEM) that was supplemented with phenol red, 10% fetal bovine serum, 100 U/ml penicillin
and 100 U/ml streptomycin (Thermo Fisher Scientiﬁc, Grand Island, NY). Mammary Epithelial
Cell (MCF10A) was gifted by our generous collaborator Dr. S. C. Chauhan laboratory and was
cultured with MEGMTM Mammary Epithelial Cell Growth Basal Medium (Catalogue No. CC3151) with supplements and growth factors (Catalogue no. CC-4136). For all experiments, cell
lines were incubated at 37°C in a humidified 5% CO2 and 95% air atmosphere (Thermo Fisher
Scientific, Waltham, MA, USA). At 80-90 % confluency, these cells were trypsinized, counted
using Trypan Blue (0.4%) and seeded as per specific experiments. Cells were allowed to adhere
to the plate surface overnight before implementing any further treatment.
Activation and Isolation of Cell Membrane
Neutrophil membrane (NEU) was activated using LPS (100 ng/ml) added to the culture
medium for 4 hours to ensure activation, followed by a wash in PBS. The rest of the cells (NK/
MSC, JUR, RAW) were extracted without any activation. To isolate the plasma membranes,
cells are suspended in Isolation Buffer composed of mannitol, sucrose, BSA, EDTA, and TrisHCl and supplemented with protease inhibitor cocktail (PCI). Cells were homogenized in
Dounce homogenizer, centrifuged at 800×g at 4°C for 10 mins and the pellet discarded to
remove the unbroken cells and nuclei. The supernatant was centrifuged at 10,000×g at 4°C to
remove the mitochondria. The supernatant was ultracentrifuge using Sorvall WX Ultra 80
(Thermo Scientific) again at 100,000×g at 4°C for 1 hour to pellet the membranes. Finally, the
plasma membrane pellet was suspended in Tris-HCl and EDTA and then stored at −80°C for
later use, to maintain the membrane integrity freeze-thaw cycles were prevented by aliquoting
membranes in smaller batches. Protein estimation was quantified using the BCA protein assay.
Preparation of Polyvinylpyrrolidone-Tannic Acid (PVT) and Membrane-Coated (PVTMEM) Nanoparticles (NPs)
Nanoparticles were prepared by the self-assembly technique and is followed by solvent
evaporation. Briefly, 2.5 mg PVP and TA were dissolved in 0.5 ml aqueous medium separately
and then mixed in 1:1 ratio in 8 ml glass vial under continuous stirring at 400 rpm on a stir plate.
Now, 100 μl of PTX dissolved in acetone (1 mg/ml) was dropwise added and the speed increased
to 900 rpm. They were stirred overnight to ensure the acetone was evaporated to finally obtain
PVT nanoparticle solution. The membrane-bound nanoparticles (PVT-MEM NPs) were prepared
by simple sonication technique. Based on the BCA assay, the protein concentration(s) were
determined for each of the different cell membrane(s). For the synthesis of PVT-MEM NPs, PVT
NPs were mixed to each of the extracted MEM, at a concentration equivalent to 16:1 and
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allowed to stir at 4 οC for 24 hours. The next day, the mixture was sonicated at 100 w for 30 secs
with intermittent cooling on ice, followed by centrifugation at 14000 rpm at 4°C for 10 mins, to
remove the unbound membranes. All batches were freshly prepared before experimental use to
maintain the membrane integrity.
Characterization of PVT and PVT-MEM NPs (PVT-NEU, PVT-NK, PVT-MSC, PVTJUR, PVT-RAW)
Particle size and zeta potential
The average particle size, particle size distribution (PDI) and zeta potential of our
developed PVT and all the five PVT-MEM NPs were measured by the dynamic light scattering
(DLS) principle using Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK). Briefly 50 μl of
freshly prepared formulation was dispersed in deionized water and was probe sonicated
(VirSonic Ultrasonic Cell Disrupter 100, VirTis) for 30 secs to ensure formation of
homogeneous nanoparticle solution and minimize the nanoparticle aggregation. Particle size
measurements were performed in water at 25°C and an average diameter of particle size
distribution were determined from three runs. Zeta potential of the samples were measured using
1X phosphate-buffered saline (PBS). The zeta potential of nanoparticle formulations was also
based on the average of 3 readings (each reading = 30 runs).
Short-term stability study
The stability of the different PVT and PVT-MEM NPs were assessed at three different
temperature condition 4, 25, 37°C using DLS particle size analysis. Briefly, samples were freshly
prepared and incubated at three respective conditions for 10 days and the change in particle size
with respect to time is assessed. Particle size of samples were measured in freshly prepared 1
mM of HEPES buffer using HEPES salt in ultrapure water, supplemented with PCI to prevent
precipitation, as mentioned in section 2.5.
Spectral analysis
Fourier transform infrared (FTIR) spectra was acquired using Universal ATR sampling
Accessory plate using a Spectrum 100 FTIR spectrophotometer (Perkin Elmer, Waltham, MA) to
confirm the structural integrity of the cell membranes inside the nanoparticles. For this, PVT and
all the five PVT-MEM NPs were prepared and lyophilized using a Labconco Freeze Dry System
(-48°C 133 × 10-3m Bar; Labconco, Kansas City, MO, USA) to obtain lyophilized powder.
These samples were placed on the tip of the ATR objective to obtain the spectra between 4000
and 650 cm-1 at a scanning speed of 4 cm-1 for 32 scans. The FTIR spectra is presented as %T vs.
cm-1 and analyzed using Spectrum 100 software.
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Transmission electron microscopy
To confirm the size obtained from the DLS and to investigate the structural morphology
of PVT and PVT-MEM NPs especially to view the cell membrane coating around the formed
nanoparticles, we imaged using JEOL 200EX transmission electron microscopy (TEM) (JEOL
Ltd, Tokyo, Japan) operating at 80 kV. Freshly prepared samples were sonicated vigorously to
prevent any agglomeration of NPs and 20 μl was slowly placed on the shiny side of the 150mesh standard TEM grid (Electron Microscopy Sciences, PA, USA). It was negatively stained
using 2% w/v uranyl acetate solution. The excess amount of stain was wicked off and the grid
was allowed to air dry, followed by imaging using an AMT camera at a direct magnification of
100,000X under the TEM.
Identification of Membrane-Associated Proteins
The presence of membrane-associated proteins on the particles was verified by
Coomassie blue staining. For this, the NEU extracted from neutrophils, as mentioned in section
2.4, were collected. They were further coated on the top of the PVT nanoparticles as described in
the previous section (Preparation of PVT NPs). After both the NEU and PVT-NEU were
obtained, a short spin on a benchtop centrifugation at a high speed of 14000 rpm for 30 secs at
4°C, was done to remove the unbound NEU from the surface of the PVT nanoparticles. For the
analysis by Coomassie blue-SDS PAGE, the samples were processed as mentioned in Kang et. al
[71]. Briefly, samples were lysed and centrifuged at 13,000×g for 5 mins at 4°C. The protein
concentration was quantified using a standard BCA assay. Followed by mixing the supernatant
protein with SDS loading buffer, heated to denature the proteins and an equivalent of 20 μg of
protein (equivalent to the NEU and in PVT-NEU) per sample was loaded in a 10-20% SDSPAGE. After the sufficient run time, the protein gels were stained Coomassie blue fast staining
solution and imaged using the ChemiDocTM MP System (Bio-Rad, Hercules, CA, USA).
In Vitro Cellular Uptake
To determine the preferential targeting of membrane coated nanoparticles, intercellular
uptake of PVT and all the five PVT-MEM NPs were conducted in BC cells (MCF7, MDA-MB468, and MDA-MB-231) and breast epithelial cells (MCF10A), which was used as an
experimental control. For this experiment, C6 was loaded instead of PTX in PVT and PVTMEM NPs and was constructed similarly (Preparation of PVT NPs). In brief, all the different
types of cells were seeded at 0.5×106 cells in a 12-well plate and allowed to adhere to the plate
surface overnight. Next day, dye equivalent to 5 μg C6 loaded PVT and PVT-MEM NPs were
treated for 3 hours to ensure the stability of C6 and such that it does not leach out of the
nanoparticles but also giving enough time for the cells to intracellularly uptake the dye an
incubation time of 3 hours was selected. After the incubation time cells were washed thrice with
1X PBS to remove the C6 bound o the outer cell surface. To further process the cells, we choose
to use DMEM phenol red-free medium to reduce the auto-fluorescence. For qualitatively images,
cells were imaged using EVOS® FL Imaging System (AMF4300, Life Technologies, Carlsbad,
CA, USA) and quantitative analysis was done after injecting samples into an Accuri C6 Flow
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Cytometer (Accuri Cytometer, Inc., Ann Arbor, MI, USA). Quantitative uptake of C6 was
acquired using the fluorescence levels in FL1 channel (488 excitation, Blue laser, 530 ± 15 nm,
FITC/GFP). Average reading and standard error of mean were calculated from 3 runs. Data
reported as normalized mean fluorescence value (after normalizing all values with respect to
control values, for the respective cell lines).
Evaluation of In Situ Uptake
For this, tumor tissues of various grades and normal breast adjacent epithelial tissue
sections were analyzed for cellular uptake of C6 and imaged by EVOS® FL Imaging System
(AMF4300, Life Technologies, Carlsbad, CA, USA. Briefly, tissue and cell micro were
procured, and a study was conducted similarly as immunohistochemistry (IHC). Slides were
deparaffinized, rehydrated by different concentrations of alcohol content followed by antigen
retrieval. 100μg/ml C6 equivalent, loaded in PVT and PVT-MEM NPs that were freshly
prepared were used to stain the slides using a PAP pen for an overnight, followed by three
consecutive washes of 5 mins each and imaged. All images will be captured using the same laser
power and gain settings to ensure comparability for intensity analysis. Fluorescent intensities
will be quantified using Image J. The corrected total cell fluorescence (CTCF) was measured
using the Equation 4-1. This was done to normalize the actual fluorescence inside the cells,
independent on the size and structure of each cells [345].
 ܨܥܶܥൌ ݕݐ݅ݏ݊݁ܦ݀݁ݐܽݎ݃݁ݐ݊ܫȂሺכ ݈݈݁ܿ݀݁ݐ݈ܿ݁݁ݏ݂ܽ݁ݎܣ
ݏ݃݊݅݀ܽ݁ݎ݀݊ݑݎܾ݂݃݇ܿܽ݁ܿ݊݁ܿݏ݁ݎݑ݈݂݊ܽ݁ܯሻ (Eq. 4-1)
Biological Assays
Cell viability assay
Cell viability assay was assessed using MTT assay on TNBC cell line: MDA-MB-231
and as non-TNBCBC: MCF7 was used. Briefly, 5×103 cells were dispersed in100 μl media/well
in 96-well culture plates were seeded and allowed to stand overnight. The next day these cells
were treated with 0-20 nM equivalent PTX or PVT/PVT-MEM NPs for 48 hours. Cell lines with
no treatment served as experimental controls. After the required incubation time, 20 μl of MTT
reagent solution was added and incubated for 2-3 hours at 37°C. After formazan crystals are
formed the media was aspirated out such that, not to disturb the formazan crystals and 100 μl of
DMSO were added to dissolve the salt formation Absorbance reading was recorded at 490 nm
using a Microplate Reader (BioTeK Cytation 3, Winooski, VT, USA). Cell proliferation with
respect to control cells was calculated. All the experiments were performed at least in triplicates.
Cell morphology changes with respect to treatment were further confirmed by imaging using
EVOS® FL Imaging System at 20X magnification.
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Cell migration
Boyden’s chamber cell migration assay was used to confirm migration by the PVT and
PVT-MEM NPs in TNBC cells (MDA-MB-231). Briefly, 0.5×105 cells were suspended in
serum-free media along with the equivalent amount of 5 nM of PTX or PVT/PVT-MEM NPs,
added to the upper chamber of the 96-transwell inserts (catalogue no.3374, Corning, NY, USA).
Cells receiving no treatment were used as an experimental control. These inserts were then
placed inside the 96-well plates in 10% FBS media. After 24 hours, the migrated cells at the
lower inside of the Transwell inserts were fixed using 4% formaldehyde and then further stained
using crystal violet. The cells on the upper side of the insert are removed using a cotton swab.
Inserts were then imaged using the EVOS® FL Imaging System.
Cellular invasion
BD Biocoat Matrigel Invasion Chambers (BD Biosciences) was used to study the
invasion assay. Briefly, MDA-MB-231 (3.5 × 104 cells) were seeded in the matrigel invasion
chambers in serum-free medium and treated with equivalent amount 5 nM of PTX or PVT/PVTMEM NPs for 24 hours. The lower chambers were placed with 10% FBS medium which served
as a chemoattractant. The cells that were able to invade were fixed with methanol and then
stained using crystal violet. The plates were imaged using EVOS® FL Imaging System
Clonogenic assay
Colony-forming assay was performed to investigate the proliferation ability of on BC
cells to form colonies as an in vitro cell survival assay based on the ability of TNBC (MDA-MB231) to grow into the form of a colony. For this study, BC cells were seeded (250 cells/well) in a
12-well plate and treated with 5 nM of PTX or PVT/PVT-MEM NPs and set in the incubator for
15 days with intermittent media change. Visible colonies were fixed, stained with hematoxylin
and imaged.
3D Spheroid assay
Cells were seeded in an ultra-low 96 well attachment plates with 1000 cells/well plated,
followed by treatment with equivalent concentrations 5 nM of PTX or PVT/PVT-MEM NPs for
10 days. The cells were allowed to grow for 7 days and then centrifuged at 200 RCF for 5 mins
and further incubated in standard cell culture conditions for 10 days. Growth rate was monitored
by imaging the spheroid on from day 0-10 using brightfield microscopy of EVOS® FL Imaging
System. The growth rate was reported in terms of volume ratio, where first the spheroid volume
was determined using Equation 4-2A. The tumor volume ratio (%) was calculated using
Equation 4-2B.
ܸ ൌ  ሺߨ݊݅݉݀ݔݔܽ݉݀ݔሻȀ for 0, 3, 7 and 10 days (Eq. 4-2A)
Tumor volume ratio (%)= (Vdayn/Vday0) x 100 (Eq. 4-2B)
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where Vdayn is the spheroid volume at the nth day (day 0, 3, 7 or 10) of treatment, and Vday0 is
the spheroid volume on day 0 prior to treatment.
In Vivo Evaluation of PVT and PVT-MEM NPs
Tumor xenograft and imaging study
To grow the orthotopic xenograft mice model we purchased six-week-old female athymic
nude mice (nu/nu) from Jackson laboratory (Bar Harbor, ME USA)) and maintained in a
pathogen-free environment. All animals were housed and maintained according to the
recommendation of the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) guidelines. All studies were conducted using UTHSC Institutional Animal
Care and Use Committee (UTHSC-IACUC) protocol. To establish orthotopic xenograft tumors
in mice, MDA-MB-231 cells (2 × 106 cells) were suspended in phosphate buffer saline (PBS)
and Matrigel (BD Biosciences) solution in 1:1 ratio and then injected subcutaneously on the hind
flanks of each mice. Tumor volume in mice was monitored using a digital Vernier caliper and
calculated using the Equation 4-3.
݁݉ݑ݈ݒݎ݉ݑݐݎ݂݈ܽݑ݉ݎ݂݀݅ݏ݈݈݅ܧሺ݉݉͵ሻ  ൌ ߨȀሺ ൈ  ܮൈ ܹ ൈ ܪሻ (Eq. 4-3)
When tumor volume reached ~ 200 mm3, mice were randomly divided (five mice per
group) into respective groups and treated with control (PBS treated), PTX (10 mg/kg), PVT and
PVT-NEU NPs (PTX equivalent to 10 mg/kg) for 4 weeks, given intraperitonally, twice a week.
For imaging, PVT and PVT-MEM NPs were loaded with Indocyanine dye (ICG) for in vivo
imaging (3 mice per group), similarly loaded inside the nanoparticles as mentioned in section
2.4. For this, tumors were grown in similar fashion MDA-MB-231 cells injected in the hind flank
and tumor size reaching 200 mm3 mice were randomly assigned into two treatment groups: 100
μg/ml of ICG-labeled PVT or PVT-MEM NPs, plain ICG solution was used as an experimental
control, given intraperitoneally. After injecting the NPs once, all mice were imaged at 3, 6, 24,
48 and 72 hours to find the fate of the NPs and retention in the body using the XRMS Imaging
System (Caliper Life Sciences, Waltham, MA) equipped with a coupled device camera (CCD)
housed at the UTHSC core facility was used. These animals were fed with a special diet of
Teklad Global Rodent Diets (Envigo, Huntingdon, United Kingdom) to avoid background autofluorescence from the diet, 24 hours before the initiation of the imaging study. Mice were
anesthetized with 2% isoflurane and imaged in immunofluorescence intensity (integration: 30
secs; binning: 4). The peak immunofluorescence signal intensity is calculated by the sum of all
detected photon counts within the region of interest (ROI) after subtraction of background
fluorescence, in photon/s/cm2/sr. Biodistribution of ICG was examined by assessing ROI of
excised heart, lungs, liver, kidney and spleen along with tumor retention. After the necessary
time, mice were euthanized, and organs excised. Mice were euthanized either when the tumor
volume reached ~ 1200 mm3 or the mice weight lost was more than 10% body weight. Mice were
sacrificed by exposing them in the CO2 incubator and cervical dislocation. Tumors were excised
and processed for tissue sections, histopathology and hemo toxicity images. Blood was collected
after post-mortem cardiac puncture and submitted to Idexx Bioresearch for histopathology and
blood chemistry analysis for complete blood cell count analysis. Also, hepatotoxicity was
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assessed by measuring serum levels of alanine aminotransferase (ALT), aspartate
aminotransferase (AST) enzymes and total bilirubin (TBIL) and kidney function marked by
blood urea nitrogen (BUN) levels.
Immunohistochemistry
The effect of PVT and three different PVT-MEM NPs were determined for expression of
BAK, BCL2, β-tubulin III isoforms, Cleaved caspase 3, PCNA. Standard IHC protocol was
followed [346], tumor tissues were deparaffinized, rehydrated, soaked with 0.3% hydrogen
peroxide and processed for antigen retrieval. After blocking with background sniper, the samples
were subjected to staining for expression of respective proteins expression on the tissues. The
slides were counterstained with hematoxylin, dehydrated, mounted Prolong Diamond Antifade
Mountant (catalog no. P36961). The histological difference in samples was analyzed by H&E
staining to study organ toxicity.
Statistical Analysis
All data were generated and analyzed using GraphPad Prism 5.03 Software (GraphPad
Software, San Diego, CA) and results are presented as mean ± standard error of mean (SEM).
Statistical significance was performed using a student’s t-test analysis when comparing between
two groups. When comparing the statistical significance among multiple treatment groups oneway ANOVA post-hoc Tukey HSD test was performed, or for estimating the statistical
difference between groups with multiple variable and multiple treatment groups, two-way
ANOVA Bonferroni posttest. A p-value ≤0.05 was considered significant.
Results
Preparation and Characterization of PVT and PVT-MEM NPs (PVT-NEU, PVT-NK,
PVT-MSC, PVT-JUR and PVT-RAW)
To preparation of PTX loaded polyvinylpyrrolidone-tannic acid (PVT) and membranecoated (PVT-MEM) nanoparticles (NPs) were processed in four steps. Firstly, it was pivotal to
ensure the cells used (neutrophils, Natural Killer cells, mesenchymal stem cells, Jurkat cells and
RAW 264.7 cells) preserves the cellular membrane functions of the source cells. Literature
suggests [342] neutrophils needs to be activated by lipopolysaccharide (LPS), a TLR-4 ligand
that induces inflammatory responses in neutrophil, which in the process would endow maximal
adhesion ability to the extracted neutrophil cell membranes (NEU). For the same purpose,
neutrophils were LPS activated for 4 hours to induce an inflammatory response for the proper
activation of the adhesion molecules on the surface of NEU. Secondly, extraction of the
membranes (MEM) from the cells took place, the rest of the cells except neutrophils were used
directly from culture condition, after harvesting them in their respective culture media. This was
followed by the construction of the core nanoparticle loaded with PTX (for in vitro imaging C6
was loaded, and for in vivo imaging ICG was loaded) by solvent evaporation technique, as
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previously described. Lastly, the coating of the extracted MEM on the surface of the PVT NPs,
to yield PVT-MEM NPs was done by mixing them together and subjecting them to sonication to
prevent agglomeration of particles and centrifugation to remove the excess of the unbound
membranes. From our preliminary studies, we have established a better intracellular uptake
occurs at 16:1 for PVT-NEU NPs, which is why we maintained this ratio for the synthesis of
PVT-MEM NPs for all the five PVT-MEM NPs throughout this study. The hydrodynamic mean
particle size (nm) of PVT and all the five PVT-MEM NPs were determined by dynamic light
scattering (DLS) (Figure 4-1A). There was a slight increase in the size after the coating of the
MEM, where PVT NPs (nanoparticles without any membrane coating) increased from
220.53+12.35 nm to 243.3+4.65, 253.36+5.20, 341.06+44.44, 269+32.23, 231.96+16.03 nm
after coating with NEU, NK, MSC, JUR, RAW respectively. Although there was no statistical
significant difference in the particle size among all the PVT-MEM NPs in comparison to
uncoated NPs (PVT NPs), there was a slight increase observed in PVT-MSC NPs. The zeta
potential of PVT was -2.89 mV and the addition of the negatively charged cellular membrane
causes the zeta potential to increase resulting in -4.26, -5.54, -4.84, -4.53, -4.11 mV, for the five
PVT-MEM NPs, respectively (Figure 4-1B), suggesting the successful coating of the cell
membranes on the surface of the nanoparticles. Short term stability study (Figure 4-1C) was
conducted to confirm the stability of the formulation especially due to the presence of cell
membrane proteins, which may tend to agglomerate. Although, there was no significant changes
in size of PVT-MEM NPs seen for 5 days after storing them at 4 or 25°C. However, a long-term
stability study needs to be warranted.
Additionally, FTIR spectra (Figure 4-2A) for the cell membranes based nanoparticles
(PVT-MEM NPs) due to the presence of lipid bilayer has presence of large number of amide
groups present and are characteristics of proteins to have band at 1638 due to (-CO-NH2) [347].
FTIR spectra of PVT NPs demonstrate distinct peaks of N-H stretching at 3258 cm-1 and C=O
stretching at 1715 cm-1 are characteristic PTX peaks [348] which are consistently present in all
the five PVT-MEM NPs, demonstrating the proper inclusion of PTX inside the core of the
nanoparticles. Additionally, characteristic peaks at 1638 cm-1 due to stretching of conjugated
C=O, 1292 cm-1 C-N and C-O at 1198 cm-1 [349, 350] confirms presence of TA and PVP in the
nanoparticles. The infusion of the membranes on the surface of the PVT NPs was further
confirmed by TEM (Figure 4-2B) which displays the core shell structure of the PVT-MEM NPs
that encapsulates the PVT NPs in the core and the surrounding MEM layer in the shell. To
ensure that the expression of the membrane proteins was successfully translocated on the surface
of the PVT nanoparticles, Coomassie blue-SDS-PAGE analysis was conducted (Figure 4-2C).
Intracellular and In Situ Uptake and In Vitro Proliferation, Migration, Invasion and
Colony Forming Assay in BC Cells
The intracellular uptake and distribution in different type of BC cells and breast epithelial
cells were determined. For this, the core shell structure of all the membrane coated nanoparticles
(PVT-NEU, PVT-NK, PVT-MSC, PVT-JUR and PVT-RAW) along with PVT used as the
respective control were synthesized together and fluorescently labeled with C6. A 3-hours
incubation time with the dye loaded nanoparticles, after normalizing the mean fluorescent
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Figure 4-1. Characterization of PVT and PVT-MEM NPs (PVT-NEU, PVT-NK, PVTMSC, PVT-JUR and PVT-RAW)
A) Dynamic light scattering measurement for PVT and PVT-MEM NPs in water using 50 μl of
freshly prepared samples were added to 1 ml of ultrapure water and probe sonicated for 30 secs
and measured using Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK) at 25°C. PVT NPs
exhibited particle size of 220.53+12.35 nm. There was a slight increase in size after addition of
cell membrane bilayer, with 243.3+4.65, 253.36+5.20, 341.06+44.44, 269+32.23, 231.96+16.03
nm, respectively. Data presented as mean + standard error of the mean (n = 3). B) Zeta potential
was measured in 1X PBS and average of 3 readings (each reading = 30 runs). PVT NPs had a
charge of -2.89 mV, causing electrostatic repulsion between the nanoparticles and the negatively
charged bilayers, resulting in zeta potential of -4.26, -5.54, -4.84, -4.53, -4.11 mV respectively.
C) Change in particle size was evaluated by measuring particle size in water as previously
described for 10 days, at three different temperature conditions, 4, 25 and 37°C. Data presented
as mean + standard error of the mean (n = 3).
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Figure 4-2. Evaluate the cloaking of cell extracted membrane on to the nanoparticles and
the inclusion of PTX in the resultant PVT and PVT-MEM NPs
A) Fourier-transform Infrared (FTIR) spectral analysis of PVT and PVT-MEM NPs were
acquired on a Universal Attenuated Total Reflectance (UATR) accessory plate by a Spectrum
100 FTIR spectrophotometer (Waltham, MA), between 4000 and 650 cm-1 at a scanning speed
of 4 cm-1 for 32 scans. Characteristic N-H stretching at 3258 cm-1 and C=O stretching at 1715
cm-1 confirms presence of PTX consistently in PVT and PVT-MEM NPs. B) PVT and the
representative PVT-MEM NPs transmission electron microscopic (TEM) images. UranyLess EM
stain was used for negatively staining the nanoparticles. Image was acquired by using JEOL
200EX TEM at a direct magnification of 100,000×. C) Presence of membrane proteins on NEU
and PVT-NEU estimated by SDS-PAGE Coomassie blue staining.
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intensity with respect to control is shown in Figure 4-3A. A statistical significant difference
between the coated PVT-MEM NPs in contrast to PVT NPs were seen in both the TNBC cells:
MDAMB-231 and MDA-MB-468. MCF7 which was a non TNBC cell lines, shows no
significant difference between coated and uncoated nanoparticles except PVT-RAW NPs. The
highest intensity was observed for uptake of PVT-MEM NPs in contrast to PVT NPs in MDAMB-231 cells, whereas breast epithelial cells, MCF10A show very minimal internalization,
demonstrating the preferential uptake in cancer cells versus non-cancer cells, (Figure 4-3B). In
all the four tested cell lines, the fold change with PVT-NEU, PVT-RAW NPs is the highest in
comparison to membrane uncoated PVT NPs, whereas PVT-MSC NPs displayed decent uptake
in the TNBC cell lines. Thus, these three membrane coated nanoparticles (PVT-NEU. PVTMSC, PVT-RAW NPs) were selected for further studies. The Rest of the In Vitro, In Situ and In
Vivo Studies from here onwards was conducted with PVT-MEM NPs (PVT-NEU, PVT-MSC
and PVT-RAW NPs).
In situ cellular uptake [351] was utilized to determine preferential targeting by the PVTMEM NPs specifically to fixed tissue slides of various tumor grades. For this BC tissue array
(TMA) with cores of normal adjacent BC tissue, Stage I which is ER, PR (-) ve. For fluorescent
imaging (Figure 4-4A) C6 loaded particles were also used and quantified using Image J (Figure
4-4B). A targeted efficacy is observed for cancerous section versus normal adjacent tissue
section, elaborating the preferential targeting ability of the PVT-MEM NPs, with significantly
higher intensity observed for Type I which is aggressive and invasive ductal carcinoma, with
PVT-NEU NPs showing the highest statistical increase in uptake with a fold change of 1.19
versus 1.02 and 0.92 for PVT-MSC and PVT-RAW NPs respectively, in comparison to uncoated
PVT NPs. The in vitro cytotoxicity of PTX in solution and PTX loaded in the PVT and PVTMEM NPs were evaluated. Cell proliferation conducted by MTT assay (Figure 4-5A) with PTX
concentration ranging from 0-20 nM when treated on highly aggressive and metastatic MDAMB-231 and BC cells MCF7. The IC50 values were significantly lowered by 2.05 folds with PVT
NPs in comparison to free PTX, whereas effects all the three selected PVT-MEM NPs showed
similar profile, with PVT-NEU NPs demonstrating the most significant change of 2.95 folds
reduction when compared to PTX alone, in MDA-MB-231. However, MCF7 demonstrates
similar cell inhibitory effects with PTX, but no significant dose-dependent inhibitory effects
were observed. Similar morphological changes at 5 nM are displayed in Figure 4-6A
proliferation panel, showing distinct morphological changes on treatment with PTX solution and
PVT NPs at similar concentrations. To further confirm superior anticancer efficacy of PVTMEM NPs over free PTX, we conducted boyden migration assay, matrigel invasion assay and
the colony forming ability on MDA-MB-231. As shown in Figure 4-6B through D.
Migration/Invasion/Colony panels at 5 nM equivalent PTX solution or nanoparticles treatment
with PVT/PVT-MEM NPs, all show a statistically significant difference with the plain drug,
PTX. Statistical significance was observed between PVT and PVT-MEM NPs, except in
migration assay where there was no statistical significance observed between PVT and PVTNEU NPs, but a trend of inhibition was confirmed. These results altogether suggest the
nanoparticles significantly improved therapeutic effect over the free drug. The 3D spheroid
model of MDA-MB-231 was conducted to predict the inhibitory effects of PTX. An inhibition
trend in tumor spheroid volume is observed in all the treatment groups (Figure 4-7A), where
PTX loaded in PVT-MEM NPs resulted in shrinkage of spheroids, indicating concomitant loss of
3D structure of cells [352] demonstrating the anticancer potential of PTX remains intact in the
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Figure 4-3. Intracellular uptake PVT and PVT-MEM NPs
A) Intracellular uptake of dye (C6) loaded nanoparticles, instead of drug, to view the fluorescent
uptake of the nanoparticles, after allowing 3 hours of incubation. The excess dye adhered to the
surface of the cells was washed with PBS, 3 times of 5 mins each. Cells were qualitatively
imaged under the EVOS® FL Imaging System (AMF4300, Life Technologies, Carlsbad, CA,
USA). B) Quantitatively analysis of the cellular uptake was conducted using Accuri C6 Flow
Cytometer (Accuri Cytometer, Inc., Ann Arbor, MI, USA). FL1 channel (488 excitation, Blue
laser, 530 ± 15 nm, FITC/GFP). Average reading and standard error of mean were calculated
from 3 runs.
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Figure 4-4. In situ dye uptake by PVT and PVT- MEM NPs
A) In Situ tumor targeting ability of PVT and PVT-MEM NPs were assessed using tissue
microarrays (TMA) slides. Slides were incubated with C6 equivalent on each slide for overnight
after processing them, followed by imaging. Type I represents the aggressive and invasive ductal
carcinoma, shows highest fold change of 1.7 folds by PVT-NEU NPs versus 1.15 and 1.45 for
PVT-MSC and PVT-RAW NPs respectively, when compared to PVT NPs. Image J was used to
quantify the fluorescence intensity. Data were measured using the distance in pixel and pixel
aspect ratio same.

Figure 4-5. Cell proliferation assay by PVT and PVT-MEM NPs in TNBC cells
A-B) Cell proliferation measured by MTT assay markedly decreased proliferation of TNBC cells
(MDA-MB-231) in comparison to breast epithelial cells MCF7 that does not show concentration
dependent proliferation, suggesting the specificity of the nanoparticles to TNBC cells after
treatment with 0-20 nM (equivalent amount of drug) for 48 hours. Untreated cells were used as
control. Cells treated with PVT and PVT-MEM NPs showed significant inhibition in cell
proliferation when compared to PTX solution and absorbance was recorded by a Microplate
Reader (BioTeK Cytation 3, Winooski, VT, USA) at 570 nm. Data presented as mean + standard
error of the mean (n = 3).
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Figure 4-6. Anticancer efficacy of PVT and PVT-MEM NPs in TNBC cells
A) Panel Proliferation: shows bright field microscopy images after MTT analysis demonstrating
significant morphological changes in MDA-MB-231 after 48 hours treatment. Imaging was done
by an EVOS® FL Imaging System. B-D) Migration & Invasion & Colony: PVT-MEM NPs after
exposure to 5 nM equivalent of PTX shows higher inhibition in comparison to PVT NPs and
significantly more than PTX solution at equivalent concentration. Significant changes in MDAMB-231 TNBC cells were noticed suggesting the targetability of PVT-MEM NPs. E)
Quantification of percent migratory cells, percent invasive cells and percent clonogenicity, with
respect to control cells.
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Figure 4-7. Spheroid forming ability of TNBC versus breast epithelial cells
A) Inhibition profile of MDA-MB-231 tumor spheroid growth was evaluated after treatment with
PTX solution and PVT/ PVT-MEM NPs, respectively, PTX equivalent to 5 nM, untreated cells
served as the blank control. Images were obtained at 0, 3, 7 and 10 days under brightfield
inverted microscope (EVOS® FL Imaging System). Image J was used to quantify the size of
each spheroid, all measurements were done keeping distance in pixel and pixel aspect ratio same.
(B) Tumor spheroid volumes ratio (%) was calculated based on change in size each day with
respect to day 0. Data presented as mean + standard error of the mean (n = 3).
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in the PVT and PVT-MEM NPs. As seen in Figure 4-7B there was no inhibition observed at day
0. As time elapsed, the inhibition trend was pronounced, with statistical difference observed in
PVT-MEM NPs with respect to control, on day 7 and day 10. A statistical significant inhibition
was noticed between PVT and PVT-RAW NPs on day 7. Although, there was no statistical
significant difference observed between PVT and PVT-MEM NPs, yet an inhibition trend could
be confirmed, exhibiting the intact inhibitory effect of PVT-MEM NPs after the membrane
coating.

In Vivo Imaging, Biodistribution, Tumor Retention and Efficacy Studies
The fluorescently labeled PVT and PVT-MEM NPs loaded with ICG were used to
evaluate the in vivo distribution in orthotopic xenograft tumor-bearing mice. MDA-MB-231 cells
were used for this and the mice were subjected to treatment with the ICG dye loaded
nanoparticles after the tumors reached ~200 mm3. Mice treated with ICG solution were used as a
control for this study and tumor retention and biodistribution of the dye in mice when delivered
(after a single dose) by PVT or PVT-MEM NPs were evaluated. ICG dye equivalent to 200
μg/ml were injected and mice were subjected to imaging at regular intervals from 0-120 hours
(Data shown for 72 hours). As shown in Figure 4-8A ICG solution is cleared out rapidly from
the system than any of the other treated groups, suggesting the prolonged retention and longer
circulation due to the enhanced EPR of nanoparticles that makes PVT and PVT-MEM NPs retain
longer. However, a conventional nanoparticular system such as PVT NPs though was retained
longer than ICG solution, they are cleared faster than the PVT-MEM NPs. PVT-MEM NPs due
to their surface coating showed a slower clearance rate as seen from their longer circulation at
least till 48 hours for all the groups, as shown in Figure 4-8A (Panels: PVT-NEU, PVT-MSC,
PVT-RAW NPs). As shown in Figure 4-8B the fluorescence intensities of PVT-MEM NPs were
greater than ICG and also for PVT NPs, that did not have long circulation time in comparison to
all the PVT-MEM NPs. PVT-NEU demonstrated statistically significant fold change of 9.13,
11.22, 14.52, 15.90 and 10.52 folds for 3, 6, 24, 48 and 72 hours with respect to ICG treated
mice (which were experimental control) when compared to PVT NPs. PVT-RAW NPs showed
the least difference with only less than a fold increase with respect to ICG for 72 hours.
After 120 hours of injecting the dye loaded nanoparticles and imaging the mice at regular
intervals, mice were euthanized and their orthotopic tumors and other organs were excised and
imaged for fluorescence intensity. The accumulation of nanoparticles on the other organs, such
as heart, lungs, liver, kidney, and spleen, are shown in Figure 4-9A. As shown, little or no
retention of ICG was found indicating the rapid clearance of the dye due to the absence of a
delivery system way before 120 hours. Tumor retention of ICG dye after 120 hours was
considerably higher with 2.64 folds increased retention observed in PVT-NEU NPs, when
compared to PVT NPs. Although there was no statistical difference in tumor retention observed
with PVT versus any of the PVT-MEM NPs, yet the biodistribution study in the other organ
provides insights about the benefit of using the membrane coating. An ex vivo analysis (Figure
4-9B) of PVT and PVT-MEM NPs shows the highest retention in the liver in comparison to any
other organ. There was significantly lower retention of the dye in all the organs, except the liver
(heart, lung, kidney, spleen). Although there was no statistical difference of the dye in the liver
through PVT and PVT-NEU NPs, unlike all other organs, yet a trend of lower retention is seen.
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Figure 4-8. In vivo tumor immunofluorescence retention of PVT and PVT-MEM NPs
loaded with Indocyanine green
A) Immunofluorescence imaging in a time dependent manner was assessed using Indocyanine
green loaded PVT and PVT-MEM NPs. After palpable tumors of MDA-MB-231 cells were
grown, mice were treated with ICG equivalent of 100 μg/ml of PVT or PVT-MEM NPs, plain
ICG solution was used as experimental control. Mice were subjected to imaging after 3, 6, 24, 48
and 72 hours to determine the retention of the fluorescent dye using IVIS Spectrum system
(Caliper Life Sciences). ICG was cleared out within 24 hours, whereas PVT-MEM NPs
prolonged retention over PVT NPs. B) To assesses the fold change of immunofluorescence
intensity signifying prolonged retention and distribution of membrane coated nanoparticles over
uncoated nanoparticles in of PVT-MEM NPs when compared to PVT NPs were calculated. Data
calculated from ROI mean values + standard error of the mean (n = 3).
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Figure 4-9. Ex vivo immunofluorescence of excised tumors and organs
A) Ex Vivo biodistribution of immunofluorescent dye ICG after 120 hours of intraperitonially
injection of ICG loaded PVT and PVT-MEM NPs. B) Quantitative analysis of the fluorescence
intensity of excised organs, heart, lungs, liver, kidney, spleen and tumor were collected, and ROI
value collected and assessed using IVIS Spectrum system (Caliper Life Sciences) at the UTHSC
core facility.
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Altogether, based on less biodistribution to other organs, prolonged longer circulation,
and higher tumor retention PVT-NEU was selected for evaluating therapeutic efficacy in in vivo
xenograft model. The ability of PVT and PVT-MEM NPs in combination with PTX to inhibit
primary tumors was evaluated in MDA-MB-231 tumor-bearing xenograft mouse model. After
the tumors reached a palpable size ~200 mm3, they were randomly separated into 6 groups (5
mice each), before initiating treatment with 10 mg/kg PTX or PTX equivalent in PVT/ PVTNEU NPs, given intraperitoneally, twice a week. Control mice received PBS treatment. PTX
solution showed ~52% tumor inhibition in comparison to control mice (Figure 4-10A through
D), whereas 67% and~72% inhibition was exhibited by PVT NPs PVT-NEU, in comparison to
control group.
A statistically significant difference was observed in inhibition profile of PTX versus
PVT and PVT-NEU NPs, however there was no statistically significant difference observed
between the PVT and PVT-NEU NPS, yet the inhibition trend was confirmed. To assess the
biocompatibility and hemotoxicity, fresh blood was withdrawn by cardiac puncture. As indicated
in Figure 4-10E mice group treated with PTX show systemic toxicity, exhibited from the
distorted morphology of the RBC, whereas PVT NPs and PVT-NEU NPs exhibit good
biocompatibility, probably due to the goodness of nanotechnology. To analyze if PTX induces
any adverse toxic effects, we evaluated the serum level of liver enzymes (ALT, AST, TBI),
kidney function markers (BUN) (Figure 4-11A). ALT 17-77 U/L, AST 54-298 U/L, TBili 0.00.9 mg/dL and BUN 8-33 mg/dL were considered normal ranges. Although there was slight
elevation of AST and TBili in PVT and PVT-MEM NPs, signifying the potential liver damage
caused probably by PTX [353, 354], also seen the liver retention in the biodistribution studies.
Other than that, all the other tested enzymes were normal, exhibiting regular kidney function. On
the contrary, PTX significantly reduced the number of WBC, neutrophil and lymphocytes with
respect to control, as seen in Figure 4-11B. Conversely, no myelosuppression was noticed in
PVT-NEU NPs with counts similar to control, although a slight decrease of WBC, neutrophil and
lymphocytes in PVT NPs with respect to control. Although there was no statistically significant
difference between PTX and PVT or PVT-NEU NPs, nevertheless, there a trend in increase in
neutrophil count by 43.33% in contrast to PTX was observed, lesser chances of PVT-NEU NPs
to cause neutropenia unlike PTX solution [355].
Tumors were excised and collected for IHC and H&E histological analysis, as shown in
Figure 4-12. As shown from the images, there was an increase in apoptotic markers, BAK and
Cleaved Caspase-3, and decrease in cell survival protein Bcl-2 expression in tumors treated with
PVT-NEU comparatively more than PVT NPs and PTX solution. The control shows
upregulation of PCNA, a cell proliferation marker whereas with treatment groups there is a
decrease in PCNA expression. IHC analysis for β-tubulin shows a higher expression of protein in
tumor treatment with treatment groups as compared to control indicating the treatment causes
mitotic cell cycle arrest of the tumor cells. The β-tubulin expression is enhanced with PVT-NEU
NPs over PTX, suggesting more inhibition of microtubules causing cell cycle arrest during
mitosis [327]. Panel H & E staining shows apoptosis, evident from the clusters of the nuclei that
are consistent with tumor inhibition, where PBS treated control group displayed fewer apoptosis
seen from the intact nuclei. Taken together, although there was no significant therapeutic
efficacy observed between PVT and PVT-NEU NPs, yet PVT-NEU NPs demonstrated a
comparatively safer profile in terms of biocompatibility, biodistribution to healthy organs and
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Figure 4-10. Tumor growth inhibition profile of PVT and PVT-MEM NPs (PVT-NEU,
PVT-MSC, PVT-RAW NPs)
A-B) PVT-NEU and PVT-RAW NPs shows significant inhibition with respect to PTX solution,
where PTX equivalent was (10mg/kg), in MDA-MB-231 xenograft mice model, as seen from the
whole mice images just before the tumors were excised and excised tumors. C) Average tumor
volume of control and PTX, PVT and PVT-MEM NPs respectively after 4 weeks treatment. D)
Net tumor growth of MDA-MB-231 tumors in control and PTX versus PVT-MEM NPs group.
E) Hemocompatibility was assessed from red blood cell morphological changes, after blood was
collected at the end point of the study by cardiac puncture. Data in bar graph represent
mean ± SEM of six tumors in each group. Data presented as mean + standard error of the mean
(n = 5.)

111

Figure 4-11. Evaluation of potential toxicity of PVT and PVT-MEM NPs PVT-NEU,
PVT-MSC, PVT-RAW NPs)
A) From Left to Right: Serum chemistry levels of liver enzymes (ALT, AST, TBI) and kidney
function markers (BUN) were determined in all the groups, dotted black line indicates the
normal range for each of the enzyme. B) From Left to Right: Blood count analysis determined
levels of WBC, RBC, neutrophil and lymphocytes were determined. WBC, Neutrophil and
lymphocyte count was significantly lower in PTX treated group, indicating changes of
myelosuppression, in contrast to PVT-NEU NPs that has WBC, RBC, neutrophil and
lymphocyte equivalent to control group. Data presented as mean + standard error of the mean (n
=5).
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Figure 4-12. Immunohistochemistry analysis and histological evaluation of tumors treated
with PVT and PVT-MEM NPs PVT-NEU NPs
A) Representative immunohistochemical images of excised xenograft tumors for expression of
apoptotic markers, BAK and Cleaved Caspase-3 and cell survival protein Bcl-2, proliferation
marker PCNA, β-tubulin suggesting mitotic cell cycle arrest and H&E staining for distinguishing
morphological difference.
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analysis of various enzymes and blood work. These demonstrate the potential of biomimetic
PVT-MEM NPs especially PVT-NEU NPs due to good biocompatibility and other effective
therapeutic virtues could possibly make progress as a personalized tool for cancer therapeutics.
Discussion
One of the main causes of hindrance in the development of treatment modalities for
TNBC, is the aggressive and metastatic nature of this subtype of BC. It is characterized by lack
of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal
growth factor receptor (HER2) [362]. This type of malignant related disease must have proper
detection, treatment, and prevention from metastasis. However, lack of finding a prognostic
marker, the heterogeneity, and the aggressiveness, makes treatment to this subtype of BC a
formidable challenge. Currently, the mainstay treatment option even for this of metastatic disease
is primarily systemic administration of chemotherapeutics, administered as a single agent or in
combination with immunotherapy. These agents though have potential therapeutic benefits to the
primary tumors yet pose adverse effects on non-targeted healthy tissues with low penetration of
drugs at the metastatic region. Therefore, the development of novel drug delivery strategies that
can improve the selectivity of drugs to the primary tumors with localization at the metastatic
regions and minimize toxicities to normal tissues, is crucial. [122]. Based on molecular profiling,
several targets for TNBC have been established [363], which has made it possible for several
potential compounds/drugs to make it to the clinical trials, to be evaluated in TNBC patients
[364]. Although several efforts are made by scientist across the globe, there are only a few FDA
approved targeted therapy that has made it through the clinical trial. Among them, very recently
Lynparza (olaparib), a PARP inhibitor was approved as monotherapy for BRCA1/2-mutation
TNBC patients [365]. Additionally, immunotherapy drug Tecentriq (atezolizumab), given in
combination with the chemotherapeutic drug Abraxane, for PD-L1-positive TNBC received
accelerated approval for treatment of TNBC, where PD-L1 comprises about ≥25% of TNBC
patients [366].
Novel techniques such as active targeting by attaching ligands (such as small molecules,
peptides, aptamers, and antibodies) on nanoparticles to specifically recognize and bind to
receptors on target cancer cells for enhancing targetability drug molecules in tumors. Such
strategies would also efficiently minimize off-targeting problems, maximize the therapeutic
window and would ensure maximum survival rate and improve the quality of the patient’s life.
Among the many new strategies employed for targeted therapy, one such strategy is the
functionalization of particles with biological compartments or naturally derived cell membranes
[356]. Biomimetic nanoparticles combine the characteristics of nanoparticles with cell membrane
characteristics, imparting a biological identity to these nanoparticles [357]. Thus, providing
enhanced targeting by interaction with the complex biological microenvironment imparting,
specificity, improved circulation, non-immunogenicity and potent therapeutic response [341].
The longer the nanoparticles are in circulation, ensures controlled delivery of the drug entrapped
in the nanoparticles and being capable of reversible binding to entrapped target proteins. This
creates a dynamic compartment for specific vascular distribution of drugs. They target selected
disease sites, thus protecting the surrounding healthy cell from toxicity. These engineered
nanoparticles are modified in such a way that they are non-immunogenic to the body, thus ae not
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opsonized, or being recognized by macrophages and rapidly cleared from circulation [ 67,68].
Various cell membranes have been explored to camouflage nanoparticles with red and white
blood cells, platelets, viruses, exosomes, extending potential therapeutic response and mimicking
properties (Figure 4-13) [358-362]. Based on these reports and our preliminary findings, we are
investigating alternative strategies that could be used for functionalizing the biomimetic
nanoparticles, that would provide a specific binding to tumors as well as metastatic sites, such
that systemic administration of chemotherapeutic drugs can be minimized. We initially
developed a PVP and tannic acid-based nanoparticle, both have their associated advantages. It
was reported by Le et. al. that PTX molecules aggregates to form the hydrophobic core with
tannic acid by a hydrogen bond. However, on addition of PVP to this tannic acid-PTX core
compact and stable core could be achieved, due to stronger hydrogen bond interaction [363]. We
thought, this would be an ideal stabilized core for our membrane coated nanoparticles, as the
membrane coating on the top of the nanoparticles would be efficient with a rigid core. This is the
reason we choose PVT (Polyvinylpyrrolidone-Tannic acid self-assembled) nanoparticles. At first
we developed a nanoparticle core (PVT NP) based on our previous findings [300, 344], that
shows therapeutic efficacy over commonly administered chemotherapeutic agent, PTX in TNBC
and prevents P-glycoprotein mediated drug efflux, one of the contributing factors for reduced
efficacy of PTX in TNBC patients [364-366].
PVT NPs were coated with neutrophil membrane (NEU) because when activated, shows
presence of membrane proteins on the bilayer, such as, Lymphocyte function-associated antigen1 (LFA-1), macrophage-1 antigen (Mac-1), platelet endothelial cell adhesion molecule-1
(PECAM-1), P-selectin glycoprotein ligand-1 (PSGL-1) that have high affinity for receptor site
specific on TNBC [367]. The membrane proteins from the SDS-PAGE Coomassie stain show
presence of LFA-1, MAC-1, PSGL-1 and PECAM-1 (molecular weights: ~140KDa, ~47KDa,
~43KDa and ~130 KDa, respectively). The profile of the membrane proteins on both NEU and
PVT-NEU seems to be intact around those molecular weights. Although, the presence of the
proteins in PVT-NEU seems to be a little faint than NEU, but the presence of the membrane
proteins suggests proper translocation of these proteins on the surface of PVT nanoparticle. We
would suggest a further verification by western blotting and bottom up proteomics analysis
[368]. This explains the enhanced PVT-NEU NPs accumulation at the tumor site, due to the
overexpression of ICAM-1, VCAM-1 and E-selectin on TNBC that alters tight junctions
between endothelial cells, resulting in increased vessel permeability [357, 369-371].
Natural killer (NK) cells are known to recognize cancer cells and have a cytotoxic effect
on them [372, 373], due to increased expression of markers such as killer-cell immunoglobulinlike receptors (KIRs) and natural cytotoxicity receptors (NCRs) [372, 374]. However, in tumor
microenvironment due to the secretion of soluble factors by the tumors, the NK cell activity may
be impaired, resulting in escape of NK mediated killing [375, 376]. Taking advantage of this
situation, we selected NK cells due to the presence of the activating markers that have shown to
be beneficial in TNBC patients [373, 377], which could be used to coat the nanoparticles.
Mesenchymal stem cells (MSC) has shown to have an antiproliferative role on TNBC cells
especially MDA-MB-231, as seen from in vitro proliferation, migration and angiogenesis assays,
suggesting the potential of using MSC for treatment of TNBC [378]. Leukocyte membranes,
when coated over nanoporous silica particles, has expression of LFA-1 that has specificity for
ICAM-1 on TNBC cells [379]. Based on these findings, we selected Jurkat cell membrane,
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Figure 4-13. Schematic representation of the preparation of cell membrane-camouflaged
nanoparticles
Various source cells used to extract cell membrane vesicles and coated on the top of the
nanoparticles designed for a variety of cancer therapy, having selectivity to the membrane
surface proteins.
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hoping that the isolated membrane would preserve some of the biological activity and would
cause enhanced adhesion to the tumor vasculature [362]. Macrophages cells or RAW 264.7 show
high expression of α4 and β1 integrins, that can bind to the metastatic BC cells due to the cellspecific binding with vascular cell adhesion molecule-1 (VCAM-1) [380].
We choose neutrophil, natural killer, mesenchymal stem cells, Jurkat cells and RAW
264.7 cells and extract the cell membrane for cell-specific binding of nanoparticles to the sitespecific tumor site and metastatic region in TNBC. After extraction of cell membranes, we
coated the nanoparticles with these membranes, which is a lipid bilayer, which probably explains
the slight increase in particle size and TEM images of PVT-MEM NPs over PVT-NPs. Also, the
hydrophobic interaction was due to the electrostatic repulsion between the negatively charged
PVT cores and the lipid membrane, that forms the coating over the nanoparticles, which
otherwise would have formed aggregates [381]. The binding of the generated nanoparticles with
the TNBC cells was confirmed using the intrinsic protein fluorescence quenching especially the
tryptophan residue, that responds to binding or any chances in the local environment surrounding
the indole ring [382]. To evaluate the interaction of activated neutrophil membranes (NEU),
membranes from NK, MSC, JUR and RAW coated nanoparticles with aggressive and metastatic
TNBC cells (MDA-MB-231) was used. Our intracellular and in-situ uptake shows the higher
uptake of PVT-MEM NPs, as per compared to PVT NPs when the nanoparticles were loaded
with fluorescent dye C6. In Vitro cytotoxicity assays as seen from cell proliferation, migration,
invasion, and colony-forming assay, suggest the efficient anticancer ability of PVT-MEM over
PVT NPs in TNBC cells. To further asses our results, we investigated the therapeutic efficacies
on 3D spheroid cell culture matrix which is better predicator of drug resistance and efficacy due
to the presence of oxygen and nutrient resulting in invasive cells on the outside and quiescent or
necrotic cells inside of the spheroid [383]. These studies suggest, the in vitro activity of the
nanoparticles were intact upon the membrane coating and did not have any impact on the
anticancer potential, A plausible reason would be a presence of self-markers on the surface of the
PVT-MEM NPs that provides cell-specific binding to the potential targets on TNBC cells, that
explains the enhanced uptake on MDA-MB-231 versus other cell lines especially the breast
epithelial cells, MCF10A.
In Vivo circulation time of plain ICG shows clearance of the dye completely within 5
days probably because of the clearance by RES, also expected to produce subtherapeutic tumor
concentration [384] over nanoparticles that though prolonged circulation over plain solution due
to the EPR effect yet are not circulated long enough as PVT-MEM NPs, that prolongs circulation
of membrane coated nanoparticles, seen throughout all the time points observed in the
bioimaging study. However, ex vivo analysis shows that higher accumulation of dye by PVT and
PVT-MEM NPs occurs in the liver which is probably because it is a highly perfused organ and is
known to cause unescapable monocytic macrophage uptake [385]. Orthotopic xenograft mouse
model for TNBC was established using MDA-MB-231 to generate spontaneous metastasis
model of BC through subcutaneous or orthotopic injections, and are considered suitable model
for evaluation of therapeutics and anticancer drug candidates for BC [352, 386, 387]. The
accumulation of membrane coated nanoparticles over plain nanoparticles causes higher tumor
inhibition as seen from PVT-NEU in in vivo model. After evaluation of the therapeutic potential
of PVT-NEU NPs and its improved efficacy over PTX solution, the safety perspective was
evaluated from serum enzymes and blood count. PTX is known to cause leukopenia and
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neutropenia and severe peripheral neurotoxicity which often ranges from 30% to 40% of patients
receiving PTX chemotherapy [331]. Although no statistical significance was observed yet a
lower trend to cause myelosuppression or neutropenia could be suggested for PVT-NEU over
PTX solution. Additionally, no hemotoxicities was observed to regular red blood cells except for
PTX solution, which also correlates to the toxicities observed from serum enzymes. Furthermore,
IHC analysis shows enhanced apoptosis wit PVT-NEU over other treatment groups morphology
of the distorted tumor elucidates the enhanced therapeutic activity. Taken together, we
demonstrate the cell membrane coated nanoparticles could be utilized for efficient delivery of
anticancer drugs to the TNBC cells, showing improved therapeutic effects.
Conclusion and Future Direction
In this study, we have demonstrated that the cell membrane-based nanoparticular system
provides prolonged circulation and enhanced therapeutic efficacy in TNBC cells, MDA-MB-231
for targeted delivery of the potential therapeutic agent, PTX. This is due to the overexpression of
adhesion moieties and/or selectins on TNBC cells that serves as a receptor-ligand for interaction
with the activated protein moieties on the surface of the membrane coated nanoparticles.
Although, further confirmation about the presence and abundance of the membrane-associated
proteins on the surface of the nanoparticle, after extrusion and coating can be confirmed through
bottom-up proteomics analysis. This would provide estimation for the quantitative analysis of
nanoparticles that would retain the membrane associated proteins from the source cells and are
being translocated on the top of the nanoparticles to provide selectivity. Herein, we report that
neutrophil membrane coated nanoparticles due to the cellular expression, potentiates binding to
the primary tumor and attenuates adverse toxic effects extended by the potent yet cytotoxic drug
PTX.
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CHAPTER 5.

CONCLUSIONS AND FUTURE PERSPECTIVES

Nanotechnology-based drug delivery systems have been utilized to overcome the
limitations of conventional drugs. Nanoparticle-based drug delivery approaches offer penetration
capability at the diseased regions, prolong circulation time, improve toxicity and tolerability.
With this respect, Abraxane, was able to reduce toxicity issues of Taxol® by improving the
overall response rate in patients by ~2-fold improvement in contrast to PTX solution or Taxol®.
Despite the immense advances there are few unmet needs that suffers adverse effects, such as
neutropenia, neuropathy. PTX is formulated as suffers serious side effect of sensory axonopathy
and ganglion-neuropathy, neutropenia, severe peripheral neurotoxicity which often ranges from
30% to 40% of patients receiving chemotherapy. However, incidence of both neuropathy and
neutropenia was significantly higher than native PTX drug. Thus, a dire need to mitigate this
deadly disease TNBC, due to the aggressive and metastatic nature is required. The main
objective of this research is to develop a delivery system that can provide active targeting at the
primary tumor site but can penetrate the of dense extracellular matrix and have therapeutic
concentration for tumor penetration. Also, specificity and targetability would ensure the adverse
side effects to other organs is minimized. This was first achieved by fabrication of polymer
based, polyvinylpyrrolidone (PVP) PTX self-assembled nanoparticles with improved anticancer
efficacies (Chapter 2). In further development of a nanoparticle system that would possess builtin chemosensitization motifs, a polyphenolic compound tannic acid-based PTX nanoparticles
was fabricated that prevent drug efflux from cancer cells (Chapter 3). Finally, the combined
effect of both these nanoparticles to obtain the core for biomimetic nanoparticle, that forms a
rigid core for the nanoparticle on which membranes from endogeneous cells were coated to
attain cell specificity to TNBC cells, as demonstrated in in vitro and in vivo models (Chapter 4).
The following summary can be drawn from Chapter 2:
x

Screening of commonly used polymer and pharmaceutical excipient, for development of
self-assemblies of PTX (polyvinylpyrrolidone, PVP).

x

The formed self-assemblies exhibited greater cellular interaction and internalization in
BC cells.

x

The self-assemblies induce superior antiproliferation activity and cellular apoptosis in BC
cells.

x

This self-assembly nanoplatform laid the foundation for further development of a drug
delivery system that can specifically target TNBC cells.
The following summary can be drawn from Chapter 3:

x

Development of tannic acid-based PTX nanoparticles, that is known to exhibit anticancer and chemosensitization properties.

x

Nanoparticles exhibited enhanced intracellular drug uptake in TNBC in comparison to
PTX drug solution.
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x

P-gp drug efflux was inhibited by these nanoparticles over drug solution, suggesting the
significant inhibitory effect of tannic acid, which is known to inhibit ATPase.

x

Tannic acid-based PTX nanoparticles inhibited cell proliferation, migration, invasion and
colony-forming ability in TNBC cells.

x

Microarray analysis demonstrates the induction of apoptosis with tannic acid-based PTX
nanoparticles, which also induces enhanced mitotic cell cycle arrest.
The following summary can be drawn from Chapter 4:

x

Combination of polyvinylpyrrolidone and tannic acid nanoparticles stabilized the
nanoparticle core due to extensive hydrogen bond interaction. This gave the base core for
the coating with exogenous cell membranes.

x

Biomimetic nanoparticles combine cell membrane characteristics imparting biological
identity to the nanoparticles. For which, we achieved cell-specific binding to the antigenreceptor on aggressive and metastatic TNBC cells due to the presence of activated
neutrophil, RAW 264.7, NK-92, Mesenchymal stem cells and Jurkat cells.

x

Prolonged circulation was achieved after membrane coating of the nanoparticles over
uncoated nanoparticles.

x

Tumor retention and biodistribution to other healthy organs was minimized in
comparison to uncoated nanoparticles and drug solution.

x

Adverse toxicities such as neutropenia was not observed with the membrane coated
nanoparticles, suggesting the safe profile of our developed nanoparticles.

In conclusion, the hypothesis of the dissertation was to develop cell membrane coated
polymeric nanoparticles that can be an effective drug delivery option for aggressive and
metastatic TNBC. We herein demonstrate the development, optimization and characterization of
these nanoparticles that prolongs circulation, retained at the primary tumors and reduce adverse
side effects on healthy organs thus minimize immunogenicity.
Limitations to the Study
We herein demonstrate in vitro and in vivo efficacies of neutrophil membrane coated
nanoparticles in comparison to either the plain drug solution or uncoated nanoparticles.
However, this study was designed to evaluate the best targeting nanoparticles from the wide
array of selection of endogenous cell membranes. Thus the in vivo study was primarily designed
for a pilot screening of the best available membrane coated nanoparticles, where a smaller
sample size of 5 mice per group was used. We only have tested the in vivo efficacies in
subcutaneous xenograft mouse model by an intraperitoneal dose, yet other sophisticated in vivo
efficacies and targeting studies could be explored.
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Future Directions
Although further warranting needs to be done, after estimating the sample size for in vivo
studies by Power analysis, to generate the required number of animals to estimate the appropriate
efficacy and targetability of neutrophil membrane coated nanoparticles in comparison to
uncoated and drug solution. Further, other clinically relevant BC models such as orthotopic
patient-derived xenograft and/or MMT Transgenic Mammary Tumor Mouse Models could be
utilized. These mouse models are highly suitable for evaluating the effects of membrane coated
nanoparticles in disease progression, metastasis, and development of drug resistance. This could
warrant the potential of these biomimetic nanoparticles to target not only the primary tumor site
but circulating tumor cells in the blood or at distant site. Also, this drug delivery system could be
employed for evaluating other diseased conditions which has an inflamed vasculature, as in
ischemia.
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